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ABSTRACT 
Sigma receptors represent a unique family of proteins that includes two subtypes: sigma-1 and 
sigma-2. Sigma-1 receptors have been implicated in the behavioral and motivational effects of 
psychostimulants as well as in the pathophysiology of depression and Alzheimer’s disease. 
Sigma-2 receptors are widely expressed on many tumor cells and they are believed to play an 
important role in tumor cell proliferation. Therefore, sigma receptors are attractive targets for 
developing pharmaceutical agents directed to the treatment of psychostimulant abuse, cancer, 
Alzheimer’s disease as well as diagnostic agents for cancer and brain imaging 
A derivatized 2(3H)-benzothiazolone, (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-
one) was reported to have high affinity (0.56 nM) and selectivity (over 1000 fold) for sigma-1 
receptors over sigma-2 receptors. A fluorinated derivative CM304, was synthesized in our 
laboratory and was found to have high affinity (0.0025 nM) for sigma-1 receptors and high 
selectivity (> 100,000 fold) over sigma-2 receptors. Both the compounds have a benzo[d]thiazol-
2(3H)one scaffold and several other structural similarities. This prompted us to investigate the 
structure-activity-relationship (SAR) of 3,6-disubstituted benzo[d]thiazole-2(3H)one for affinity 
and selectivity at sigma receptors. A library of benzo[d]thiazol-2(3H)one analogues were 
synthesized and their receptor binding affinities were evaluated in rat liver membranes using a 96 
well format high throughput methodology. An additional goal of this project was to conduct 
microsomal stability studies on some promising sigma receptor analogues. The data gathered 
from the pharmacokinetic studies has provided valuable information towards the mechanism of 
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biotransformation of this class of sigma ligands. This knowledge is helpful in designing future 
sigma ligands with better druggable and therapeutic profiles. 
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CHAPTER 1. SIGMA RECEPTORS
  16 
1.1 History 
Sigma receptors (σ) are a unique class of binding proteins that have received much attention 
from the drug discovery field due to their probable association with cancer, schizophrenia, 
seizures, anxiety, neuropsychiatric disorders and the psychostimulant effects of drugs of abuse. 
Before their discovery as a unique class of receptor, sigma receptors were first described as a 
subclass of opioid receptors. Based on the psychotomimetic effects of  (±)-SKF-10,047 (N-
allylnormetazocine) (Table 1.1) and related benzomorphans which were not reversed by opioid 
antagonists, Martin and coworkers named this distinct class of receptor as “ sigma,”1 derived 
from the first letter “S” from SKF-10,047. Subsequent studies with the (+) and (-) enantiomers of 
SKF-10,047 revealed that the (-)-isomer was responsible for the majority of opioid-mediated 
effects that were specifically antagonized by classical opioid antagonists such as naltrexone 
(Table 1)2,3. However, (+)-SKF-10,047 produced actions that were insensitive to classical opioid 
antagonists4-6. Subsequently, for many years, it was thought that the sigma receptors and N-
methyl-D-aspartate (NMDA) receptor/phencyclidine (PCP) sites were identical. This hypothesis 
was contradicted by studies using selective NMDA ligands, wherein they only partly displaced 
[3H](+)-SKF-10, 0477. Sigma receptors were then classified as a unique protein family, different 
from opioid and NMDA/PCP receptor sites. Sigma receptors are distributed in several brain 
areas and are also abundant in various peripheral tissues. 
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Table 1.1: Selectivity of different enantiomers of SKF-10,047 to receptor sites 
(±)-SKF-10,047 (-)-SKF-10,047 (+)-SKF-10,047 
HO
N
CH3
CH3
 
 
1.1 
HO
N
CH3
CH3
 
1.2 
OH
N
H3C
H3C
 
1.3 
Opioid (µ, κ) receptor,  
NMDA receptor (PCP 
site), σ receptor 
Opioid (µ, κ) receptor NMDA receptor (PCP 
site), σ receptor 
 
1.2 Subtypes of Sigma Receptors 
 
Two subtypes of sigma receptors are known and they are designated as sigma-1 and sigma-2 
receptors These two subtypes are distinguished on the basis of protein size, tissue distribution 
and drug selectivity pattern (Table 1.2). The (+)-isomer of benzomorphans have high affinity for 
the sigma-1 subytpe as compared to the sigma-2 subtype8 whereas, (-)-benzomorphans have low 
affinity for both the receptor subtypes. The sigma-1 receptor is a 29-kD polypeptide whereas 
sigma-2 receptor appears to be a smaller protein with an apparent molecular weight of 18-21.5 
kD. Pharmacological studies show that sigma-1 receptors are well distributed in the CNS 
especially in the motor, sensory and memory regions. Sigma-1 receptors are also widely 
distributed in the peripheral organs, particularly, in the heart and spleen9-11. Regarding sigma-2 
receptors, much less biochemical or structural data is available because the protein structural 
information has yet to be obtained. Both the receptor subtypes are highly expressed on tumor cell 
lines174,175. However, malignant cells show a higher expression of sigma-2 receptors than 
quiescent tumor cells31. 
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Table 1.2: Classification of sigma receptors 
Feature Sigma-1 receptor Sigma-2 receptor 
Size 25-29 kDa 18-22 kDa 
High tissue expression Brain, heart, liver, spleen, GI tract Brain, liver, GI tract 
Relative affinity of (+)-
benzomorphans 
High to moderate Low 
 
1.3 Role of Sigma Receptors 
Sigma receptors modulate diverse physiological functions. At the cellular level, they modulate 
action-potential firing in neurons46, 47 and contractions in various kinds of muscle fibers48. These 
are greatly attributed to modulation of potassium and calcium channels 26,45-50. Sigma receptors 
are also invloved in the release and modulation of various neurotransmitters such as  dopamine52, 
acetylcholine55, serotonin and glutamate51,56. Sigma receptor ligands have also shown 
neuroprotective and anti-amnesic activity87-89. The anti-amnesic actions are based on the 
observation that selective sigma receptor agonists potentiate N-methyl-D-asparatate (NMDA)-
induced neuronal activation of CA3 hippocampal pyramidal neurons. Sigma receptors have also 
been proposed to play a role in the pathophysiology of depression. Both preclinical and clinical 
data suggest that sigma agonists could act as antidepressants. The sigma receptor ligands are 
believed to enhance 5-HT neurotransmission and modulation of the NMDA response to exert 
their anti-depressant properties139-140. Sigma receptors also play a role in the pathophysiology of 
schizophrenia, which involves modulation of dopaminergic and glutamatergic neurotransmitter 
systems51-56. Their roles in endocrine and immune systems have also been suggested. The 
expression of sigma-1 receptors in immune systems is well established. SR31747A61-64 and 
SSR125329A65 (1.26 & 1.27, Fig. 1.3) show potent immunomodulatory and anti-inflammatory 
activities in different models. Many drugs of abuse interact with sigma receptors, and the 
involvement of sigma receptors specifically in methamphetamine and cocaine-induced toxicity 
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provide a new avenue for development of medications in this therapeutic area 77,102,103,124. 
1.4 Sigma-1 (σ-1) Receptor 
The sigma-1 receptor subtype is pharmacologically well characterized because of the receptor 
sequence information and availability of selective sigma-1 ligands. The sigma-1 subtype was 
first purified and cloned from guinea pig liver11. The 223 amino acid sigma-1 receptor with two 
transmembrane spanning regions9,10 has subsequently been purified and cloned from several 
other mammalian species, including mouse, rat, guinea pigs and human12-16. The sigma-1 
receptor protein contains 90% identical amino acis sequences across different species. The 
sequence of the sigma-1 receptor does not resemble any of the known mammalian proteins, but it 
has a 30% identity and 66% homology to ergosterol-­‐Δ8/Δ7-­‐isomerase enzyme. However, sigma-1 
receptors do not possess sterol isomerase activity11. The sigma-1 receptor ligand binding domain 
has also been identified with the help of protein purification17 and photoaffinity labeling 
studies18-20. Receptor protein consists of three hydrophobic domains and two of these appear to 
be transmembrane domains. The steroid binding domain like I (SBDLI), steroid binding domain 
like II and N-terminal region of transmembrane domain I (TM1) form a portion of the ligand 
binding site. 
1.4.1 Anatomical Distribution of Sigma-1 Receptor 
The sigma-1 subtype is widely distributed in the CNS and peripheral tissue. In the CNS they are 
predominantly distributed in the areas that are involved in memory, emotions, sensory and motor 
functions. Sigma-1 receptors in the CNS have been visualized using different radioligands and 
immunocytochemical techniques21-24. They are concentrated in the hippocampus, hypothalamus, 
cerebral cortex, and various motor and cranial nuclei as well as dorsal horn in the spinal cord.  
Sigma-1 receptor are widely expressed in the peripheral organs such as the heart25, 26, spleen27, 
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liver28, and kidney28 where the actions of sigma-1 are presumed to dominate over those of the 
sigma-2 subtype. The liver contains significant concentrations of both sigma receptor subtypes 
however their physiological function in the liver is currently unknown. The sigma-1 subtype is 
widely expressed on the heart and is implicated in cardiac muscle contractility and calcium 
influx25, 26. In addition sigma-1 receptors are also overexpressed in various human and rodent 
cancer cell lines. Higher expression of sigma-1 receptors have been observed in small cell lung 
cancer, prostrate cancer, breast cancer and neuroblastoma29-32. 
1.4.2 Subcellular Distribution of Sigma-1 Receptors 
Radioligand binding and immunohistochemical studies have confirmed the distribution of sigma-
1 binding sites in the microsomal membranes of endoplasmic reticulum (ER) in neurons24, 
oligodendrocytes33, lymphocytes34, retinal cells35 and some cancer cells. Immunostaining and 
electron microscopic study of rat brain slices indicated that sigma-1 receptors show a 
postsynaptic distribution and the receptors localize on the ER of the cell body of neurons. 
Immunofluorescence studies have shown that sigma-1 receptors co-localize with S100 protein of 
Schwann cells in rat sciatic nerve162. Sigma-1 receptor have also been found to translocate from 
the ER to the plasma membrane and mitochondria-associated membrane of cells upon treatment 
with sigma-1 receptor ligands36-38. This was further confirmed by the subcellular fractination 
studies and real-time monitoring of GFP (Green Fluorescent Protein) tagged sigma receptor 
migration in living NG108 cells163. This result indicates that sigma-1 receptors can influence 
plasma membrane bound signal transduction. 
1.4.3 Physiological Functions of Sigma-1 Receptor 
Modulation of voltage gated Ion channels 
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Sigma-1 receptors modulates the cell membrane potential by regulating the activity of many 
voltage gated ion channels. Selective sigma-1 agonists reduce K+ currents in frog melanotropic 
cells and this effect can be reversed by sigma-1 antagonists39, 40. Potassium (Kv 1.4) channels 
have been shown to co-localize with sigma-1 receptors through co-immunoprecipitation 
experiments9. The sigma-1 receptor modulates inositol 1,4,5-triphosphate (IP3) receptor-
mediated Ca2+ signaling at the endoplasmic reticulum41, 42. Sigma-1 agonists potentiate Ca2+ 
mobilization via IP3 receptors in neuronal cell lines43 and this action is blocked by sigma-1 
receptor antagonists. Recent studies have proposed that sigma-1 receptors are chaperone proteins 
that modulate Ca2+ signaling at Mitochondrion-associated ER membrane (MAM)38. It was 
demonstrated that sigma-1 receptor selective ligands (SKF-10047 and (+)-pentazocine, 
nonselective ligands (Haloperidol (1.4) and DTG) and progesterone (1.10) inhibit voltage gated 
Na+ channels (Nav1.5) in HEK293 cells, COS-7 cells and neonatal mouse cardic myocytes44. 
Sigma-1 receptor agonist, (+)-pentazocine (1.60) has been shown to block Na+, K+ and Ca2+ 
channels in rat intracdiac gangilion neurons45-48. Sigma-1 receptors form a complex with acid-
sensing ion channels (ASIC)1a49. It was demonstrated that endogenously expressed sigma-1 
receptors on rat cortical neurons inhibit intracellular Ca2+ accumulation via ASIC1a50. 
Modulation of Neurotranismitter system and second messengers 
The sigma-1 receptor chiefly has a modulatory role on NMDA mediated glutamatergic 
neurotransmission51, dopaminergic 52,53, cholinergic 54,55, serotonergic51, GABA56 and, 
adrenergic57 neurotransmission. 
It has been documented that sigma-1 receptors are involved in the modulation of NMDA type 
glutamate receptors. Neurosteroid dehydroepiendrosterone sulfate (DHEAS) enhances 
spontaneous glutamate release in rat hippocampus through sigma-1 receptors 58,59. Additionally, 
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DHEAS increases intrathecal NMDA-induced nociception which is blocked by sigma-1 receptor 
antagonists suggesting a facilitatory role of sigma-1 receptor in NMDA mediated 
nociception60,61. Sigma-1 agonists potentiate glutamate induced intracellular Ca2+ influx through 
NMDA receptors62. The sigma-1 receptor antagonist, BD1047, was found to reduce NMDA 
induced neurotoxicity during methamphetamine withdrawl63. Several sigma-1 receptor agonists 
such as (+)-pentazocine, DHEA, clorgyline and sertraline were found to modulate N-methyl-D-
aspartate-induced neuronal firing and dopmaine release in the brain64, 65. These agonists exhibit a 
low-dose stimulation and a high-dose inhibition of NMDA induced firing.  
Sigma-1 receptors have been found to amplify the dopamine (D1) receptor agonist induced 
protein kinase (PKC) activation66. A recent study has proposed that sigma-1 receptors may 
colocalize with dopamine (D1) receptors in a steady state (in absence of ligand) however, cocaine 
may increase the heteromerization of these receptors67. 
Sigma receptors are implicated in the modulation of cholinergic system. Sigma-1 receptor 
agonist SA4503 was found to increase the electrically stimulated release of 3H-acetylcholine 
from rat hippocampal neurons in a dose dependant manner55. Sigma-1 receptor agonists (+)-SKF 
10,047, (+)-3-PPP, (+)-Pentazocine and DTG were found to increase the extracellular levels of 
acetylcholine in the frontal cortex of rat brain. These effects were dose dependant and could be 
reversed by the sigma receptor antagonist haloperidol68. The sigma-1 agonist (±)-PPCC was able 
to improve the working memory in animal models with induced colinergic lesions of variying 
severity. This experiment also demonstrated that the sigma-1 receptor agonist improves the 
cognitive ability in animals with complete colinergic dysfunction69.  
Sigma-1 receptor are understood to translocate from ER to plasmalemma or nuclear membrane 
during signaling, and are linked to the modulation or production of various intracellular second 
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messengers9, 42. Sigma-1 receptors are colocalized with neutral lipids and cholesterol on the ER 
and form a trimeric complex with ankyrinB and InsP3 receptors in NG-108-15 neuroblastoma 
cells70,42. Upon activation by sigma-1 receptor agonists the sigma-1/ankyrin complex dissociates 
from InsP3 triggering the calcium efflux that further activates PLC system41,43,71,72 and this affect 
is blocked by sigma-1 receptor antagonists 41,43,72. 
1.4.4 Exogenous and Endogenous Ligands of Sigma-1 Receptor 
The sigma-1 receptors bind structurally diverse classes of compounds, including diverse 
psychotherapeutic agents such as neuroleptics (haloperidol, 1.4)73, antidepressants (fluvoxamine, 
1.5)74, antitussives (carbetapentane, 1.6)75, agents to treat parkinson’s disease (donepezil, 1.7)76,72 
and  drugs of abuse (cocaine (1.8), methamphetamine, (1.9))73, 77 and steroid hormones such as 
progesterone (1.10). The general pharmacophoric element appears to be an N-alkyl, N,N-dialkyl 
or N-arylalkyl amine78.  
F
O
N
OH
Cl
 
F3C
N
O CH3
O
NH2  
1.4, Haloperidol 1.5, Fluvoxamine 
O
O
O
N
CH3
CH3
 
O
O
CH3
H3C
O
N
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1.6, Carbetapentane 
 
1.7, Donepezil 
N
CO2CH3
O
O
H3C
 
H
N
CH3
CH3  
1.8, Cocaine 1.9, Methamphetamine 
H
N
CH3
CH3
O
O  
1.10, MDMA 
                               Figure 1.1: Exogenous ligands of sigma-1 receptors. 
Surprisingly, progesterone (1.11, Fig. 1.2), a lipophilic steroid lacking a basic nitrogen, is 
recognized as one of the putative endogenous ligands for sigma-1 receptors79-81. Progesterone 
(1.11) acts as an antagonist at sigma-1 and sigma-2 receptors. Progesterone has been found to 
inhibit the modulation of voltage gated sodium channels by sigma-1 and sigma-2 receptor 
agonists to varying degree depending on the choice of agonists44,48. Other neurosteroids such as 
dehydroepiandrosterone (DHEA) (1.12, Fig. 1.2 ) and pregnenolone sulfate behave as weak 
agonists at sigma-1 receptor80. In recent studies N,N-Dimethyltryptamine (1.13, Fig. 1.2)  has 
been identified as a potential endogenous ligand for sigma-1 receptors82 although the 
physiological concentration in the brain tissues is very low and hence its role as a sigma-1 
modulator is not clear. Neuropeptide Y and peptide YY have been proposed as endogenous 
ligands for sigma receptors83. It has been suggested that the anticonvulsant effect of 
Neuropeptide Y are mediated through sigma-1 receptors84. D-erythro-sphingosine (1.14, Fig. 
1.2) and sphinganine (1.15, Fig. 1.2) are other endogenous alkylamines that act as sigma-1 
receptor modulators85,86. 
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Figure 1.2: Endogenous ligands of σ-1 receptors. 
1.4.5 Therapeutic Potential of Sigma-1 Receptor 
Sigma-1 receptors: Cognition and Alzheimer’s disease 
Sigma-1 receptors are potent modulators of colinergic neurotransmission as well as NMDA-
induced neuronal firing. Colinergic neurotransmission and NMDA receptors have been widely 
implicated in the memory and cognitive functions. Selective sigma-1 agonists such as (+)-SKF-
10,047, (+)-3-PPP, (±)-Pentazocine, DTG and SA4503 have been found to increase the 
extracellular acetylcholine levels in the frontal cortex in a dose dependant manner and these 
effects were reversed by sigma-1 receptor antagonists68,87-89. Several sigma-1 receptor agonists 
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have been found to attenuate the cognitive impairment induced by NMDA antagonist dizocilpine 
in rats and mice. This effect was reversed by sigma-1 receptor antagonists amd antisense 
oligodeoxynucleotides90–93.  
Fluvoxamine (1.5, Fig 1.1), an selective serotonin reuptake inhibitor (SSRI) and a sigma-1 
receptor agonist was found to improve cognitive impairment, memory and concentration in 
animal models of schizophernia94,95. Acetylcholine esterase (AChE) inhibitors donepezil (1.7, 
Figure 1.1) has been shown to provide neuroprotection against amyloid toxicity96,97. Donpezil 
also shows significant sigma-1 receptor affinity in human brain98. Selective sigma-1 receptor 
agonists such as PRE-084 as well as mixed muscarnic/sigma-1 receptor ligands have shown 
neuroprotective effects in models of amyloid β25-35 peptide- induced neurotoxicity99-101.  
Sigma-1 receptors: Drugs of Abuse 
Drug abuse has been a growing social and health concern in the US and currently there is no 
effective pharmacological intervention available to treat drug abuse. According to the 2009 
National Household Survey on Drug Use and Health (NSDUH) estimated that 21.8 million 
Americans aged 12 or older were illicit drug users. This estimate represents 8.7 percent of 
population aged 12 or older and it is higher than the rate of drug abuse recorded in pevious 
years160. Illicit drugs include marijuana, psychotherapeutics, psychostimulants (cocaine, 
methamphetamine, MDMA), opioids (morphine, heroin), hallucinogens and inhalants.  Two of 
the most commonly abused drugs, cocaine and methamphetamine, partially exert their 
psychostimulant action by interacting with sigma receptors. Cocaine is a dopamine reuptake 
inhibitor but it also binds to sigma-1 receptors at physiologically relevant concentrations102. 
Cocaine has a preference for the sigma-1 receptor subtype over the sigma-2 subtype103. Several 
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studies have shown that cocaine’s psychomotor stimulant104,105, behavioral106,107, rewarding108,109 
and toxic effects110,111 might be mediated, in part, by sigma-1 receptors. Sigma receptors 
influence the pharmacological actions of cocaine by three different mechanisms: 
i.  Direct binding of cocaine with sigma receptors. 
ii.  Modulation of other receptors as well as neurotransmitter systems. 
iii.  Altering the gene expression161. 
Cocaine was found to induce the expression fos-related antigen 2 followed by upregulation of 
sigma-1 receptors in the brain regions that are involved in the drug reward mechanism112,113,107. 
These neuroadaptions might be responsible for the long-term affects of cocaine as well as drug 
relapse. It is believed that sigma receptors influence the action of cocaine by modulating 
neurochemical systems particularly, the dopaminergic system114-116. Several studies have 
reported that sigma-1 receptor antagonists such as haloperidol (1.4, Fig. 1.1), BD-1008, BMY-
14802 (1.23, Fig. 1.3), rimcazole (1.24, Fig. 1.3) as well as anti-sense oligonucleotides attenuate 
the acute locomotor stimulatory effects, sensitization and convulsions induced by cocaine in 
rats103,108,115. Sigma-1 receptor agonists potentiate the toxic and locomotor effects of cocaine. 
Sigma-1 receptor antagonist BD-1047 (1.20, Fig. 1.3) was found to attenuate the reinstatement 
of cocaine-reinforced behavior however it did not block the self-administration of cocaine117.  
In order to develop anti-cocaine medication two strategies could be utilized: 
i. Development of small molecule antagonists to block the access of cocaine to sigma 
receptors. 
ii. Development of anti-sense oligonucleotides to block the synthesis of sigma receptor 
protein. 
Methamphetamine (1.9, Fig. 1.1) has moderate affinity (2.2µM) for sigma-1 receptors77. Studies 
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have shown that sigma-1 receptor selective antagonists block the behavioral sensitization caused 
by methamphetamine in rats118-120. Sigma-1 receptors were found to be upregulated in the 
midbrain region in rats that self-administered methamphetamine as compared to rats that were 
forcefully administered the drug. This result suggests that sigma-1 receptor might be involved in 
the motivational aspect of methamphetamine self-administration rather than the acute stimulant 
effect of the drug121. In a later study sigma-1 receptors were found to be upregulated and co-
expressed with dopamine (D1) receptors in the olfactory bulb region of brain in rats self-
administering methamphetamine122.  In a recent study, a sigma-1 receptor agonist has been 
shown to attenuate and enhance the effect the methamphetamine suggesting that some effect of 
methamphetamine may be mediated by sigma-1 receptors123. Hence, sigma receptors are valid 
targets for developing pharmaceutical agents for the treatment of cocaine and methamphetamine 
abuse as well as diagnostic agents for brain imaging. 
MDMA (ecstasy) (1.10, Fig. 1.1) shows higher preference for the sigma-1 subtype as compared 
to the sigma-2 subtype. The sigma-1 receptor antagonist, BD-1063, attenuated the locomotor 
stimulant effects of MDMA in a dose dependant manner124. The sigma-1 receptor has also been 
implicated in the behavioral effects of ethanol. Sigma-1 receptor antagonist, BD-1047 (1.20, Fig. 
1.3), was found to attenuate the behavioral and motivational effects of chronic ethanol 
consumption in mice125. In another study, the sigma-1 receptor antagonist, BD-1063 (1.21, Fig. 
1.3), was found to reduce ethanol self-administration and reinforcing effects of ethanol in two 
different models of excessive ethanol intake126. Ethanol does not interact with sigma receptors 
but based on the above studies it has been hypothesized that sigma-1 receptor might be involved 
in neuroadaptive mechanisms that lead to chronic ethanol abuse.   
Sigma-1 Receptors: Analgesia 
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Sigma receptors are expressed in the central nervous system (CNS) in areas that control 
nociception such as the superficial layer of the spinal cord and dorsal horn, the periaqueductal 
gray matter, the locus ceruleus and rostroventral medulla24,127. Sigma receptor ligands alone were 
found to be ineffective in alleviating pain in animal models of acute nociception. However, 
sigma-1 receptor antagonists such as haloperidol were able to enhance analgesia induced by 
opioid receptor agonists128,129. Similar results were obtained in sigma receptor knockout 
mice130,132 and mice treated with sigma-1 receptor antisense oligodeoxyneucleotides131. Sigma-1 
receptor knockout mice as well as mice systemically administered with haloperidol and its 
metabolites had a higher tolerance for pain in both phases of formalin induced pain132-134. 
However, intrathecally administered sigma-1 receptor antagonists BD-1047 (1.20, Fig. 1.3) and 
BMY-14802 (1.23, Fig. 1.3) were able to attenuate only the second phase of pain induced by 
hind paw formalin injection135. This behavior has been attributed to the ability of sigma-1 
receptor to modulate the response of NMDA receptors in the spinal cord. In a recent study it was 
demonstrated that sigma-1 receptor agonists are able to enhance NMDA induced pain via 
phosphorylation of NMDA subunit NR1 in the dorsal horn of spinal cord. The expression of 
pNR1 was significantly reduced by the sigma-1 receptor antagonist BD-1047 (1.20, Fig. 1.3)136. 
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Fig. 1.3 Sigma-1 receptor ligands cited for their role depression. 
Sigma-1 Receptors: Depression 
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Sigma-1 receptors have been implicated in the pathophysiology of depression based on several 
lines of evidence such as: 
i. Antidepressants such as fluvoxamine (1.5, Fig. 1.1), fluoxetine, sertraline (SSRI), 
clorgyline (MAO inhibitor) have moderate to high affinity for sigma-1 subtype74,138. 
ii. Sigma-1 agonists like SA4503 (1.17, Fig. 1.3), pentazocine, JO-1748 (1.19, Fig. 1.3) and 
SKF-10,047 (1.1, Table 1.1) have been found to be effective antidepressants when tested 
in various behavioral models of depression139-140. 
Sigma-1 receptor agonists DHEAS (1.12, Fig. 1.2), PRE-084 (1.18, Fig. 1.3) , SKF-10,047 (1.1, 
Table 1.1) have demonstrated antidepressant activity in forced swim, tail suspension and 
conditioned fear stress test. Their anti-depressant action was blocked by the sigma-1 receptor 
antagonist NE-100. The sigma-1 receptor agonist igmesine (JO-1748) (1.19, Fig. 1.3) has shown 
antidepresant activity in the olfactory bulbectomy (OBX) depression model141. The compound 
showed statistically significant results in phase-I clinical trials however its development was 
discontinued due to marketing reasons. The pre-clinical and clinical data suggests that sigma-1 
receptor ligands have a potential to be developed as antidepresssant medication. 
Sigma-1 receptors: Cancer 
Sigma-1 receptors are overexpressed in Human SH-SY5Y neuroblastoma cells, NCI-H1299 lung 
tumor cells, breast cancer cells and in Caco-2 cell lines. Sigma-1 receptor antagonists BD-1047 
(1.20, Fig. 1.3), BD-1063 (1.21, Fig. 1.3), reduced haloperidol (RHAL) (1.22, Fig. 3) and 
rimcazole (nonselective sigma-1 ligand) have shown significant tumoricidal activity. It is 
believed that the anti-cancer activity is mediated though capsase activation leading to increase in 
cytoplasmic calcium resulting in cellular apoptosis. Sigma-1 receptor agonists, SKF-10,047 and 
(+)-pentazocine were able to attenuate the supressant effect of antagonists142. Sigma-1 receptor 
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antagonists haloperidol, reduced haloperidol and progesterone were shown to inhibit cell growth 
in a dose dependant manner in human breast cancer cell lines32. At a higher concentration sigma-
1 antagonists, haloperidol and RHAL (1.22, Fig. 1.3) induce cell death by causing G1 arrest in 
mouse and human melanoma cells143. Selective sigma-1 receptor agonist 4-(N-benzylpiperidine-
4-yl)-4-iodobenzamide (4-IBP) (1.25, Fig. 1.3) was found to decrease cellular proliferation in 
human A549 NSCLC and PC3 prostrate cancer cells in a dose dependant manner144. Sigma-1 
receptor agonists, PRE-084 (1.18, Fig. 1.3) and cocaine were found to promote tumor cell 
growth by inducing the expression of interleukin-10 at the tumor site. The tumor growth could be 
prevented by administering sigma-1 antagonists or IL-10 neutralizing antibodies145,146. 
Sigma-1 receptors: Immunity 
The expression of σ-1 receptors in immune systems is well established. Sigma receptor ligands 
SR31747A61-64 (1.26, Fig. 1.3) and SSR125329A65 (1.27, Fig. 1.3) show potent 
immunomsuppressive and antiproliferative activity on lymphocyte. SR31747A (1.26) was found 
to inhibit pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 and INF-γ and increase the 
expression of anti-inflammatory cytokines IL-10147-150,164. The sigma-1 receptor agonist, PRE-
084 was found to inhibit inflammatory response after stroke-induced brain injury in rats. The 
anti-inflammatory effects of PRE-084 (1.18, Fig. 1.3) were attributed to its dual effect on 
cytokine release as observed in SR31747165. Cocaine was found to enhance HIV replication in 
microglial cell cultures in a concentration dependant manner. The cocaine mediated up-
regulation of HIV expression was blocked by sigma-1 receptor antagonists, BD-1047 (1.20, Fig. 
1.3)166,167. 
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1.5 Sigma-2 (σ-2) receptors                       
The protein corresponding to sigma-2 sites has not yet been cloned. In comparison to the sigma-1 
receptor, it appears to be slightly smaller in size (Table 1.2)151,152. Pharmacological experiments 
reveal that sigma-2 receptors may be lipid raft proteins that affect calcium signaling via 
sphingolipid products153,154. Unlike sigma-1 receptors, sigma-2 receptors do not appear to 
translocate. Both the subtypes of sigma receptors are highly expressed on tumor cell lines from 
human and rat cancer tissues. However, malignant tumor cells show a higher expression of 
sigma-2 receptors than quiscent tumor cells31. The over expression of sigma-2 receptors in 
human and murine tumors suggests that sigma-2 receptors may be a biomarker of tumor cell 
proliferation29,155-159. 
Sigma-2 receptor specific ligands WC-26168 (1.28, Fig. 1.4) and SV119 (1.29, Fig. 1.4)169 have 
been found to induce capsase-3 dependant cell death in mice and human pancreatic cell lines170.  
SV119 (1.29) and SW43 was also found to agument the tumoricidal activity of gemcitabine and 
paclitaxel in animal models of pancreatic cancer171,179. In contrast sigma-2 receptor selective 
agonists like siramesine (1.17), CB64D (1.31) and CB184 (1.32) induce apoptosis by a p53 and 
caspase-independent mechanism172,173. Apoptosis may be induced in tumor cells by regulation of 
the sphingolipid biosynthetic pathway154. Evidence also suggests that this receptor is linked to 
potassium channels and intracellular calcium release in NCB-20 cells11. Also, studies using 
sigma-2 selective ligands such as CB64D (1.31), CB184 (1.32), and ibogaine (1.33, Fig. 1.4) as 
well as non-selective sigma-2 ligands such as haloperidol (1.4, Fig. 1.1)  induced growth arrest 
and cell death in various tumor cell lines172,174,175,181. 
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                        Figure 1.4: Sigma-2 Receptor ligands with cytotoxic activity. 
PB28 (1.34, Fig. 1.4) a sigma-2 agonists and sigma-1 antagonist was found to potentiate 
cytotoxicity of existing chemotherapeutic agents by decreasing the expression of a P-
glycoprotein, that acts as an efflux pump for classical antitumor agents176. Thus, sigma-2 
agonists, with their capability to induce apoptosis, may act as potential antineoplastic agents. In 
contrast, sigma-2 antagonists have been reported to attenuate convulsions caused by cocaine177, 
178,182. Due to the lack of availability of detailed protein structural information and truly selective 
sigma-2 ligands, the pharmacological characterization of the sigma-2 subtype with regard to its 
mechanism of action and biochemical role in various biological effects has been very limited. 
However, with the help of photoaffinity probe WC21 the putative sigma-2 receptor binding site 
has been identified as PGRMC1 (progesterone receptor membrane component180. 
1.6 Early Development of Sigma Ligands 
After the discovery of sigma receptors  as a unique class of receptor in 1970, medicinal 
chemistry research peaked in the year 1993. Early reports in ligand development suggested that 
diverse classes of compounds interact with sigma receptors. These classes include various 
antipsychotic agents (butyrophenones, phenothiazines, thioxanthenes), anxiolytics, tricyclic 
antidepressants, anticholinergics, antineoplastic agents, drugs of abuse such as cocaine (1.8, Fig. 
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1.1), methamphetamine (1.9, Fig. 1), methylenedioxy- methamphetamine (MDMA) (1.10, Fig. 
1.1), phencyclidine and steroid hormones such as progesterone (1.11, Fig. 1.2), DHEA (1.12, 
Fig. 1.2) and pregnenolone183-185. A diverse chemical structural class of compounds having good 
affinity to sigma receptors were reported, which included  haloperidol (1.4, Fig. 1.1)186, non 
competitive NMDA receptor antagonist, eliprodil (1.38, Fig. 1.5), phenylalkylpiperazine (1.39, 
Fig. 1.5)187, phenylalkylpiperidine (1.40, Fig. 1.5)187, octahydrobenzo [f]quinoline (1.41, Fig. 
1.5)188, BD1008 (1.42, Fig. 1.5)189 and alkylamines (1.43, Fig. 1.5)190. 
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Figure 1.5: Structural classes of compounds having affinity for sigma receptors. 
As sigma receptors bind to compounds with diverse structures it was assumed that sigma 
receptors might have good flexibility at the active site, or, alternatively, these diverse agents 
might be sharing some common features. It was later confirmed by studies that the presence of 
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the basic nitrogen is a requirement for sigma receptor affinity78. Due to the diverse structural 
range of compounds binding to sigma receptors with low selectivity, ligand design mostly 
focused on identification of novel ligands with good selectivity in an effort to develop probes to 
explore the unknown biological functions exhibited by sigma receptors. Initial identification of 
structural elements for sigma receptor affinity started by evaluation of structural determinants 
from various drug classes191. It was observed that the opioids (1.44, 45; Fig. 1.6) and morphinans 
(1.46, 1.47; Fig. 1.6) which are more bulky, having A, B and C rings, had lower affinity. 
However, smaller benzomorphans (1.48, 1.49; Fig. 1.6) which lacked the  C ring had higher 
affinity exhibiting the importance of lipophilicity of certain portions of the molecule. Similarly, 
4-N-substituted piperidines such as fentanyl (1.50, Fig. 1.6) and meperidine (1.51, Fig. 1.6) also 
exhibited higher affinity for σ receptors than bulky opioids and morphinans. 
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    Figure 1.6: Sigma receptor affinity of opiates. 
Variations in the receptor affinity were also related to stereochemistry. Generally, (+) 
enantiomers with (S) stereochemistry were found to have higher affinity for sigma receptors. For 
example, (S)(+)-apomorphine (1.52, Fig. 1.7) had higher affinity than (R)(-)-apomorphine (1.53, 
Fig. 1.7)191. In addition, in the morphinan series, the (+) isomer, dextrallorphan (54, Fig. 7) had 
higher affinity than the (-) isomer, levallorphan (1.43, Fig. 1.7)191. 
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Figure 1.7: Effects of stereochemistry on the sigma receptor affinity.  
 
It was evident that the primary pharmacophore requirement at sigma sites was substituted 
piperidine ring, which was embeded in most of the ligands. Affinity was markedly influenced by 
N-alkyl substituents with more lipophilic substituents affording greater affinity to sigma receptor 
binding 191. Subsequently, after the classification of σ receptors into two subtypes, Gilligan et al. 
identified a lead compound (Fig. 1.8) with good selectivity for sigma receptors over dopamine 
D2 sites (Ki, σ = 6 nM, dopamine D2 IC50 >1000 nM, phencyclidine receptors Ki >10000 nM)192. 
The lead compound was divided into four pharmacophore regions, namely: 1) distal aromatic 
ring (A); 2) space between heterocycle and distal aromatic ring (B); 3) substituent on nitrogen 
heterocycle (C); 4) nitrogen heterocycle (D) as shown in Fig. 1.8. The structure activity 
relationship of the lead compound showed that these four pharmacophore elements contribute to 
optimal sigma receptor binding. The selectivity over dopamine (D2) and the 5-HT2 receptor was 
governed by the chemical nature of the N-susbtituent and its distance and orientation from basic 
nitrogen 192.  
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Figure 1.8: Structure of phenylpiperidine lead molecule 
Glennon and Ablordeppy later confirmed that rigid benzomorphan is not an essential 
structural requirement for high sigma receptor affinity. The non-rigid substructure 1-phenyl-
aminopropane (1.57, Fig. 1.9) of benzomorphan (1.56, Fig. 1.9) still retained affinity to sigma 
receptors193. A flexible compound (1.58, Fig. 1.10) with an increased number of rotatable bonds 
exhibited high affinity for sigma receptors (Ki = 2.6 nM)194.  
N
H
H3C
OH
CH3
H2C
 
N
H
CH3
CH3
 
1.56 1.57 
Figure 1.9. Rigidity and sigma receptor affinity 
    On further structure activity relationship with compound (1.58, Fig. 1.10) it was observed that 
a phenylpentylamine moiety was important for high affinity. Both secondary and tertiary amines 
showed good affinity, with tertiary amines′ substituent’s not much larger than the methyl group. 
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Phenyl rings were not considered significant, because their replacement with 
hydrophobic cyclohexyl group (1.59, Fig. 1.11) exhibited high affinity to sigma receptor (Ki, σ = 
2.6 nM)194. The terminal amine was found to tolerate hydrophobic substitution 1.60 (Ki, σ-1 = 
2.4 nM), revealing the presence of a hydrophobic pocket in the sigma-1 receptor. 
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Figure. 1.11. Effect of aromaticity on sigma receptor affinity. 
 
The significance of the basic nitrogen was determined by synthesis and evaluation of 
compounds 1.61 and 1.62 (Fig. 1.12). Compound 1.62, without the basic piperidine nitrogen 
exhibited reduced affinity (Ki, σ-1 > 36, 000 nM) in comparison to 1.61 (Ki, σ-1= 38 nM), 
indicating the importance of basic nitrogen for sigma-1 receptor binding78. 
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Figure. 1.12. Importance of basic nitrogen. 
The significance of the basic nitrogen was further substantiated by evaluation of compound 1.64 
(Fig. 1.13) in the quaternized form. Compound 1.64 showed decreased affinity (Ki, σ-1= 242 
nM) in comparison to the non-quarternized compound 1.63 (Fig. 1.13) (Ki, σ-1= 5.1 nM)195. 
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Figure. 1.13. Importance of basic nitrogen. 
In the case of piperazines, it was observed that basic nitrogen attached to the alkyl chain was 
significant for sigma receptor binding. Absence of a second nitrogen atom increased the affinity 
by 20-fold as shown by compounds 1.65 (Fig. 1.14) (Ki, σ-1= 1.4 nM) and 1.66 (σ-1 = 0.07 
nM)196. 
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Figure. 1.14. Importance of basic nitrogen 
Bulky steroids such as progesterone (1.10, Fig. 1.2), 3β-hydroxy-5androsten-17-one 
[dehydroepiandrosterone (DHEA)] and pregnenolone, which lack basic nitrogen exhibited an 
affinity of 300 nM, 1 µM, and 3 µM, respectively, for the sigma-1 receptor80. The 
cyclopentanoperhydrophenanthrene steroid nucleus was found to embed an aryl ring and a 
carbon chain of five atoms in the rigid structure. The introduction of basic nitrogen in the form of 
a piperidine ring led to compound 1.67 with high affinity for both the subtypes (Ki, σ-1 = 66 nM, 
Ki, σ-2 = 24 nM)196. 
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Figure. 1.15 Cyclopentanoperhydrophenanthrene steroid nucleus  
Based on the above study, three point pharmacophore model containing two hydrophobic 
residues linked by a basic amine was developed by Glennon and Ablordeppy as shown in Fig. 
1.16 196,197. 
 
 
 
Figure 1.16: Schematic representation of Glennon/Ablordeppey pharmacophore  
                 model for sigma-1 receptor ligand 196. 
 
The salient features of the pharmacophore were: 
 
`x´ methylene linker 
• Can be linear/branched (unsaturation/cyclic structures) 
• Can contain functionalities such as ketone, amino or ester groups 
• Highest affinity with alkyl chain (5 carbon chain optimal) 
Terminal amine 
• Can be secondary, tertiary or quaternary 
• Limited bulk tolerated with tertiary/quaternary amines 
Hydrophobic regions 
• Bulk tolerance allows the “x” group to be longer or shorter than five atoms 
For Ar-X5-N  
• Ar not required to be aromatic function 
• Ar interaction with receptor is hydrophobic 
A five point pharmacophore model consisting of four hydrophobic features and one positive 
ionizable group was developed by Moebius et al. It was then used for the screening and retrieval 
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of new hit compounds from drug and metabolite database198. Several other pharmacophore 
models have been proposed for sigma-1 and sigma-2 receptor199-203 but they explain the binding 
characteristic of one class of compounds and hence cannot be used for database mining. 
1.7 Sigma-1 Selective Ligands 
Compound E-5842 (1.68, Fig. 1.17), a haloperidol derivative, had an affinity of 4 nM for 
sigma-1 receptors and 55 fold selectivity over sigma-2 receptors. However, E-5842 also had 
moderate affinity for α2B adrenergic (Ki = 89 nM), α1A adrenergic (Ki = 119 nM), α1B adrenergic 
(Ki = 116 nM) receptors and low affinity for dopamine D2 (Ki  >1000 nM), D3 (Ki = 418 nM) 
receptors or 5-HT1A (Ki = 460 nM) and 5-HT2 (Ki = 817 nM) receptors 204-206. N-(1-
benzylpiperidin-4-yl)phenylacetamides (1.69, Fig. 1.17) having similar structural skeleton to E-
5842, had a selectivity of 187 fold over sigma-2 receptors with no affinity for dopamine D2 (Ki 
>1000 nM), D3 (Ki >1000 nM) receptors207. NE-100 (1.70, Fig. 1.17), a dipropylamine class of 
compound exhibited  high affinity for sigma-1 receptors with an IC50 of 1.54 nM and moderate 
selectivity of 55 fold over sigma-2 receptors208. A simple achiral monoamine, AC915 (1.71, Fig. 
1.17), showed high affinity for sigma-1 receptors  (Ki = 4.89 nM) and excellent selectivity of 
>2040 fold over sigma-2 receptors209. Similarly, (+)-pentazocine (1.72, Fig. 1.17), which is used 
as a sigma-1 receptor radioligand in binding assays, has 500-fold selectivity over sigma-2 
receptors209. 1′-benzyl-3,4-dihydrospiro[2H-1-benzothiopyran-2, 4′-piperidine] (Spipethane) 
(1.73, Fig. 1.17) has been shown to possess 832 fold selectivity for sigma-1 receptors with low 
affinities for other receptors such as dopamine D2 (Ki = 10,400 nM), α1A adrenergic (Ki >10,000 
nM),  α1B adrenergic (Ki >10,000 nM), 5-HT2 (Ki = 7,600 nM), M2 (Ki = 10,800 nM), M3 (Ki 
>10,000 nM), opioid (Ki >10,000 nM) and PCP (Ki >10,000 nM) receptors210. 1’-benzyl-3-
methoxy-3H-spiro[isobenzofuran-1,4’-piperidine] (1.74, Fig. 1.17) has shown 1000 fold 
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selectivity for sigma-1 receptors211 
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1.74, 1’-benzyl-3-methoxy-3H-
spiro[isobenzofuran-1,4’-piperidine] 
Ki, σ-1 = 1.14 nM, σ-2 = 1280 nM 
1.75, N,N-dibutyl-3-(4-
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Ki, σ-1 = 0.3 nM, σ-2 = 404 nM 
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σ-2/σ-1 = 1130 σ-2/σ-1 = 1347 
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σ-2/σ-1 > 1000 
1.77, PD144418 
Ki, σ-1 = 0.08 nM, σ-2 = 1377 nM 
σ-2/σ-1 > 1000 
 
 
Figure 1.17: Sigma-1 selective ligands. 
Fenpropimorph derivatives such as N,N-dibutyl-3-(4-nitrophenyl)propylamine (1.75, Fig. 1.17) 
has shown high affinity (Ki = 0.3 nM)  and selectivity for sigma-1 receptors212. 3-(2-(azepan-1-
yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one (1.76, Fig. 1.17) has shown high affinity (Ki = 0.56 
nM) and over 1000 fold selectivity for sigma-1 receptor. This compound was also tested against 
a panel of receptors including dopamine (D1 and D2), 5-HT, α1, α2, β1, β2, H1, H2 and was found 
to have only moderate affinity for a 2 (Ki = 205 nM) and H1 (Ki = 311 nM) receptors213. An 
isoxazole derivative, PD144418 was identified as selective sigma-1 receptor ligand (Ki = 0.08 
nM) devoid of any off target activity. In vitro study using rat cerebral slice, the ligand reversed 
the NMDA induced increase in cGMP suggesting a role of sigma-1 receptors in glutamine-
induced actions214. 
1.8 Sigma-2 Selective Ligands 
The search for selective sigma-2 ligands was initiated with benzylidene phenylmorphans215 
such as CB-64D (1.31, Fig. 1.18) and CB-184 (1.32, Fig. 1.18), which possesed the aryl 
morphinan skeleton of opioids that exhibited low nanomolar affinity for sigma-2 receptors and a 
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selectivity of 185 and 555 fold respectively over sigma-1 receptors. However, a drawback of this 
class of compounds was that they displayed potent in vivo µ opioid receptor agonism 172,173,216. 
Ibogaine (1.33, Figure 1.18), a psychoactive indole alkaloid from the root of the African shrub 
Tabernanthe iboga, also demonstrated good selectivity for sigma-2 receptors over sigma-1 
subtype. However, ibogaine also had interactions with an array of other receptors and hence was 
not suitable to explore the sigma-2 effects in vivo217,218. Spiro[2]benzopyran-1,4′-piperidine 
(1.77, Fig. 1.18) has been shown to possess high affinity (IC50 = 0.90 nM) and 59 fold selectivity 
for sigma-2 receptors219. A tropane-based analog (1.78, Figure 1.18) had high affinity for sigma-
2 receptors (Ki = 5 nM) and 500 fold greater selectivity over sigma-1 receptors220. (±) SM-21 
(1.79, Fig. 1.18), also a tropane-containing analog, had good affinity for sigma-2 receptors (Ki = 
67.5 nM)221 and acts as an antagonist in behavioral assays222. Siramesine (Lu-28-179);1′-[4-[1-
(4-fluorphenyl)-1H-indol-3-yl]butan-1-yl]spiro[isobenzofuran-1(3H),4′-piperidine] (1.80, Fig. 
1.18), a piperidine analogue, had a subnanomolar affinity for sigma-2 receptors (Ki = 0.12 nM) 
with a selectivity of 140 fold over sigma-1 receptors. In addition, siramesine had low affinities 
for dopamine D2 (IC50 = 800 nM), α1 (IC50 = 330 nM),  5-HT1A (IC50 = 21,000 nM) and 5-HT2A 
(IC50 = 2000 nM) receptors223. Interestingly, compound 1.81 had high affinity for sigma-2 
receptors (Ki = 8.2 nM), low affinity for dopamine D2 (Ki = 2200 nM), D3 (Ki = 627 nM) 
receptors and 1570-fold selectivity over sigma-1 receptors. Compound 1.81 is one of the most 
highly selective sigma-2 ligands reported to date224. These synthesized selective sigma-2 ligands 
can play an important role as tracers for in vivo visualization of sigma-2 receptors, as biomarkers 
of tumor proliferation225, and for imaging tumor diagnosis by PET imaging. 
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            Figure 1.18: Sigma-2 selective ligands 
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1.9 Sigma Receptor Radioligands and PET Imaging Agents 
Selective radiolabelled probes find tremendous application in determining binding 
characteristics of specific sites through in vitro and in vivo biological studies and to elucidate the 
role of receptors under consideration.  
1.9.1 Sigma-1 Receptor Radioligands and PET Imaging Agents 
(+)-Pentazocine (1.60), which exhibited high affinity and selectivity for sigma-1 receptor (Ki, σ-
1 = 3.1 nM; Ki, σ-2=1542 nM; σ-2/σ-1=500), was developed into an enantiomerically pure 
radioligand (1.82, Fig. 1.11)226. However, pentazocine in particular is not readily available due to 
the complex synthesis of the tricyclic system. 
NH3C
CH3
H
H3C
OH
CH3
H33H
 
 
1.82, [3H]-(+)-Pentazocine 
 
Figure 1.19. Radioligand for Sigma-1 receptor. 
Positron imaging tomography (PET) is a noninvasive technique that is widely used to study 
sigma-1 receptor expression in mammalian brain as well as to quantify receptor occupancy and 
physiological response. The most widely used radiotracer is 11C labeled 1-(3,4-
dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine ([11C]SA4503) 1.83 (Fig. 1.20)227. This 
compound is a sigma-1 agonist and it has been used in the PET imaging of sigma-1 receptors in 
monkey228,229 and human brain230. 18F-1-(3-Fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine 
[18F]FPS (1.84) has subnanomolar affinity and moderate subtype selectivity for sigma-1 
  50 
receptors. This radioligand has been evaluated in rat brain and tumor bearing animal models231. 
Preclinical acute toxicity studies in rodents and beagle dog suggest that the radioligand is safe for 
human administration at a maximum dose of 5 mCi and 2.8 µg/injection232. A sigma-1 receptor 
selective fluorine-18-labeled SA4503 (1.85) analogue was synthesized by Ishiwata et al. 
Biodistribution, kinetic and metabolism studies of this radioligand were performed in rodents 
and rhesus monkeys233 however, no human studies have been reported. Spirocyclic sigma-1 
receptors ligand WMS-1813 (1.86) with high affinity (Ki = 1.4 nM) and excellent subtype 
selectivity was labelled with 18F and evaluated in experimental animals. Radiotracer showed high 
uptake in the brain (∼4% ID/g)234. 
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Figure 1.20. PET imaging agents for sigma-1 receptor. 
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1.9.2  Sigma-2 Receptor Radioligand and PET Imaging Agents 
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1.89, [3H]PB28 
Ki, σ-1 = 13.6 nM; σ-2 = 0.34 nM 
σ-1/σ-2 = 40 
Figure 1.21. Radioligand for sigma-2 receptor. 
Sigma-2 receptor-selective radioligands are less common. A non subtype selective [3H]-DTG 
(1,3-di(2-tolyl)guanidine) 1.87 (Fig. 1.21) that has a mixed affinity for both sigma-1 and sigma-2 
receptors is used in the presence of (+)-pentazocine (to block binding to σ-1 sites)235. Other 
tritium labeled radioligands are [3H]RHM-1 (1.88)117, [3H]PB28 (1.89)236 and [3H]Lu 28-179 
(Siramesine)240.  
Sigma-2 receptors are over expressed on malignant tissues therefore sigma-2 selective 
radiotracers may be clinically useful in tumor imaging. One of the sigma-2 selective radiotracer 
is 5-76Br-bromo-N-(4-(3,4-dihydro-6,7-dimethoxy-isoquinolin-2(1H)-yl)butyl)-2,3-dimethoxy- 
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benzamide 1.90 (Fig. 1.22). This compound has been studied in the mice EMT-6 tumor 
models237.  
OCH3H3CO
76Br
HN
O
N
OCH3
OCH3  
H3CO
I
HN
O
N
OCH3
OCH3
O
18F
 
 
1.90 
Ki, σ-1 = 12,900 nM; σ-2 = 8.2 nM 
σ-1/σ-2 = 1573 
1.91 
Ki, σ-1 = 2150 nM; σ-2 = 0.26 nM 
σ-1/σ-2 = 8190 
H3CO
125I
HN
O
N
OCH3
OCH3
O
F
 
1.92 
Ki, σ-1 = 2150 nM; σ-2 = 0.26 nM 
σ-1/σ-2 = 8190 
Figure 1.22. PET and SPECT imaging agents for sigma-2 receptor. 
Fluorine-18 labeled radiotracers N-(4-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)butyl-2-
(2-[18F]-fluoroethoxy)-5-iodo-3-methoxy benzamide 1.91 238 and its structurally similar I-125 
labeled analogue N-(4-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)butyl-2-(2-
fluoroethoxy)-5-[125I]iodo-3-methoxy benzamide 1.92239 (Fig. 1.22) have been examined in 
ETM-6 tumor mouse models as potential PET and SPECT probes respectively. 
Sigma-2 receptors have been found to be up-regulated in metastatic tissues. Therefore, sigma-2 
receptor selective radioligands should prove to be useful diagnostic tools for the assessment of 
malignant state of tumors.  
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CHAPTER 2: BIOTRANSFORMATION OF XENOBIOTICS 
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2.1 Introduction 
Conversion of a lipophilic xenobiotic to a water-soluble form occurs by chemical process known 
as biotransformation, which is catalyzed by enzymes in liver and other body tissues. Without 
biotransformation extremely lipophilic xenobiotics will remain in the body longer than intended 
leading to drug toxicity. The reactions catalyzed by biotransforming enzymes are classified into 
two types: Phase I and Phase II metabolism. Phase I metabolism involves introduction of polar 
functional groups (OH, COOH, NH2, SH etc.) into the xenobiotic which results in a small 
increase in their hydrophilicity. Phase II biotransformation reactions include glucoronidation, 
acetylation, methylation, conjugation with glutathione, glycine or glutamic acid. Phase II 
biotransformation leads to substantial increase in the hydrophilicity of xenobiotic promoting 
rapid excretion in urine. Drug metabolism leads to the deactivation of molecules in such a way 
that they are unable to interact with the receptor and elicit a desired pharmacological response. 
Metabolism generally has a favorable consequence of elimination of a xenobiotic from the body 
within a stipulated time frame. However, in certain instances metabolism may lead to 
undesirable effects: 
1. It may lead to generation of products that have undesirable biological activities such as 
toxic and carcinogenic effects. 
2. Bioactivation may decrease the drugs half-life and its concentration in the blood. 
Exposure-activity-toxicity relationship study is an integral component in the drug discovery 
process. Metabolite identification and characterization in the early stage of drug discovery is 
crucial to predict the toxicological potential of the parent drug in humans.   
2.2 Biotransformation and Intrinsic Clearance 
Intrinsic clearance is a measure of enzymatic activity towards a drug and it is independent of 
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hepatic blood flow and protein binding. Intrinsic clearance provides a good correlation between 
the in vitro metabolism data and in vivo hepatic clearance241.  
Clint = Vmax/Km = Rate of metabolism/Ce 242  
Vmax = Maximum rate of metabolism; Km = Michaelis-Menton constant 
Ce = Concentration of drug at enzyme site = Free concentration of the drug in the liver 
Studies have shown that in vitro metabolism data (Vmax) can be used to calculate the in vivo 
hepatic clearance by using appropriate scaling factors for liver microsomes and hepatocytes. 
Liver microsomes are the most commonly used in vitro models for predicting hepatic clearance. 
Other in vitro systems include isolated hepatocytes, 9000g supernatant (S9) fractions, 
recombinant CYP isozymes, liver slices and in situ gastrointestinal/liver single-pass perfusion 
preparations243. Although intrinsic clearance provides a reasonable correlation between in vitro-
in vivo hepatic clearance there are other factors that may influence in vivo metabolic fate of the 
drug such as: self-inhibition of drug metabolizing enzymes, saturable metabolism, nonlinear 
pharmacokinetics and drug-drug interactions. 
2.3 Biotransformation Enzymes 
Xenobiotic biotransforming enzymes have broad substrate specificity and are widely distributed 
in the body. In mammals liver is the principle source of many biotransformation reactions. While 
in liver the enzymes involved in biotransformation are primarily located in the endoplasmic 
reticulum, cytosol or in lesser amount in the mitochondria and lysosomes.  
2.3.1 Cytochrome P450 mediated biotransformation 
Cytochrome P450 enzymes are involved in oxidative metabolism of wide variety of endogenous 
molecules and xenobiotics. Cytochrome P450 enzymes are responsible for the introduction of 
polar functional groups into a molecule that are suitable for conjugation reactions. The P450 
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enzymes are widely distributed in the endoplasmic reticulum of liver, kidney, lungs and gut244. 
The enzymes are capable of catalyzing the hydroxylation of saturated hydrocarbons, epoxidation 
of double bonds, oxidation of aromatics, oxidation of heteroatoms, dealkylation reactions, 
oxidation of aldehydes and dehydrogenation reactions245. Cytochromes are electron-transport 
proteins that contain a heme-prosthetic group.  Iron alternates between ferrous and oxidized 
(ferric, Fe3+) state during electron transport process. The catalytic cycle of cytochrome P450 
enzyme is triggered when the substrate molecule enters the active site of the enzyme and 
displaces the water molecule. The next step is the sequential transfer of electron from NADPH-
cytochrome 450 reductase to Cyp P450. This step involves reduction of Fe(III) to its ferrous 
form followed by reaction of triplet dioxygen with the ferrous Cyp P450 to form Fe3+—O2-–—
substrate species. A second electron transferred from the flavoprotein results in the generation of 
a Fe3+—O22- substrate complex. This results in the formation of an iron-peroxo intermediate 
which is then protonated by threonine.  
The overall reaction can be summarized as: 
NADPH + H+ + O2 + RH º NADP+ + H2O + ROH 
CYP3A4 is the major cytochrome P450 isoform present in the hepatocyte and is responsible for 
60-70% of all biotransformation reactions in humans. Other major isoforms of the enzyme are 
CYP1A2, 2A6, 2B6, 2C, 2D6 and 2E1246. Cytochrome P450 enzymes are also capable of 
catalyzing reductive reactions particularly under anaerobic conditions247. For example 
dehalogination of alkyl halides and reduction of azo and nitro compounds248.  
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Fig 2.1: Reductive reactions of cytochrome P450: (A) Azo reduction of prontosil; (B) Nitro 
reduction of chloramphenicol.  
2.3.2 Flavin-Containing Monooxygenase (FMO) 
FMO’s are microsomal enzyme systems that are capable of oxygenating xenobiotics containing 
soft nucleophiles such as nitrogen, sulfur, phosphorus and selenium249-251. FMO is a flavoprotein 
containing a tightly bound flavin adenine dinucleotide (FAD) cofactor and a glycine rich binding 
domain for FAD and NADPH. FMO utilizes the reducing equivalents of NADPH to reduce one 
atom of molecular oxygen into water and the other atom is used to oxidize the substrate252, 253. 
Flavin-containing monooxygenases have five functional families; FMO3 and FMO5 are 
expressed in human liver microsomes; FMO1 in human kidney, FMO2 in human lungs and 
FMO5 in human intestine254. Unlike P450 enzymes, FMO’s do not require reductases to transfer 
electrons from NADPH. Another distinction is that FMO system is not induced by xenobiotics. 
In humans FMO’s are capable of catalyzing the oxidative metabolism of several functional 
groups such as amines, hydrazines, thiols, sulfides, thiocarbamates, thioethers and compounds 
containing selenium and phosphorus atoms253. 
  58 
2.3.3 Molybdenum Hydroxylases 
Molybdenum hydroxylases is a family of metalloflavoproteins that includes aldehyde oxydase 
(AO), xanthine dehydrogenase (XDH) and xanthine oxidase (XOD). The enzyme is a 
homodimer and it consists of a central FAD containing region, molybdenum cofactor and a 
substrate-binding site and two nonidentical iron-sulfur redox centers. Molybdenum hydroxylases 
are cytosilic enzymes and ther are highly expressed in liver. Small amounts of XOR are also 
found in small intestine and lipid globules255. Molybednum hydroxylases are implicated in the 
biotransformation of following category of therapeutic agents256: 
i. Anticancer Drugs: Antimetabolites (5-fluorouracil, methotrexate), topoisomerase 
inhibitors and immunosuppressants (6-mercaptopurine, azathioprine). 
ii. Antivirals: Famciclovir is a prodrug that is activated to penciclovir by XOR. 
iii. CNS agents: AO ‘s are responsible by the metabolism of CNS acting agents such as 
neurotoxins (MPTP), sedative-hypnotics (zaleplon), anticonvulsants (zonisamide). 
iv. Antimalarials: Alkaloids such as quinine, quinidine, cinchonine and epiquinine. 
Molybdenum hydroxylases are also involved in the metabolism of several endogenous 
compounds such as pyridoxal, nicotinamide and retinaldehyde. 
2.3.4 Phase II Biotransformation Enzymes 
Phase II biotransformation enzymes are generally located in the cytosol or microsomes (e.g. 
UDP-glucuronosyltransferase). Glucuronidation is the main reaction in the biotransformation of 
xenobiotics in most of the mammalian species. Uridine diphosphate (UDP)-glycosyltransferases 
are a group of enzymes that catalyzes the transfer of sugar (glucoronic acid, glucose and xylose) 
to xenobiotics containing electron rich nucleophilic heteroatoms (O, N or S)257,258. In certain 
xenobiotics (e.g. sulfinpyrazone) the carbon atom is sufficiently nucleophilic to form C-
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glucuronides259. UDP-glucuronyltransferases (UGT’s) are located in the endoplasmic reticulum 
of hepatocytes, kidney, intestine, spleen and brain. Glucuronidation is responsible for over 30% 
of all drug metabolism during Phase II detoxification process260.  
Sulfate conjugation produces highly water-soluble sulfuric acid esters of xenobiotics. Sulfation is 
catalyzed by sulfotransferase enzymes that are primarily found in the liver, kidney, intestinal 
tract, platelets and brain. The cofactor for sulfation reaction is 3’-phosphoadenosine-5’-
phosphosulfate (PAPS). Sulfate conjugation involves transfer of sulfonate (SO3-) form the 
cofactor to xenobiotics such as phenols (acetaminophen), aliphatic alcohols (chloramphenicol), 
and aromatic amines (anilines)261,262. 
Acetylation is an important route of biotransformation for xenobiotics containing aromatic or 
aliphatic amines and hydrazine. The reaction is catalyzed by N-acetyltransferases and requires 
the cofactor acetyl-coenzyme A263. Glutathione conjugation and amino acid conjugation are 
other important enzymatic Phase II biotransformation reactions of xenobiotics.  
2.4 Strategies to Enhance Metabolic Stability 
There are two approaches to predict the metabolic liabilities of a compound: in vitro and in vivo. 
In vitro metabolism studies are performed to determine the type of metabolites as well as to 
quantify major metabolites. Some of the most popular in vitro systems are liver microsomes, 
isolated hepatocytes and liver slices. High throughput in vitro studies may be used to develop 
SAR around metabolic stability of a series of compounds. On the other hand in vivo metabolic 
study provides a comprehensive pharmacokinetic profile of a compound in living system in the 
early stage of drug discovery process. However, in vivo studies are time-consuming, have low-
throughput and suffer from inter specie differences. Several strategies have been used to modify 
the structure a compound to improve metabolic profile: 
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• Deactivation of aromatic rings towards oxidation by substitution with strong electron 
withdrawing groups (F, CF3, SO2NH2, SO3-). 
• Reducing size and lipophilicity. 
• Introduction of groups such as methyl and bulky groups such as N-t-butyl to prevent N-
dealkylation. 
• Replacing ester group with amides and introducing reverse amides in place of amides. 
• Replacing hydrogen with deuterium.  
• Introducing molecular constraints that are unfavorable for metabolic deactivation. 
• Avoiding phenolic functionality to prevent rapid glucuronidation.  
2.4.1 Reducing Lipophilicity 
The binding sites of major metabolic enzymes are lipophilic in nature and hence they prefer 
lipophilic substrates. One of the most successful strategies to improve the metabolic stability is 
to reduce the lipophilicity of the molecule. Lipophilicity is an important factor for drug receptor 
interaction. Metabolic stability can be improved without compromising the lipophilicity by 
introducing metabolically stable lipopholic groups. 
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Figure. 2.2. Reducing Lipophilicity 
Pyrazolopyrimidine analogue 2.6 (Fig. 2.2) was identified as a promising CRF-1 antagonist. 
However, this compound was highly lipophilic and exhibited poor metabolic stability in human 
liver microsome stability studies. Replacing one of the aryl methyl substituent with a methoxy 
group and replacing the secondary nitrogen substituents with C,C-dicyclopropylmethyl (2.7) not 
only reduced the lipophilicity but also retained the activity at the receptor264. 
Another approach to the reduction of lipophilicity is through the introduction of ionizable or 
polar groups. Piperidine-4-carboxamide derivative 2.8 (Fig. 2.3) was found to be a potent CCR5 
antagonist. The compound exhibited good pharmacokinetic profile in dogs however it suffered 
from rapid oxidative metabolism on the piperidine ring when tested in human liver microsomes. 
Replacing the methylsulfonyl group with carbamoyl group improved the metabolic stability 
while retaining the potency265. 
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Figure. 2.3. Reducing Lipophilicity by introducing Ionizable Groups. 
2.4.2 Blocking Metabolically Labile Sites 
Blocking vulnerable sites of a molecule by introduction of a stable atom such as a halogen or by 
replacing the site with a bioisostere is one of the approaches to deal with biotransformation.  
Piperidinopiperadine analogue 2.10 (Fig. 2.4) was identified as a potent CCR5 antagonist but it 
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exhibited poor oral bioavailability in rats. The benzylic carbon was identified as a metabolic site 
and variety of isosteres were introduced at this position. Methoxime analogue (2.11) was 
identified as a potent metabolically stable derivative266. 
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Figure. 2.4. Blocking Metabolically Labile Sites. 
Bioisosteric replacement of a labile site with a stable group is an alternative approach towards 
improving metabolic stability. This approach was used in the design of potent HIV protease 
inhibitor ritonavir (2.13, Fig. 2.5).  
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Figure 2.5. Bioisosteric Replacement of Metabolically Labile Group with a Stable Group. 
Early lead compound containing pyridylgroups was found to be susceptible to N-oxidation at the 
pyridyl nitrogen’s. When pyridyl groups were replaced with thiazoles the new analogue  (2.13, 
ritonavir) exhibited improved bioavailability267. 
2.4.3 Modification of Metabolically Labile Groups 
Compound 2.14 (Fig 2.6) was identified as a potent notch-1-sparing γ-secretase inhibitor 
however in in vitro metabolic stability studies on human liver microsomes the compound was 
found to have a very short half-life (8 min). Converting the metabolically labile methyl groups 
into trifluoromethyl afforded a more metabolically stable analogue begacestat (2.15, Fig. 2.6)268. 
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Figure. 2.6. Development of Begacestat. 
5-HT1A receptor ligand 2.16 (Fig. 2.7) exhibited low brain uptake in humans due to rapid 
metabolism of amide functional group. However, cyclizing the amide group afforded a derivative 
(2.17, Fig. 2.7) with improved metabolic stability269.  
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Figure 2.7. Amide Cyclization. 
2.5 Strategies for Metabolite Identification and Characterization: 
Addressing biotransformation issues during the drug discovery process involves both qualitative 
and quantitative assessment of drugs to determine the potential for formation of reactive 
intermediates. The qualitative assessment involves identification of potentially metabolically 
labile sites in a molecule so that necessary chemical modifications can be made to block the 
metabolic pathways. Quantitative estimation of metabolites is necessary to make appropriate 
comparison among lead candidates as well as for the regulatory approval of drugs. Nowadays 
scientists rely on several high-throughput approaches to identify the biotransformation potential 
of a lead candidate early in the drug discovery process. 
2.5.1 Chemical Structural Alerts  
Certain substructures of a molecule are particularly prone to forming reactive metabolites that 
are capable of intercalating with DNA or other protein molecules. These substructures include α, 
β-unsaturated carbonyls, thiophenes, alkenes, alkynes, hydrazines, anilines etc. Substituting 
theses substructures with metabolic stable groups could lead to the development of safer drug 
candidates. Other potential toxicophores are piperazine, piperidines, thiazolidinediones furans 
etc. However avoiding all the possible structural alerts is not a practical approach, as it will 
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severely limit the chemical diversity necessary for structure-activity relationship studies 270,271. 
2.5.2 In silico screens 
Computer-based in silico softwares are increasingly used to predict potential metabolites, 
hypothetical metabolite structures and their toxicity profiles in the early stages of drug discovery. 
Several software packages are commercially available such as Topkat, DEREK, Hazard expert, 
Pallas, MetaboLynx and ACD/MS. In silico studies in conjunction with high-throughput 
functional assays provide useful information to chemists to carryout necessary structural 
modifications in the lead drug candidates272. 
2.5.3 Identification of Metabolites using Mass Spectrometry 
Liquid chromatography coupled with mass spectrometry (LC-MS and LC-MS/MS) is a widely 
used technique to identify the metabolites and metabolic pathways that result in the 
biotransformation of the drugs. The use of quadrupole time-of-flight mass spectrometry (QTOF-
MS) allows rapid construction of molecular fragment maps. The in vitro metabolism studies 
involve incubation of drug candidates with liver preparations (hepatocytes or microsomes) from 
selected mammalian species (rat, mouse humans). Often time stable metabolites can be directly 
identified via LC-MS. However certain reactive metabolites such as electrophiles formed during 
the bioactivation process are not sufficiently stable to allow identification by LC-MS. These 
reactive species can be trapped using nucleophiles during incubation. Nucleophiles such as 
tripeptide glutathione (GSH), N-acetylcystein, cystein and 2-mercaptoethanol are some 
commonly used trapping agents. These thiol derivatives are soft nucleophiles and they readily 
react with soft electrophiles. Hard electrophilic intermediates (iminium ions, aldehydes and 
ketones) can be trapped using hard nucleophiles such as cyanides, semicarbazide, 
methoxylamine and guanine.  
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Figure 2.8: (A) Trapping of soft nucleophile (epoxide) with GSH; (B) Trapping of hard 
nucleophile (iminium ion) with cyanide. 
Nucleophiles are also responsible for certain types of drug-induced toxicities. For example, 
carboxylic acid groups in a molecule can conjugate with amino acids such as glycine and 
glutamine via coenzyme A (CoA) thioester intermediate. These CoA can be easily identified by 
LC-MS.  
Deuterium labeling coupled with LC-MS facilitates the estimation of labile hydrogen atoms in 
functional groups such as OH, COOH, NH and SH. This information is crucial in the structural 
elucidation of metabolites and interpretation of MS/MS data273-274.  
2.5.4 LC-MS-NMR  
 NMR coupled to liquid chromatography and often in conjunction with mass spectrometry is 
used for the structural elucidation of metabolites without the need for extensive pre-purification. 
While using NMR in conjunction with LC it is necessary to separate low intensity signals of 
analytes from high intensity signals of HPLC solvents. Several solvent suppression methods 
(softwares) are available to circumvent this problem. Alternatively deuterated solvents may be 
used for the purification. Metabolite identification in biological fluids is complicated by the 
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presence of a large number of endogenous substances. Isotope labeling (3H or 14C) is a common 
technique used to enable the detection of drug related material in bio-fluids.    
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CHAPTER 3: SIGMA RECEPTOR LIGAND DESIGN RATIONALE 
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Sigma receptors have proved to be valid targets for development of therapeutics for the 
treatment of various disease states as well as for designing imaging agents to understand the 
pathophysiology associated with sigma receptors. The main focus our laboratory is to design 
novel ligands for the treatment of drugs of abuse. Several research groups over the years have 
demonstrated the involvement of sigma receptors in modulating the physiological actions of 
drugs of abuse such as cocaine and methamphetamine. Our research involves the design and 
synthesis of novel sigma receptor ligands as potential anticocaine medications. Our research also 
represents an effort to contribute to the identification of structural features necessary to obtain 
ligands with high affinity and selectivity towards sigma receptor subtypes.   
Specific aims of this project are: 
1. To synthesize a library of novel compounds targeting sigma-1 and sigma-2 receptors. 
2. To demonstrate that these ligands have affinity and selectivity and selectivity for sigma 
receptor subtypes. 
3. To optimize sigma receptor ligands and improve their metabolic stability. 
 
In case of sigma receptors, structure based ligand design approach is not fesible due to 
unavailability of sigma protein structure. Cloning of sigma-1 receptor has provided some insights 
about the protein structure. However, this information cannot be used to generate a homology 
model due to lack of any similarity between sigma receptor and other mammalian proteins. In 
such cases the design of ligands begins with the structural and stereochemical knowledge of 
previously discovered active and inactive compounds or by using high throughput screening to 
identify an active scaffold. Based on the available structural features, a structure activity 
relationship (SAR) is developed for a novel template to determine the functional groups or the 
pharmacophoric elements that influence the affinity and selectivity of ligands for a particular 
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receptor (or receptor subtype). In short, ligand-based or indirect drug design strategy seems 
appropriate as the three-dimensional structure of the target receptor is not known. 
 
3.1 Sigma-1 Ligand Design Rationale and SAR study. 
 
2(3H)-Benzoxazolone (3.1, Fig 3.1) is an important building block in the synthesis of 
compounds with analgesic, antiseptic, antimicrobial and antifungal activities. A derivative 6-
benzoyl-2(3H)-benzoxazolones has analgesic property275. The corresponding sulfur analogue 
2(3H)-benzothiazolone (3.2, Fig 3.1) and its derivatives have been synthesized and characterized 
as compounds with sigma-1 and sigma-2 receptor affinity 276-278,213.  
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3.1 benzo[d]oxazol-2(3H)-one 3.2 benzo[d]thiazol-2(3H)-one  
Figure 3.1: Building blocks.  
The 2(3H)-benzoxazolone (3.1) and its bioisostere 2(3H)-benzothiazolone (3.2) heterocycle are 
bicyclic ring systems which promote high versatility in organic synthesis involving N-
substitution (either N-alkylation or N-acylation) and aromatic ring electrophilic substitution 
reactions. 2(3H)-benzoxazolone (3.1) mimics a phenol or a catechol moiety in a metabolically 
stable template as it is a weak acid in aqueous solution (pKa = 8.7), comparable to pyrocatechol 
(pKa = 9.2). 2(3H)-benzoxazolone (3.1) has a LogP of 0.97 and a diople moment of 4.47 Debye 
which is due to its hydrophilic nature, resulting from the incorporation of two hydrogen-bonding 
accepting sites and a single hydrogen-bonding donating site. 
3.2 Initial Studies in the Design of Sigma-1 Receptor Ligands 
  71 
A derivatized 2(3H)-benzothiazolone, (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-
one) (3.3, Fig 3.2) was reported to have high affinity (0.56 nM) and selectivity (over 1000 fold) 
for  sigma-1 receptor as compared to the sigma-2 subtype. This compound was also tested 
against a panel of other receptor subtypes (D1, D2, 5-HT, α1, α 2, β1, β2, H1and H2) and was 
found to have only moderate affinity for α 2 (Ki = 205 nM) and H1 (Ki = 311 nM) receptors213. 
CM304 (3.4, Fig 3.2) (3-(2-(azepan-1-yl)ethyl)-6-(3-fluoropropyl)benzo[d]thiazol-2(3H)-one) 
was synthesized in our laboratory and was found to have high affinity (0.0025 nM) for sigma-1 
receptors and high selectivity (> 100,000 fold) over sigma-2 receptors 
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Figure 3.2: Selective Sigma-1 ligands.  
Both these compounds have following structural similarities: 
• A benzo[d]thiazol-2(3H)-one heterocycle. 
• Azepane ring. 
• A two carbon chain linker between benzo[d]thiazol-2(3H)-one and azepane ring. 
• Propyl chain at the sixth position of benzo[d]thiazol-2(3H)-one ring.  
 
On the basis of these observations I have hypothesized that benzo[d]thiazol-2(3H)-one 
heterocycle and hexamethyleneimine (azepane) ring could be necessary features for sigma-1 
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receptor preference. This warranted me to investigate the SAR of these compounds.  
Bezothiazolone derivative (3.3, SN56) was resynthesized in our laboratory. In the bioassay, it 
showed subnanomalor affinity of 0.12 nM for sigma-1 receptors and a selectivity of about 7000-
fold over sigma-2 receptors. Changing the position of the propyl chain from the 6th to the 5th 
position in (3.6, SN72) with the  “O” atom at the 1 position lowered the selectivity to 544-fold. 
However, this lower selectivity could also be attributed to the change in the heteroatom. When 
the affinities of 5-propionyl (3.5, SN71) and 5-propyl derivatives were compared, it was 
observed that the presence of carbonyl groups decreased the affinity for sigma-1 receptors and 
thereby assisting in sigma-2 preference.  
Similarly, when the affinities of 6-benzoyl (3.7, SN78) and 6-benzyl (3.8, SN81) (Fig. 
3.3) derivatives were compared, reduction of the 6-keto group in SN78 (3.7) to develop SN81 
(3.8) led to an increase in affinity for sigma-1 receptors, which probably explained that a keto 
group at 6-position might improve sigma-2 preference. Similarly, introducing 4-
cyclohexylpiperazine with no acyl group in compound (3.9, SN97) completely abolished the 
sigma-1 receptor selectivity.  
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Figure 3.3. Sigma-1 receptor analogues 
To further our understanding of the SAR I decided to identify the importance of following 
structural features: 
1. Linker Length and Aryl substution: 
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• To investigate the effect of spacer length between benzo[d]thiazol-2(3H)-one and 
azepane ring on the biological activity by varying it from three to six carbons.  
• To investigate the effect of small substituent’s and alkyl chain lengths at the sixth 
position of benzo[d]thiazol-2(3H)-one.  
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Figure 3.4. SAR – Linker length and aryl substitution 
 
2. Hydrophobic Cycloalkylamine ring: In the next stage of SAR studies I investigated the 
biological effect of changing the hexamethyleneimine (azepane) heterocycle with other ring 
systems by: 
• Replacing the seven membered ring (azepane) with five membered (pyrrolidine), six 
membered (piperidine), and eight membered (azocane) rings. This change was made to 
investigate the importance of cycloalkylamine ring expansion or contraction on the 
activity. 
• Piperizine and Homopiperazine rings.  
• Changing the position of Nitrogen on the azepane ring.  
• Bringing the Nitrogen outside the closed ring system.  
  75 
• Introducing more polar cycloalkylamine rings like piperazine, homopiperazine and 
oxazepane with the intention of decreasing the logP of the compound without 
compromising the affinity and selectivity at sigma-1 subtype. This modification could be 
crucial as existing sigma-1 compounds tend to be very lipophilic and this could be a 
liability when we take into consideration the low half-life of sigma-1 selective 
compounds such as SN56 and CM304. 
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Figure 3.5. Substitutions of arylcycloalkylamine moiety.  
 
4. Different Heterocycles: I decided to replace Benzothiazolone heterocycle with its 
chemical or bioisosteres to investigate their effect receptor binding of the ligands. 
Following heterocycles were considered as replacements for bezothiazolone ring:  
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3.11, 1H-benzo[d]imidazol-2(3H)-one
3.12, benzo[d]isothiazol-3(2H)-one
3.10, benzo[d]oxazol-2(3H)-one
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Figure 3.6. Bioisosteric replacement for benzo[d]thiazol-2(3H)-one ring. 
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CHAPTER 4: APPROACHES TO ADDRESS BIOTRANSFORMATION ISSUES WITH 
SIGMA LIGANDS 
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Optimization of the metabolic profile of a drug is one of the key considerations during the drug 
discovery process. CM304 (Fig. 4.1) is one of the most sigma-1 selective ligand synthesized in 
our laboratory. However, this compound is very lipophilic and has two major issues: 
(a) Very short half-life in rat liver microsome assay (t1/2 = 12.6 min; Fig. 4.1). 
(b) Poor oral bioavailability (0.7%) in rats. 
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N                       t1/2 = 12.6 min (Rat liver microsomes)
                             = 115 min (in vivo; i.v.) 
                             = 135 min (in vivo; oral)
                       Oral bioavailability = 0.7% (Rat)
    
                                         4.1 CM304  
                     (σ-1 = 1.0 nM; σ-2 = 467 nM; σ-2/σ-1 = 467)  
Figure 4.1 Sigma-1 selective ligand, CM304. 
Low half-life could be attributed to the possible biotransformation pathways (illustrated in Fig. 
4.2) and higher lipophilicity of the molecule. Despite these shortcomings CM304 has proved to 
be an excellent candidate for PET imaging studies. Other analogues based on the 
benzothiazolone scaffold can have similar issues. Visual observation of our laboratory’s lead 
sigma-1 compounds CM304 (4.1) and SN56 (4.2) will lead to the conclusion that these 
compounds are highly lipophilic. Both these compounds have a ClogP greater than 4. Higher 
ClopP renders the compound susceptible to rapid biotransformation as well as off-target 
activities such as hERG channel activity. 
Possible biotransformation routes of sigma selective compounds synthesized by our laboratory 
are illustrated in Figure 4.2 
  79 
X
N
O
N
Y
Hydroxylation, Reduction
N-oxidation, 
N-dealkylation
3,4-Hydroxylation
X = S, O
Y = O, H2
Z
Oxidation (Z = H)
Dehalogination (Z = F, Cl, Br)
 
Figure 4.2 Possible metabolic sites of sigma ligands. 
 
I have synthesized some analogues of our research group’s lead sigma-1 compounds (CM304, 
SN56, SN79) to address some of these biotransformation issues.   
4.1. Fluorinated Analogues: 
The advantages of fluorine in drug design are related to some of the special physiochemical 
properties of fluorine: 
• Small size: The small size of fluorine enables it to be used as a substitution for hydrogen. 
The C-F bond length (1.39 A°) is isosteric with C-O bond length (1.43 Ao)279 and 
therefore, it can also serve as a bio-isosteric replacement for a hydroxyl group. 
• High Electronegativity: This property can be used to modulate the lipophilicity and pKa 
of the molecule. Monofluorination of alkyl group decreases lipophilicity whereas mono 
or poly fluorination at the aromatic group increases lipophilicity280. Fluorine lowers the 
electron density on adjacent carbon and thereby prevents certain reactions like oxidation. 
• The strong C-F bond leads to drug molecules that are more robust towards undesirable 
metabolic transformations, thus prolonging the activity of the drug in vivo. 
Keeping the above given physiochemical properties in mind, I have developed some analogues 
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of sigma-1 selective compounds and one analogue of a sigma-2 preferring compound. 
Monofluorinated and bis-fluorinated analogues of SN56 (4.2) were synthesized. The objective of 
these modifications was to prevent oxidation at the benzylic carbon.  
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Figure 4.3. Fluorinated analogues of SN56. 
4.2 Introduction of Steric Bulk 
Observation: From rat liver microsome studies it was found out that the half-life of CM304 
(4.1) and SN56 (4.2) was 12.6 min and 2 min respectively. In the absence of any metabolite data 
I had to make an assumption that piperazine ring containing compounds such as AZ66 (4.6, Fig. 
4.4) and azepane containing compounds such as CM304 and SN56 metabolize in a similar 
manner i.e. by N-dealkylation. With this assumption I proposed the following objective: 
Objective of Study: To introduce steric-bulk (methyl) adjacent to the metabolic handle to inhibit 
N-oxidation.  
Rationale: Previous study with a sigma-2 preferring compound (4.1, Fig 4.3) indicated that 
introduction of steric bulk delays N-oxidation (4.2, Fig 4.3). 
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Figure. 4.4 Introduction of steric bulk. 
Some analogues of sigma-1 compounds were synthesized in which steric bulk (methyl group) 
was introduced adjacent to the nitrogen atom as shown in Fig 4.5 
S
N
O
N
Z S
N
O
N
4.8
Z = H, F
S
N
O
N
4.9, RB5-255-11 
t1/2 = 1.6 min
S
N
O
N
4.10, RB5-249-99
t1/2 = 20.4 min
4.11, RB7-336-69
S
N
O
N
4.12
F
F
 
Figure 4.5 Analogues of CM304 and SN56.  
Metabolic studies with one of the derivatives indicated that introduction of methyl group on the 
azepane ring adjacent to the nitrogen does not improve the half-life of the compound. However, 
the half-life is marginally improved when the linker chain is moved on carbon adjacent to the 
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azepane nitrogen.  
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Fig. 4.6 N-dealkylation by hydrogen atom transfer (HAT) pathway. 
The probable reason for the lower half-life of the compound 4.9 (Fig. 4.5) would be either 
oxidation of the methyl group or that the N-dealkylation reaction proceeds by oxidation of the 
methylene carbon on the linker chain. The proposed mechanism of N-dealkylation is shown in 
Fig. 4.6. 
4.3 Deuterium labeling 
Advantages of substituting hydrogen with deuterium: 
• Carbon deuterium bond (C-D) requires greater energy of activation. C-H bond cleavage 
is 6-10 times faster than C-D bond cleavage. 
• Replacement of hydrogen with deuterium has negligible effect on the physiochemical 
properties of the molecule. 
To take advantage of these properties a deuterated analogue of SN56 was synthesized (Fig. 4.6). 
The hypothesis was that the carbon deuterium bond should be able to resist cleavage and 
increase the half-life of the compound.  
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Fig. 4.7 Deuterium labeling of SN56. 
4.4 Metabolite Profiling of CM304 
I have done some metabolite profiling of our lead sigma-1 compound CM304. The positive ion 
mass spectrum of CM304 showed a 307 [M+ + H] ion peak. The daughter ion peaks were 
identified at m/z 238, 210, 190 and 162 by collision-induced dissociation (CID). CM304 was 
incubated in rat liver microsomes for 60 minutes. The mixture was centrifuged and supernatant 
was analyzed by UPLC-MS-MS. Major metabolites were identified by precursor scan of the 
daughter ion peak at 162. Four major metabolites were identified: M1 (369 [M+ + H]) and 
M2/M3/M4 (353 [M+ + H]).  Possible routes of metabolism are illustrated in the Fig. 4.8.  
4.5 Method 
The metabolic stability studies of were conducted in rat liver microsomes. Compounds were 
incubated in the presence of an NADPH-generating system at 37°C for 60 min in test tubes. The 
basic incubation mixture consisted of 5 µM substrate, 1 mg/ml microsomal protein, 3 mM 
MgCl2, 1 mM NADP, 5 mM glucose-6-phosphate, 1 IU/ml glucose-6-phosphate dehydrogenase, 
100 mM Tris HCl buffer (pH 7.4) in a final volume of 1mL. The reaction was initiated by adding 
cofactors and quenched at designated time points (0, 5, 10, 15, 30, 45, 60 min.) by addition of 
equal volume of ice-cold methanol. The mixture was centrifuged at 3000 rpm for 10 min, and the 
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supernatant was analyzed by UPLC/MS/MS. 
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Fig. 4.8 Possible routes of metabolism of CM304. 
4.6 Results and Discussion:  
The metabolism of sigma compounds was estimated in vitro using rat liver microsomes for 60 
min. Table 4.1 summarize the percent substrate remaining and intrinsic clearance of sigma 
compounds. The t1/2 of the sigma compounds is in the rancge of 1.5 - 21 minutes. Among all the 
sigma compounds submitted for metabolic stability studies compound RB5-249-99 (4.10) 
exhibits the highest t1/2 of 20.4 minutes and it is a significant improvement over the half-life of 
CM-304 and SN56. However, most of the analogues were found to be unstable in rat liver 
microsomes. The results revealed that the metabolism was fast. In the metabolic stability study I 
have identified some major metabolites of CM304 and with the available information I was able 
to propose possible routes of metabolism of this compound. 
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Table. 4.1 Metabolic stability of RB series of compounds in rat liver microsomes 
 
Compound 
Time 
(min) % Remaining (±)SD Half life (t1/2) ± SD  CL(liver) ± SD  
4.5 
RB5-219-41 0 100     
  2 60.9 ± 1.1 1.5 ± 0.1 188 ± 14 
  5 12.1 ± 2.7     
  10 1.2 ± 0.3     
4.4 
RB79 0 100     
  2 71.6 ± 7.7 1.9 ± 0.1 147.6 ± 5.8 
  5 13.6 ± 2.1     
  10 3.1 ± 0.4     
4.9 
RB6-255-11 0 100     
  2 95 ± 5.2 1.5 ± 0.1 187.5 ± 11.1 
  5 51.7 ± 12.2     
  10 1.1 ± 0.3     
4.10,  
RB5-249-99 0 100     
  1 89.3 ± 1.9 20.4 ± 0.4 13.6 ± 0.3 
  5 81.4 ±1.2     
  7 75.9 ± 2.0     
  10 68.8 ± 0.3     
  15 54.3 ± 0.5     
  20 47.7 ± 2.6     
  30 31.0 ± 0.7     
  45 22.6 ± 0.8     
4.18 
RB7-310-19   1.3± 0.2  201.2 ± 21.3 
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CHAPTER 5 : SAR STUDY: BIOLOGICAL SCREENING, RESULTS AND 
DISCUSSION 
  87 
5.1 Biological Screening Method 
Radioligand binding assays play a critical role in the preliminary stages of drug development. 
The assays can be performed using conventional cell harvester method with a low throughput or 
by using high throughput techniques such as a 96 well filtration methodology. Higher throughput 
methods facilitate the efficient screening of large numbers of novel compounds. In this study, a 
96-well method for radioligand competition binding was used for the determination of sigma 
ligand binding affinities. The medium high throughput 96-well assay utilized rat liver 
membranes for the determination of binding at known sigma receptor subtypes (σ1 and σ2) 
because this tissue contains high densities of both subtypes and fulfills criteria required for 
reliable use with the 96-well format.  
5.1.1 Membrane Preparation  
Rat liver P2 fractions were prepared as described previously from frozen tissues obtained from 
Pel-FreezE281. Tissues were homogenized batch-wise with a Potter-Elvehjem homogenizer (5-10 
strokes with motor driven Teflon pestle) in ice-cold 10 mM Tris-sucrose buffer (0.32 M sucrose 
in 10 mM Tris, pH 7.4) using 10 ml buffer per g of tissue with ~3 g of tissue per batch. 
Homogenates from multiple batches were combined and centrifuged for 10 min at 1,000 x g, at 4 
°C. Supernatants were decanted, combined and centrifuged for 15 min at 31,000 x g, at 4 °C. To 
reduce levels of bound endogenous ligand(s) the resulting P2 membrane was washed as follows: 
1) pellets were re-suspended in 10 mM Tris, pH 7.4 using 3 ml buffer per g of wet tissue, 2) the 
resulting suspension was incubated for 30 min at 25 °C, 3) following incubation, the suspension 
was centrifuged for 15 min at 31,000 x g, at 4 °C. The resulting pellets were re-suspended in 10 
mM Tris, pH 7.4 buffer at a final concentration of 1 g starting tissue weight/1.5 ml. Tissue 
preparations were aliquoted in 1 ml portions and stored at -80 °C.  
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5.1.2 Competition Binding Assay 
Radioligand binding assays utilized optimized buffer and incubation conditions. Stock solutions 
of test ligands were prepared in DMSO or deionized water at 5 or 25 mM. Dilutions of reference 
ligands for competition studies were made with assay buffer (50 mM Tris, pH 8). Dilutions of 
2(3H)-benzothiazolone analogues were prepared in 1 mM HCl. The use of 1 mM HCl for 
dilution of 2(3H)-benzothiazolone analogues was required to reduce binding of these compounds 
to glass tubes or polypropylene microplates and had no effect on the final pH of the samples or 
on total binding relative to samples prepared in assay buffer alone (data not shown). For samples 
requiring DMSO for solubilization, a final concentration of up to 1-2% DMSO in assay samples 
had no effect on total binding. 40 µg of rat liver P2 membrane was added to a polypropylene 
plate (catalogue number 07-200-697, Fisher Scientific) containing test ligand and radioligand in 
assay buffer in a total volume of 0.25 ml. Assays for σ-1 receptors used a final concentration of 5 
nM [3H](+)-pentazocine. Labeling of sigma-2 was effected with 5 nM [3H]DTG. Non-specific 
binding was determined by the addition of haloperidol to a final concentration of 10 µM. 
Samples were incubated for 120 min at 25 °C for assay. Samples prepared in microplates for 96-
well filtration were agitated during incubation on a 96-well plate shaker. Following incubation, 
samples were filtered and washed. Samples processed by 96-well filtration were washed 5 times 
with 0.2 ml of 10 mM Tris, pH 8. Prior to use, GF/B filter papers and Unifilter GF/B filter plates 
were soaked in 0.5% polyethyleneimine (PEI) for 30 min to reduce non-specific binding. For the 
determination of binding affinities, each test compound was assayed at 11 concentrations varying 
from 0.001 – 10 µM. Samples were prepared and processed in duplicate for each binding curve 
and triplicate determinations of binding curves were made for each compound. Samples were 
counted on a Perkin Elmer Microbeta2 2450 microplate counter (Waltham, MA), in the Unifilter 
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plates, following a 2 hour incubation at room temperature with 40 µl Microscint-20 cocktail per 
well. The competition binding data were analyzed with GraphPad Prism software (San Diego, 
CA). 
5.2 SAR Study Results and Discussion 
 
5.2.1 Role of Chain Length in Homologues of SN56 
 
 
S
N
O
N
n
X
5.1e-f  
 
Compound No. n X σ1 
Ki (nM) 
σ2 
Ki (nM) 
σ2/σ1 
5.1a, RB2 2 H 4.1 177 43 
5.1b, RB4 3 H 3.2 101 31 
5.1c, RB6 4 H 7.0 2.5 0.4 
5.1d, RB8 5 H 7.5 2.4 0.3 
5.1e,  
RB7-307-13 
1 F - - - 
5.1f 
RB6-259-19 
1 CN - - - 
 
Compound SN56 was selected as a lead compound for the sigma receptor SAR investigation. In 
the first study several analogues were synthesized in which the alkyl chain length was elongated 
from three to six methylene groups (5.1a-d) and there was no substitution on the aryl ring. Two 
analogues (5.1e and 5.1f) had a fluoro and cyano substitution on the aryl ring respectively. All 
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the derivatives displayed good affinity towards both the receptors. The shorter chain analogues 
(5.1a and 5.1b) demonstrated high sigma-1 affinity (Kis 4.1 and 3.2 nM respectively) and 
moderate selectivity (43 and 31 fold respectively) over sigma-2 receptor subtype. 
5.2.2 The Effect of Aryl Substitution and Chain Length 
 
S
N
O
X
O
n
N
m
5.2 a-i  
    
 
Compound No. m n X σ-1 Ki 
(nM) 
σ-2 Ki 
(nM) 
σ-2/σ-1 
5.2a, RB74 1 1 CH3 4.5 2181 484 
5.2b, RB26 1 2 CH3 3.7 269 73 
5.2c, RB28 1 3 CH3 10 30 3.0 
5.2d, RB30 1 4 CH3 12 8.3 0.7 
5.2e, RB32 1 5 CH3 10 1.1 0.1 
5.2f, RB36 2 2 CH3 2.6 104 39 
5.2g, RB38 2 3 CH3 4.8 22 4.5 
5.2h, RB40 2 4 CH3 16 5.7 0.4 
5.2i, RB70 2 5 CH3 11 2.3 0.2 
 
In order to elucidate the influence of aryl substitution and chain length on sigma receptor binding 
several aryl substituted (propionyl//butyryl/) analogues were synthesized with chain length 
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varying from two to six methylene groups. Analogues with a propionyl/butyryl substitution and a 
shorter chain length (5.2a, 5.2b, 5.2f and 5.2g) exhibited higher affinity for sigma-1 subtype. 
However, analogues with propionyl substitution had highest sigma-1 preference. 
S
N
O
X
n
N
m
5.3 a-i  
Compound No. m n X σ-1 Ki 
(nM) 
σ-2 Ki 
(nM) 
σ-2/σ-1 
5.3a, SN56 1 1 CH3 1.6 270 168 
5.3b, RB10 1 2 CH3 1.4 17 13 
5.3c, RB14 1 3 CH3 6.1 4.3 0.7 
5.3d, RB16 1 4 CH3 4.6 1.6 0.3 
5.3e, RB18 1 5 CH3 6.3 2.3 0.4 
5.3f, RB20 2 2 CH3 2.2 15 7.0 
5.3g, RB34 2 3 CH3 1.9 4.4 2.4 
5.3h, RB24 2 5 CH3 12 4.1 0.3 
5.3i, RB5-233-67 1 1 Br - - - 
 
Generally, reduction of the benzylic ketone led to a slightly increased affinity at both the receptor 
subtypes. However, the increased affinity came at the expense of subtype selectivity. The best 
analogues (5.3a and 5.3b) of this series of compounds exhibited a lower selectivity for sigma-1 
subtype as compared to their corresponding anologues (5.2a and 5.2b) with a benzylic ketone 
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functionality. 
5.2.3 Effect of cycloalkylamine Ring Size 
S
N
O
R1
N
n
5.4 a-d  
 
Comp. No. 
 
R1 n  σ1 
Ki 
(nM) 
σ2 
Ki 
(nM) 
σ2/σ1 
5.4a, RB65 H 1 578 8264 14 
5.4b, RB67 H 4 10 716 72 
5.4c, RB75 
O  
1 116 4787 41 
5.4d, RB77 
O  
4  - - 
  
In order to elucidate the importance of ring size on sigma receptor affinity and selectivity some 
analogues were synthesized in which the hexamethyleimine ring was replaced with five 
membered pyrrolidine or eight membered octylamine ring. When the ring size was increased 
(5.4b) the compound still retained good affinity for sigma-1 subtype (Ki = 10 nM) however it 
lost affinity at sigma-2 subtype (Ki = 716 nM). Decreasing the ring size had a detrimental effect 
on the affinity of the compound (5.4a and 5.4c) for both the receptor subtypes as well as the 
selectivity over sigma-2 subtype. Propionyl group at the sixth position of benzothiazolone ring 
slightly improved the affinity and selectivity of the compound 5.4c for sigma-1 subtype as 
  93 
compared to its non-substituted analogue 5.4a. 
5.2.4 Other Structural Changes to the Azepane ring 
5.2.4.1 Bringing Nitrogen outside the cycloalkane ring 
S
N
O
N
X
R1
R2
5.5 a-f  
 
Compound No. X R1 R2 
5.5a, RB6-278-57 H2 
 
H 
5.5b, RB81 O 
 
H 
5.5c, RB6-268-37 H2 
 
H 
5.5d, RB6-279-59 H2 
 
CH3 
5.5e, RB6-270-41 H2 
 
CH3 
5.5f, RB6-271-43 H2 
 
-CH2CH3 
 
Previous study demonstrated that seven or eight membered nitrogen containing cyclo-alkane ring 
is crucial for sigma-1 receptor binding. To further explore the surrounding of nitrogen atom we 
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decided to bring the nitrogen atom outside the ring. Several N,N-disubstututed analogues were 
synthesized in which one of the substituent was either a cycloheptane or a cyclooctane ring.  
5.2.4.2 Substituted hexamethyleneimine ring 
To further explore the surroundings of basic N-atom certain analogues with substituted azepane 
ring were synthesized.  
S
N
O
F
N
CH3
S
N
O
N
CH3
5.6, RB5-249-99 5.7, RB5-249-99  
5.2.4.3 Azepane Ring altered analogues 
The main objective of these studies was to obtain analogues with greater selectivity for sigma 
receptor subtypes. In this series of compounds, modifications were made by substituting the 
azepane ring with conformationally rigid piperazine and homopiperazine rings. Ring 
enlargement from piperazine to homopiperazine should result in increase in receptor affinity and 
improvement of receptor selectivity against sigma-2 subtype. One of the issues we have with 
SN56 and molecules based on this template is their high lipophilicity. Higher lipophilicity makes 
the molecule more susceptible to biotransformation by cytochrome P450 enzymes. Azepane in 
SN56 and similar analogues contributes substantially to the lipophilicity of the molecule. 
Therefore, the second objective of this modification was to introduce polarity into the molecule 
without compromising the affinity and selectivity for sigma receptors. 
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S
N
O
R1
N
N
m
R2
5.8 a-j  
 
 
Comp. No. R1 n R2 
5.8a, RB3-105-20 H 2 H 
 
5.8b, RB3-108-26 
 
H 
 
2 
CF3
 
 
5.8c, RB3-121-50 
 
H 
 
2  
5.8d, RB3-122-52 H 2 
 
 
5.8e, RB3-124-56 O  
 
2 
 
H 
 
5.8f, RB3-125-58 O  
 
2  
5.8g, RB4-160-23 
O  
1 
 
5.8h, RB4-162-27 
O  
2 
 
5.8i, RB6-272-45 -(CH2)2CH3 2 H 
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5.8j, RB6-273-47 -(CH2)2CH3 2 CH3 
 
Compounds with a piperazine or a homopiperazine ring were synthesized to explore the effect of 
second tertiary nitrogen on sigma receptor binding and selectivity. 
5.3 Conclusion: 
Some trends observed during the SAR study include: 
1. Increasing in linker arm length (from n = 2 to n = 5), reflects marginal changes in affinity 
at σ1 and significant increase in affinity for the sigma-2 subtype. 
2. Modification of aryl substitution at position 6 from propyl (5.3a, SN56) to propionyl 
(5.2a, RB74) results in dramatic decrease in sigma-2 affinity with a marginal change in 
sigma-11 affinity. 
3. Reduced affinity for both σ-subtypes when the azepine ring of SN56 (5.3a) is replaced 
with a pyrrolidine ring as demonstrated by RB65  (5.4a) and RB75 (5.4c). 
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CHAPTER 6. CHEMICAL SYNTHESIS OF SIGMA RECEPTOR ANALOGUES 
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GENERAL 
Reagents and starting materials were obtained from commercial suppliers and were used without 
purification. Precoated silica gel 60 F254 aluminium backed plates from Merck were used for 
thin-layer chromatography (TLC). Column chromatography was performed on silica gel 60 
(Sorbent Technologies). 1H and 13C NMR spectra were obtained on a Bruker APX400 at 400 and 
100 MHz, respectively. The high-resolution mass spectra (HRMS) were recorded on a Waters 
Micromass Q-T of Micro mass spectrometer with a lock spray source. The mass spectra (MS) 
were recorded on a Waters Aquity Ultra Performance LC with ZQ detector in ESI mode. 
Analytical HPLC was performed on an automated Waters Alliance system equipped with a 
Xterra® C18 RP18 (4.6 × 100 mm i. d., 3.5 µm) column or Xterra® C8 RP8 (4.6 × 100 mm i. d., 
3.5 µm), with a flow rate of 1 ml/min.; λmax = 254 nm; mobile phase A: CH3CN and mobile 
phase B: H2O (0.2% triethylamine) linear gradient in 12 min. Elemental analyses (C, H, N) were 
recorded on an elemental analyzer, Perkin-Elmer CHN/SO Series II Analyzer. Chemical names 
were generated using ChemDraw Ultra (CambridgeSoft, version 12.0). The overall yields, 1H 
and 13C NMR data for final compounds are reported in its free base form. 
6.1 Synthesis of Benzo[d]thiazol-2(3H)one Analogues  
 
The initial series of compounds were synthesized to investigate the effect of spacer length 
between benzo[d]thiazol-2(3H)-one and azepane ring varying it from three to six carbons atoms. 
Commercially available benzo[d]thiazol-2(3H)one (6.1) was treated with dibromoalkane 
followed by hexamethyleneimine (azepane) to give analogue 6.33a-f (Scheme 1). Hydrochloride 
salts were formed for biological testing. 
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Scheme 1 
 
                    
S
N
O
Br
n
S
H
N
O
a b
6.1
S
N
O
R
n
6.2 (a-e) 6.3 (a-f)  
Compound n R 
6.3a, RB2 2 
N
 
6.3b, RB4 3 
N
 
6.3c, RB6 4 
N
 
6.3d, RB8 5 
N
 
6.3e, RB65 1 
N
 
6.3f, RB67 1 
N
 
 
Reagents and conditions: (a) Dibromoalkanes, K2CO3, DMF, 600C, 3h; (b) 
Hexamethyleneimine, K2CO3, DMF, 600C, 2h. 
General Procedure for the preparation of RB1, RB3, RB5, RB7, RB64. 
3-(3-bromopropyl)benzo[d]thiazol-2(3H)-one (6.2a, RB1). Benzothiazol-2(3H)-one (1.51 g, 
10 mmol) and potassium carbonate (4.14 g, 30 mmol) was added to 8 ml of DMF. The mixture 
was heated at 600C and 1,3-dibromopropane (80 mmol) was added. The mixture was stirred and 
heated at 600C for 3 h. After completion, the mixture was cooled and poured into water. The 
product was extracted in ethyl acetate and washed with saturated aqueous NaCl. The solvent was 
evaporated under reduced pressure and the product was purified by column chromatography over 
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silica gel using Hexane: Ethyl acetate (9:1) to give 2.05 g (76 %) of 3-(3-
bromopropyl)benzo[d]thiazol-2(3H)-one as a transparent oil. 1H NMR (400 MHz, CDCl3) δ 7.45 
(d, J = 7.8, 1H), 7.38 – 7.32 (m, 1H), 7.18 (dd, J = 9.2, 8.1, 2H), 4.12 (t, J = 7.1, 2H), 3.48 (t, J = 
6.4, 2H), 2.38 – 2.27 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 169.98, 136.91, 126.50, 123.25, 
122.78, 122.74, 110.48, 41.35, 30.68, 30.06. MS (ESI) m/z 272, 274 (M+ + 2). 
3-(4-bromobutyl)benzo[d]thiazol-2(3H)-one (6.2b, RB3) 73%. 1H NMR (400 MHz, CDCl3) δ 
7.43 (dd, J = 7.8, 0.9, 1H), 7.37 – 7.29 (m, 1H), 7.16 (td, J = 7.7, 1.0, 1H), 7.07 (d, J = 8.1, 1H), 
3.99 (t, J = 6.7, 2H), 3.46 (t, J = 6.1, 2H), 2.01 – 1.87 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 
169.93, 136.88, 126.40, 123.14, 122.79, 122.74, 110.51, 41.68, 32.89, 29.56, 26.15. MS(ESI) 
m/z 286, 288 (M+ + 2). 
3-(5-bromopentyl)benzo[d]thiazol-2(3H)-one (6.2c, RB5) 65%.  1H NMR (400 MHz, CDCl3) 
δ 7.43 (d, J = 7.8, 1H), 7.32 (t, J = 7.8, 1H), 7.16 (t, J = 7.6, 1H), 7.04 (d, J = 8.1, 1H), 3.96 (t, J 
= 7.3, 2H), 3.40 (t, J = 6.7, 2H), 2.02 – 1.87 (m, 2H), 1.78 (dt, J = 15.2, 7.6, 2H), 1.55 (dt, J = 
15.3, 7.6, 2H). 13C NMR (101 MHz, CDCl3) δ 169.87, 137.01, 126.32, 123.04, 122.83, 122.72, 
110.47, 42.46, 33.26, 32.19, 26.78, 25.33. MS (ESI) m/z 300, 302 (M+ + 2). 
3-(6-bromohexyl)benzo[d]thiazol-2(3H)-one (6.2d, RB7) 70%. 1H NMR (400 MHz, CDCl3) δ 
7.43 (d, J = 7.8, 1H), 7.32 (t, J = 7.3, 1H), 7.16 (t, J = 7.6, 1H), 7.04 (d, J = 8.0, 1H), 3.95 (t, J = 
7.3, 2H), 3.40 (t, J = 6.7, 2H), 1.91 – 1.82 (m, 2H), 1.76 (dt, J = 14.8, 7.5, 2H), 1.56 – 1.37 (m, 
4H). 13C NMR (101 MHz, CDCl3) δ 169.99, 137.17, 126.39, 123.10, 122.93, 122.79, 110.62, 
42.70, 33.78, 32.63, 27.85, 27.55, 26.05. MS (ESI) m/z 314, 316 (M+ + 2). 
3-(2-bromoethyl)benzo[d]thiazol-2(3H)-one (6.2e, RB64) 75%. 1H NMR (400 MHz, CDCl3) δ 
7.44 (d, J = 7.7, 1H), 7.34 (t, J = 7.5, 1H), 7.19 (t, J = 7.5, 1H), 7.12 (d, J = 8.1, 1H), 4.34 (t, J = 
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7.1, 2H), 3.62 (t, J = 7.1, 2H). 13C NMR (101 MHz, CDCl3) δ 169.93, 136.51, 126.49, 123.47, 
122.87, 122.63, 122.61, 110.48, 44.02, 26.79. MS (ESI) m/z 258, 260 (M+ + 2). 
General Procedure for the preparation of RB2, RB4, RB6, RB8, RB65, RB67. 
3-(3-(azepan-1-yl)propyl)benzo[d]thiazol-2(3H)-one (6.3a, RB2). 3-(3-bromopropyl) benzo 
[d]thiazol-2(3H)-one (RB1) (1.5 g, 5.53 mmol) and potassium carbonate (2.3 g, 16 mmol) were 
added to 5ml of DMF. The reaction mixture was heated at 600C and azepane (0.7 ml, 5.53 mmol) 
was added. The mixture was stirred and heated at 600C for two hours. After completion, the 
reaction mixture was cooled to room temperature and poured into water and the product was 
extracted in ethyl acetate and the organic layer was washed with brine. The solvent was 
evaporated under reduced pressure and the product was purified by column chromatography over 
silica gel using methylene chloride: methanol (9:1) to give 1.2 g (77 %) of 3-(3-(azepan-1-
yl)propyl)benzo[d]thiazol-2(3H)-one as an oil.  
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 7.7, 1H), 7.30 (t, J = 7.8, 1H), 7.21 – 7.10 (m, 2H), 
4.01 (t, J = 7.1, 2H), 2.63 – 2.57 (m, 4H), 2.53 (t, J = 6.7, 2H), 1.88 (dd, J = 13.9, 6.9, 2H), 1.62 
(d, J = 13.9, 10H). 13C NMR (101 MHz, DMSO-d6) δ 168.84, 136.64, 126.65, 123.20, 122.91, 
121.51, 111.45, 53.59, 53.44, 25.92, 22.83, 22.32. Anal. Calcd for C16H22N2OS.1HCl: C, 58.79; 
H, 7.09; N, 8.57. Found: C, 58.77; H, 7.10; N, 8.53. HRMS m/z 291.1531 (Cal), found 291.1517 
(M+ + H). 
3-(4-(azepan-1-yl)butyl)benzo[d]thiazol-2(3H)-one (6.3b, RB4) 80%. 1H NMR (400 MHz, 
CDCl3) δ 7.43 (dd, J = 7.8, 0.8, 1H), 7.35 – 7.28 (m, 1H), 7.16 (td, J = 7.7, 1.0, 1H), 7.09 (d, J = 
8.1, 1H), 4.02 – 3.93 (m, 2H), 2.76 – 2.65 (m, 4H), 2.64 – 2.56 (m, 2H), 1.79 (dt, J = 15.0, 7.4, 
2H), 1.72 – 1.58 (m, 10H). 13C NMR (101 MHz, CDCl3) δ 169.83, 137.16, 126.21, 122.91, 
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122.60, 110.70, 57.41, 55.50, 42.63, 27.99, 26.96, 25.38, 24.67. Anal. Calcd for 
C17H24N2OS.1HCl.0.2 H2O: C, 59.27; H, 7.43; N, 8.13. Found: C, 59.5; H, 7.32; N, 7.99. MS 
(ESI) m/z 305.6 (M+ + H). 
3-(5-(azepan-1-yl)pentyl)benzo[d]thiazol-2(3H)-one (6.3c, RB6) 72%. 1H NMR (400 MHz, 
CDCl3) δ 7.43 (d, J = 7.7, 1H), 7.31 (t, J = 7.8, 1H), 7.15 (t, J = 7.6, 1H), 7.04 (d, J = 8.1, 1H), 
3.95 (t, J = 7.4, 2H), 2.74 – 2.62 (m, 4H), 2.56 – 2.46 (m, 2H), 1.77 (dt, J = 15.2, 7.6, 2H), 1.60 
(t, J = 24.8, 10H), 1.39 (dt, J = 15.1, 7.7, 2H). 13C NMR (101 MHz, CDCl3) δ 169.88, 137.12, 
126.25, 122.95, 122.64, 110.57, 57.81, 55.38, 42.69, 27.41, 26.98, 26.75, 24.63. HRMS m/z 
319.1844 (Cal), found 319.1852 (M+ + H). 
3-(6-(azepan-1-yl)hexyl)benzo[d]thiazol-2(3H)-one (6.3d, RB8) 65%. 1H NMR (400 MHz, 
CDCl3) δ 7.42 (d, J = 7.8, 1H), 7.35 – 7.25 (m, 1H), 7.15 (t, J = 7.2, 1H), 7.03 (d, J = 8.0, 1H), 
3.99 – 3.88 (m, 2H), 2.69 – 2.57 (m, 4H), 2.50 – 2.40 (m, 2H), 1.74 (dt, J = 15.1, 7.5, 2H), 1.61 
(d, J = 21.1, 8H), 1.49 (dt, J = 15.1, 7.4, 2H), 1.43 – 1.30 (m, 4H). 13C NMR (101 MHz, CDCl3) 
δ 169.94, 137.25, 126.34, 123.02, 122.94, 122.74, 110.68, 58.17, 55.57, 42.87, 27.77, 27.66, 
27.28, 27.09, 26.82. Anal. Calcd for C19H28N2OS.1HCl.0.33 H2O: C, 60.86; H, 7.97; N, 7.47. 
Found: C, 61.09; H, 7.93; N, 7.38. HRMS m/z 333.2001 (Cal), found 333.2005 (M+ + H). 
3-(2-(pyrrolidin-1-yl)ethyl)benzo[d]thiazol-2(3H)-one (6.3e, RB65) 64%. 1H NMR (400 
MHz, MeOD) δ 7.59 (d, J = 7.8, 1H), 7.42 (dt, J = 15.8, 7.9, 2H), 7.27 (t, J = 7.4, 1H), 4.84 (s, 
3H), 4.44 (t, J = 6.0, 2H), 3.63 (t, J = 6.0, 2H), 3.32 (s, 3H), 2.11 (s, 4H). 13C NMR (101 MHz, 
CDCl3) δ 170.24, 135.79, 127.44, 123.92, 122.71, 122.13, 111.66, 53.73, 50.96, 38.39, 23.43. 
MS (ESI) m/z 249 (M+ + H). 
3-(2-(azocan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one (6.3f, RB67) 65%. 1H NMR (400 MHz, 
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MeOD) δ 7.58 (d, J = 7.7, 1H), 7.44 (d, J = 3.9, 2H), 7.29 – 7.23 (m, 1H), 4.47 (t, J = 6.6, 2H), 
3.56 (t, J = 6.6, 3H), 3.34 – 3.30 (m, 2H), 1.85 (d, J = 94.1, 11H). 13C NMR (101 MHz, MeOD) 
δ 171.22, 136.15, 126.76, 123.70, 122.72, 122.35, 110.80, 53.05, 52.07, 48.23, 48.02, 47.81, 
47.59, 47.38, 47.17, 46.96, 37.43, 25.11, 24.09, 22.40. MS (ESI) m/z 291.73 (M+ + H). 
6.2 Synthesis of 6-fluorobenzo[d]thiazol-2(3H)-one analogue. 
6-fluoro analogue (109) was synthesized as shown in scheme 2. The 2-aminobenzothiazole (6.6) 
was prepared by bromine oxidation of 4-fluorophenylthiourea (6.5). The aminobenzothiazole 
(6.6) on alkaline hydrolysis yielded 2-amino-5-fluorobenzenethiol282,283 (6.7). The cyclization of 
benzenethiol by CDI under refluxing condition gave 6-fluorobenzo[d]thiazol-2(3H)-one (6.8). It 
was treated with dibromoalkane followed by azepane to give analogue 6.9  (Scheme 2).  
Scheme 2 
          
F
NH2
S
N
NH2
F
NH2
SHF
S
H
N
O
F S
N
O
N
F
6.4
6.9
a c
d e, f
F
H
N NH2
S
b
6.5 6.6 6.7
6.8  
Reagents and conditions: (a) NaSCN, H2SO4; (b) Br2, CHCl3; (c) KOH, H2O, reflux, 24h; (d) 
CDI, THF, reflux, 6h; (e) Dibromoethane, K2CO3, DMF, 600C, 3h; (f) Hexamethyleneimine, 
K2CO3, DMF, 600C, 2h. 
6-fluorobenzo[d]thiazol-2-amine (6.6, RB7-303-05) 1H NMR (400 MHz, DMSO-d6) δ 7.56 
  104 
(dd, J = 8.8, 2.7, 1H), 7.44 (s, 2H), 7.29 (dd, J = 8.8, 4.9, 1H), 7.02 (td, J = 9.1, 2.7, 1H). 13C 
NMR (101 MHz, DMSO-d6) δ 166.33, 158.30, 155.96, 149.45, 131.93, 131.82, 118.13, 118.04, 
112.81, 112.57, 107.90, 107.63. 
2-amino-5-fluorobenzenethiol (6.7, RB7-304-07) 1H NMR (400 MHz, CDCl3) δ 6.99 – 6.88 
(m, 2H), 6.68 (dd, J = 8.5, 4.5, 1H), 4.01 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 156.28, 153.91, 
145.02, 122.05, 121.83, 119.05, 118.82, 116.22, 116.15. 
6-fluorobenzo[d]thiazol-2(3H)-one (6.8, RB7-305-07) 1H NMR (400 MHz, DMSO-d6) δ 11.90 
(s, 1H), 7.54 (d, J = 8.2, 1H), 7.11 (dd, J = 7.4, 3.5, 2H). 13C NMR (101 MHz, DMSO-d6) δ 
169.84, 159.09, 156.73, 132.84, 124.72, 124.62, 113.66, 113.42, 112.42, 112.33, 110.08, 109.81. 
3-(2-(azepan-1-yl)ethyl)-6-fluorobenzo[d]thiazol-2(3H)-one  (6.9, RB7-307-13) 40%. 1H 
NMR (400 MHz, CDCl3) δ 7.18 (dd, J = 7.7, 2.6, 2H), 7.12 – 6.99 (m, 1H), 4.13 (s, 2H), 2.93 – 
2.86 (m, 2H), 2.82 (s, 4H), 1.65 (d, J = 34.6, 8H). 13C NMR (101 MHz, CDCl3) δ 169.55, 
160.25, 157.83, 133.43, 123.87, 113.88, 113.64, 111.78, 111.70, 110.22, 109.95, 55.80, 54.58, 
27.66, 26.99.  
6.3 Synthesis of Benzothiazolecarbonitrile analogue. 
 
The nitrile intermediate (6.12) was prepared by treating the brominated benzothiazolinone (6.11) 
with CuCN at an elevated temperature under inert gas atmosphere (Scheme 3)284. The nitrile 
intermediate was then alkylated with dibromoethane followed by treatment with azepane to get 
the desired analogue. 
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Compound R 
6.13a, RB4-151-05 Br 
6.13b, RB6-259-19 CN 
 
                      
Reagents and condition: (a) Br2, AcOH, AcONa, 150C to rt, 12h; (b) CuCN, DMF, 1500C, 6h; 
(c) 1,2-dibromoethane, K2CO3, DMF, 600C, 3h; (d) hexamethyleneimine, K2CO3, DMF, 600C, 
2h. 
6-bromobenzo[d]thiazol-2(3H)-one (6.11, RB87) 
To a solution of glacial acetic acid was added sodium acetate (1.3 g, 16.0 mmol) and 
benzo[d]thiazol-2(3H)-one (2.0 g, 13.25 mmol). The suspension was cooled to 150C and bromine 
(0.7 ml, 13.64 mmol) was added dropwise over 1h and the mixture was stirred for 12h at room 
temperature. The solids were filtered, washed with water and dried under vacuum to give 6-
bromobenzo[d]thiazol-2(3H)-one (90%) as a off-white solid. 1H NMR (400 MHz, DMSO-d6) δ 
12.01 (s, 1H), 7.84 (s, 1H), 7.42 (dd, J = 8.5, 1.8 Hz, 2H), 7.04 (d, J = 8.5 Hz, 1H). MS (ESI) m/z 
228, 230 (M+2). 
2-oxo-2,3-dihydrobenzo[d]thiazole-6-carbonitrile (6.12, RB6-257-15) 
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To a solution of DMF was added 6-bromobenzo[d]thiazol-2(3H)-one (1.94 g, 8.43 mmol) and 
CuCN (1.28 g, 14.33) and the mixture heated to 1500C for 6h under nitrogen. The reaction 
mixture was cooled to room temperature, H2O and sodium cyanide was added and the reaction 
mixture was stirred at room temperature for 2h. The product was extracted in ethyl acetate. The 
organic layer was concentrated in vacuo and the product was purified by column 
chromatography using hexane: ethyl acetate (8:2) to give 2-oxo-2,3-dihydrobenzo[d]thiazole-6-
carbonitrile (9%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 12.39 (s, 1H), 8.13 (s, 1H), 
7.71 (d, J = 8.3 Hz, 1H), 7.23 (d, J = 8.3 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 169.87, 
140.01, 130.78, 126.81, 124.56, 118.78, 112.08, 104.71.  
3-(2-bromoethyl)-2-oxo-2,3-dihydrobenzo[d]thiazole-6-carbonitrile (RB6-258-17) 
2-oxo-2,3-dihydrobenzo[d]thiazole-6-carbonitrile (0.12 g, 0.68 mmol) and potassium carbonate 
(0.28 g, 30 mmol) was added to 0.5 ml of DMF. The mixture was heated at 600C and 1,2-
dibromoethane (0.35 ml, 4.09 mmol) was added. The mixture was stirred and heated at 600C for 
3 h. After completion, the mixture was cooled and poured into water. The product was extracted 
in ethyl acetate and washed with saturated aqueous NaCl. The solvent was evaporated under 
reduced pressure and the product was purified by column chromatography over silica gel using 
hexane: ethyl acetate (9:1) to give 3-(2-(azepan-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazole-
6-carbonitrile (83 %) as a transparent oil. 
3-(2-(azepan-1-yl)ethyl)-6-bromobenzo[d]thiazol-2(3H)-one (6.13a, RB4-151-05) 74%. 1H 
NMR (400 MHz, CDCl3) δ 7.52 (d, J = 1.2 Hz, 1H), 7.44 – 7.36 (m, 2H), 6.97 (d, J = 8.6 Hz, 
1H), 3.98 (t, J = 7.0 Hz, 3H), 2.79 (t, J = 7.0 Hz, 3H), 2.74 – 2.64 (m, 6H), 1.67 – 1.46 (m, 17H). 
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13C NMR (101 MHz, CDCl3) δ 169.15, 136.38, 129.24, 125.13, 124.59, 115.32, 112.01, 55.87, 
54.88, 41.70, 28.45, 26.97. 
3-(2-(azepan-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazole-6-carbonitrile (6.13b, RB6-259-
19). 3-(2-bromoethyl)-2-oxo-2,3-dihydrobenzo[d]thiazole-6-carbonitrile (0.15 g, 0.53 mmol) and 
potassium carbonate (0.22 g, 1.6 mmol) were added to 0.5 ml of DMF. The reaction mixture was 
heated at 600C and azepane (0.06 ml, 0.53 mmol) was added. The mixture was stirred and heated 
at 600C for two hours. After completion, the reaction mixture was cooled to room temperature 
and poured into water and the product was extracted in ethyl acetate and the organic layer was 
washed with brine. The solvent was evaporated under reduced pressure and the product was 
purified by column chromatography over silica gel using methylene chloride: methanol (9:1) to 
give 3-(2-(azepan-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazole-6-carbonitrile (69 %) as an oil.  
 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 1.5 Hz, 1H), 7.61 (dd, J = 8.4, 1.6 Hz, 1H), 7.22 (d, J 
= 8.4 Hz, 1H), 4.06 (t, J = 6.9 Hz, 2H), 2.83 (t, J = 6.9 Hz, 2H), 2.78 – 2.65 (m, 4H), 1.67 – 1.47 
(m, 8H). 13C NMR (101 MHz, CDCl3) δ 169.32, 140.78, 130.62, 126.28, 123.96, 118.48, 111.29, 
106.51, 77.48, 77.16, 76.84, 56.02, 55.02, 42.01, 28.35, 26.96. MS (ESI) m/z  302 (M+ + H). 
6.4 Synthesis of 6-acyl\alkyl benzo[d]thiazol-2(3H)-one analogues. 
6-acyl benzothiazolone intermediates (6.14 a-c) were synthesized by Friedel-Crafts acylation of 
benzo[d]thiazol-2(3H)-one (6.1) followed by reduction (acyl to alkyl) which led to regiospecific 
6-alkyl derivatives (6.17a-c)278. The acyl/alkyl derivatives were then treated with dibromoalkane 
and further treated with aminocycloalkane to give the final products (6.16a-i/6.19a-i, Scheme 4).  
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Compound No. l m n X 
6.16a, RB74 2 1 1 CH3 
6.16b, RB75 1 1 1 CH3 
6.16c, RB77 3 1 1 CH3 
6.16d, RB26 2 1 2 CH3 
6.16e, RB28 2 1 3 CH3 
6.16f, RB30 2 1 4 CH3 
6.16g, RB32 2 1 5 CH3 
6.16h, RB36 2 2 2 CH3 
6.16i, RB38 2 2 3 CH3 
6.16j, RB40 2 2 4 CH3 
6.16k, RB70 2 2 5 CH3 
6.19a, RB10 - 1 2 CH3 
6.19b, RB14 - 1 3 CH3 
6.19c, RB16 - 1 4 CH3 
6.19d, RB18 - 1 5 CH3 
6.19e, RB20 - 2 2 CH3 
6.19f, RB34 - 2 3 CH3 
6.19g, RB22 2 2 4 CH3 
6.19h, RB24 - 2 5 CH3 
6.19i, RB5-233-67 - 1 1 Br 
 
Reagents and Conditions: (a) AlCl3-DMF, acyl halides (or anhydrides), 450C - 800C, 4-5h; (b) 
Dibromoalkanes, K2CO3, DMF, 600C, 3h; (c) Triethylsilane, trifluoroacetic acid, rt, 5h; (d) 
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Hexamethyleneimine, K2CO3, DMF, 600C, 2h. 
General procedure for the preparation of RB11a and RB19a.  
6-propionylbenzo[d]thiazol-2(3H)-one (6.14a, RB11a). DMF (8.6 ml, 115 mmol) was slowly 
added to AlCl3 (53.3 g, 400 mmol) under vigorous stirring. The mixture was heated at 450C and 
2(3H)-benzothiazole (6 g, 40 mmol) was added. After 30 min propionic anhydride was added 
and the reaction mixture was heated at 750C for 3h. The hot mixture was then carefully poured 
onto ice and the crude product was collected by filtration, washed with water and air-dried. The 
solid was recrystallized from ethanol to give 2.6 g (45%) of 6-propionylbenzo[d]thiazol-2(3H)-
one as a faint yellow solid. 1H NMR (CDCl3): δ 8.17, 7.96 (dd, J = 6.8 Hz, 1.6 Hz, 2H), 7.22 (d, 
J = 7.6 Hz, 1H), 3.06 (q, J = 7.6 Hz, 2H), 1.20 (t, J = 6.8 Hz, 3H). 13C NMR: δ 199.89, 140.26, 
131.88, 126.75, 124.35, 123.64, 122.64, 110.83, 31.00, 7.23. HRMS m/z 208.0432 (Cal), found 
208.0427 (M+ + H).  
6-butyrylbenzo[d]thiazol-2(3H)-one (6.14b, 19a) 32%. 1H NMR (CDCl3): δ 10.71 (s), 8.04 (s, 
1H), 7.90 (dd, 2Hz, 6.4 Hz, 1H), 7.24 (d, J = 8 Hz, 1H), 2.94 (t, J = 7.6 Hz, 2H), 1.78 (m, J = 6.8 
Hz, 2H), 1.01 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 199.00, 173.40, 139.32, 
132.64, 127.30, 124.52, 122.97, 111.67, 40.45, 17.98, 13.95. MS (ESI) m/z 220 (M-1). 
Procedure for the preparation of RB11b and RB19b. 
6-propylbenzo[d]thiazol-2(3H)-one (6.17a, RB11b). Triethylsilane (3.3 ml, 20.7 mmol) was 
added to the stirred solution of 6-propionylbenzo[d]thiazol-2(3H)-one (RB11a)  (1.6 g, 9 mmol) 
at room temperature in trifluoroacetic acid (8 ml). The mixture was vigorously stirred at room 
temperature for 3h, poured onto ice and the pH was adjusted to 8 with saturated K2CO3 solution. 
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The mixture was extracted with ethyl acetate, washed with brine and dried. The solvent was 
removed under vacuum and the residue was taken in petroleum ether. The solid was collected by 
filtration and dried.  The compound was purified by column chromatography using hexane : 
ethyl acetate (8:2) to give 1.2 g (70%) of 6-propylbenzo[d]thiazol-2(3H)-one as a white solid. 1H 
NMR (CDCl3): 1H NMR (400 MHz, CDCl3) δ 10.38 (s, 1H), 7.22 (s, 1H), 7.09 (s, 2H), 2.60 (t, J 
= 7.5, 2H), 1.64 (dd, J = 14.8, 7.4, 2H), 0.95 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 
173.63, 138.13, 133.53, 127.00, 123.95, 122.18, 111.76, 37.80, 24.84, 13.79. HRMS m/z 
194.0640 (Cal), found 194.0645 (M+ + H).  
6-butylbenzo[d]thiazol-2(3H)-one (6.17b, RB19b) 70%. 1H NMR (400 MHz, DMSO-d6) δ 
11.73 (s, 1H), 7.36 (s, 1H), 7.07 (d, J = 8.1, 1H), 7.00 (d, J = 8.1, 1H), 2.59 – 2.51 (m, 2H), 1.52 
(dt, J = 15.2, 7.5, 2H), 1.27 (dq, J = 14.7, 7.3, 2H), 0.87 (t, J = 7.3, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ 170.41, 137.33, 134.63, 126.97, 123.69, 122.53, 111.68, 34.87, 33.76, 22.07, 14.19. 
MS (ESI) m/z 206 (M+ - H). 
General Procedure for the preparation of RB57, RB25, RB27, RB29, RB31, RB9, RB13, 
RB 15, RB17, RB33, RB35, RB37, RB39, RB69, RB19c, RB21, RB23. (Scheme 4) 
3-(2-bromoethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.15a, RB57). 6-propionylbenzo[d] 
thiazol-2(3H)-one (0.6 g, 2.9 mmol) and potassium carbonate (1.2 g, 8.7 mmol) was added to 3 
ml of DMF. 1,3-dibromoethane (2 ml, 23.2 mmol) was added and the reaction mixture was 
stirred and heated at 600C for 3 h. After completion, the mixture was cooled and poured into 
water. The product was extracted in ethyl acetate and washed with saturated aqueous NaCl. The 
solvent was evaporated under reduced pressure and the product was purified by column 
chromatography over silica gel using hexane: ethyl acetate (9:1) to give 0.8 g (88 %) of 3-(2-
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bromoethyl)-6-propionylbenzo[d]thiazol-2(3H)-one as a transparent oil. 1H NMR (400 MHz, 
CDCl3) δ 8.09 (d, J = 1.4, 1H), 7.97 (dd, J = 8.5, 1.5, 1H), 7.20 (d, J = 8.5, 1H), 4.38 (t, J = 6.9, 
2H), 3.65 (t, J = 6.9, 2H), 3.00 (q, J = 7.2, 2H), 1.24 (t, J = 7.2, 3H). 13C NMR (101 MHz, 
CDCl3) δ 198.82, 170.16, 140.17, 132.65, 127.08, 123.10, 110.35, 44.49, 31.74, 27.00, 8.39. MS 
(ESI) m/z 314, 316 (M+ + 2). 
3-(3-bromopropyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.15b, RB25) 75%. 1H NMR 
(400 MHz, CDCl3) δ 8.09 (d, J = 1.6, 1H), 7.99 (dd, J = 8.5, 1.7, 1H), 7.24 (d, J = 8.5, 1H), 4.21 
– 4.11 (m, 2H), 3.47 (t, J = 6.2, 2H), 3.01 (q, J = 7.2, 2H), 2.33 (dt, J = 13.1, 6.4, 2H), 1.25 (t, J 
= 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 198.91, 170.26, 140.49, 132.51, 127.22, 123.24, 
123.06, 110.18, 41.78, 31.75, 30.70, 30.01, 8.44. MS (ESI) m/z 328, 330.4 (M+ + 2). 
3-(4-bromobutyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.15c, RB27) 72%. 1H NMR (400 
MHz, CDCl3) δ 8.07 (d, J = 1.5, 1H), 7.96 (dd, J = 8.5, 1.7, 1H), 7.12 (d, J = 8.5, 1H), 4.03 (d, J 
= 6.5, 2H), 3.46 (t, J = 5.9, 2H), 2.99 (q, J = 7.2, 2H), 2.00 – 1.90 (m, 4H), 1.23 (t, J = 7.2, 3H). 
13C NMR (101 MHz, CDCl3) δ 198.88, 170.16, 140.42, 132.36, 127.07, 123.21, 123.00, 110.16, 
42.12, 32.84, 31.69, 29.54, 26.23, 8.41. MS (ESI) m/z 342, 344 (M+ + 2). 
3-(5-bromopentyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.15d, RB29) 74%. 1H NMR (400 
MHz, CDCl3) δ 8.06 (d, J = 1.6, 1H), 7.95 (dd, J = 8.5, 1.7, 1H), 7.09 (d, J = 8.5, 1H), 3.98 (t, J 
= 7.3, 2H), 3.39 (t, J = 6.6, 2H), 2.99 (q, J = 7.2, 2H), 1.97 – 1.84 (m, 2H), 1.78 (dt, J = 15.2, 7.6, 
2H), 1.60 – 1.47 (m, 2H), 1.23 (t, J = 7.2, 3H).13C NMR (101 MHz, CDCl3) δ 198.87, 170.07, 
140.54, 132.25, 126.98, 123.19, 122.97, 110.12, 42.87, 33.30, 32.17, 31.66, 26.88, 25.35, 8.39. 
MS (ESI) m/z 356, 358 (M+ + 2).  
3-(6-bromohexyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.15e, RB31) 77%. 1H NMR (400 
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MHz, CDCl3) δ 8.06 (d, J = 1.6, 1H), 7.94 (dd, J = 8.5, 1.7, 1H), 7.08 (d, J = 8.5, 1H), 3.97 (t, J 
= 7.3, 2H), 3.38 (t, J = 6.7, 2H), 2.98 (q, J = 7.2, 2H), 1.88 – 1.71 (m, 4H), 1.53 – 1.36 (m, 4H), 
1.22 (t, J = 7.2, 3H).13C NMR (101 MHz, CDCl3) δ 198.85, 170.04, 140.61, 132.21, 126.95, 
123.19, 122.93, 110.15, 43.01, 33.68, 32.55, 31.65, 27.77, 27.54, 25.97, 8.39. MS (ESI) m/z 370, 
372 (M+ + 2). 
3-(3-bromopropyl)-6-butyrylbenzo[d]thiazol-2(3H)-one (6.15f, RB35) 79%. 1H NMR (400 
MHz, CDCl3) δ 8.08 (d, J = 1.5 Hz, 1H), 7.98 (dd, J = 8.5, 1.6 Hz, 1H), 7.23 (d, J = 8.5 Hz,1H), 
4.15 (t, J = 7.1 Hz, 2H), 3.47 (t, J = 6.2 Hz, 2H), 2.94 (t, J = 7.3 Hz, 2H), 2.38 -2.28 (m, 2H), 
2.17 (s, 1H), 1.84 - 1.72 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
198.49, 170.24, 140.46, 132.67, 127.28, 123.21, 123.11, 110.16, 41.76, 40.45, 30.69, 30.00, 
17.99, 14.00.  MS (ESI) m/z 343, 345 (M+ + 2). 
3-(4-bromobutyl)-6-butyrylbenzo[d]thiazol-2(3H)-one (6.15g, RB37) 81%. 1H NMR (400 
MHz, CDCl3) δ 8.08 (s, 1H), 7.97 (d, J = 8.5, 1H), 7.13 (d, J = 8.5, 1H), 4.03 (s, 2H), 3.47 (s, 
2H), 2.94 (t, J = 7.3, 2H), 1.95 (s, 4H), 1.78 (dd, J = 7.3, 14.7, 2H), 1.01 (t, J = 7.4, 3H). 13C 
NMR (101 MHz, CDCl3) δ 198.39, 170.10, 140.33, 132.46, 127.07, 123.13, 123.00, 110.07, 
42.04, 40.33, 32.76, 30.95, 29.45, 26.15, 17.88, 13.90. MS (ESI) m/z 357, 359 (M+ + 2). 
3-(5-bromopentyl)-6-butyrylbenzo[d]thiazol-2(3H)-one (6.15h, RB39) 74%. 1H NMR (400 
MHz, CDCl3) δ 8.08 (d, J = 1.7, 1H), 7.96 (dd, J = 1.7, 8.5, 1H), 7.09 (d, J = 8.5, 1H), 4.00 (t, J 
= 7.3, 2H), 3.40 (t, J = 6.6, 2H), 2.94 (t, J = 7.3, 2H), 2.00 – 1.87 (m, 2H), 1.78 (dd, J = 7.3, 14.6, 
4H), 1.57 (d, J = 7.4, 2H), 1.02 (t, J = 7.4, 3H). 13C NMR (101 MHz, CDCl3) δ 198.36, 169.78, 
140.47, 132.41, 126.98, 123.16, 122.98, 110.01, 42.82, 40.32, 33.15, 32.10, 26.82, 25.29, 17.90, 
13.88.  
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3-(6-bromohexyl)-6-butyrylbenzo[d]thiazol-2(3H)-one (6.15i, RB69) 83%. 1H NMR (400 
MHz, CDCl3) δ 8.04 (d, J = 1.6, 1H), 7.92 (dd, J = 8.5, 1.7, 1H), 7.07 (d, J = 8.5, 1H), 3.95 (t, J = 
7.3, 2H), 3.36 (t, J = 6.7, 2H), 2.90 (t, J = 7.3, 2H), 1.87 – 1.70 (m, 6H), 1.53 – 1.34 (m, 4H), 
0.98 (t, J = 7.4, 3H). 13C NMR (101 MHz, CDCl3) δ 198.31, 169.94, 140.59, 132.42, 126.98, 
123.15, 122.95, 110.10, 42.97, 40.31, 33.56, 32.52, 27.73, 27.49, 25.93, 17.92, 13.89. MS (ESI) 
m/z  384.57, 386.59 (M+ + 2) 
3-(3-bromopropyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.18a, RB9) 84%. 1H NMR (400 
MHz, CDCl3) δ 7.28 (d, J = 5.3, 1H), 7.16 (d, J = 9.4, 1H), 7.08 (d, J = 8.3, 1H), 4.11 (t, J = 7.0, 
2H), 3.48 (t, J = 6.4, 2H), 2.67 – 2.59 (m, 2H), 2.38 – 2.29 (m, 2H), 1.72 – 1.60 (m, 2H), 0.97 (t, 
J = 7.3, 3H).13C NMR (101 MHz, CDCl3) δ 170.05, 138.09, 134.87, 126.74, 122.63, 122.48, 
110.21, 41.34, 37.58, 30.74, 30.08, 24.69, 13.67. MS (ESI) m/z 314, 316 (M+ + 2). 
3-(4-bromobutyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.18b, RB13) 76%. 1H NMR (CDCl3): 
δ 7.26 (s, 1H), 7.15 (d, J = 8 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 3.99 (t, J = 6.8 Hz, 2H), 3.47 (t, J 
= 6 Hz, 2H), 2.62 (t, J = 7.8 Hz, 2H), 1.95 (m, J = 3 Hz, 2H), 1.66 (m, J = 7.6 Hz, 2H), 0.96 (t, J 
= 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.09, 138.07, 134.98, 126.75, 122.81, 122.57, 
110.35, 41.80, 37.70, 32.98, 29.69, 26.31, 24.81, 13.79. MS (ESI) m/z 330 (M+ + H). 
3-(5-bromopentyl)-6-propyl-2,3-dihydrobenzo[d]thiazole (6.18c, RB15) 79%. 1H NMR (400 
MHz, CDCl3) δ 7.24 (s, 1H), 7.12 (d, J = 8.2, 1H), 6.94 (d, J = 8.2, 1H), 3.93 (t, J = 7.3, 2H), 
3.39 (t, J = 6.7, 2H), 2.65 – 2.55 (m, 2H), 1.97 – 1.86 (m, 2H), 1.76 (dt, J = 15.2, 7.6, 2H), 1.65 
(dt, J = 15.0, 7.4, 2H), 1.60 – 1.48 (m, 2H), 0.94 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 
169.91, 137.87, 134.99, 126.62, 122.70, 122.45, 110.28, 42.48, 37.61, 33.36, 32.26, 26.85, 25.38, 
24.78, 13.75. MS (ESI) m/z 342, 344 (M+ + 2). 
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3-(6-bromohexyl)-6-propylbenzo[d]thiazole (6.18d, RB17) 80%. 1H NMR (CDCl3): δ 7.26 (s, 
1H), 7.14 (d, J = 8 Hz, 1H), 6.96 (d, J = 8 Hz, 1H), 3.94 (t, J = 7.2 Hz, 2H), 3.41 (t, J = 6.8 Hz, 
2H), 2.62 (t, J = 8Hz, 2H), 1.88 (m, J = 7.6 Hz, 2H), 1.77 (dt, J = 7.6 Hz, 2H), 1.66 (m, J = 7.6 
Hz, 2H), 1.48 (m, J = 6.8 Hz, 2H), 1.28 (t, J = 7.6 Hz, 2H), 0.96 (t, J = 7.6 Hz, 3H). 13C NMR: δ 
169.89, 137.78, 135.05, 126.51, 122.73, 122.39, 110.23, 42.61, 37.58, 33.60, 32.55, 27.76, 27.48, 
25.95, 24.70, 13.68. MS (ESI) m/z 356, 358 (M+ + 2). 
3-(3-bromopropyl)-6-butylbenzo[d]thiazol-2(3H)-one (6.18e, RB19c) 75%. 1H NMR 
(CDCl3): δ 7.26 (s, 1H), 7.15 (d, J = 7.2 Hz, 1H), 7.07 (d, J = 8 Hz, 1H), 4.09 (t, J = 7.2 Hz, 2H), 
3.47 (t, J = 6.4 Hz, 2H), 2.64 (t, J = 7.6 Hz, 2H), 2.32 (m, J = 6.8 Hz, 2H), 1.61 (m, J = 7.6 Hz, 
2H), 1.37 (dq, J = 7.6 Hz, 2H), 0.94 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.05, 
138.35, 134.88, 126.76, 122.67, 122.47, 110.29, 60.42, 41.39, 35.26, 33.83, 30.81, 30.17, 22.27, 
21.08, 13.96. MS (ESI) m/z 330 (M+ + H). 
3-(4-bromobutyl)-6-butylbenzo[d]thiazol-2(3H)-one (6.18f, RB33) 80%. 1H NMR (400 MHz, 
CDCl3) δ 7.25 (s, 1H), 7.13 (d, J = 8.2, 1H), 6.97 (d, J = 8.2, 1H), 3.97 (t, J = 6.4, 2H), 3.46 (t, J 
= 5.8, 2H), 2.63 (t, J = 7.7, 2H), 2.02 – 1.88 (m, 4H), 1.60 (dt, J = 15.3, 7.6, 2H), 1.36 (dq, J = 
14.7, 7.3, 2H), 0.94 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 170.09, 138.29, 134.91, 
126.70, 122.80, 122.51, 110.36, 41.78, 35.32, 33.90, 33.01, 29.67, 26.29, 22.33, 14.01. MS (ESI) 
m/z 342, 344 (M+ + 2). 
3-(5-bromopentyl)-6-butylbenzo[d]thiazol-2(3H)-one (6.18g, RB21) 81%. 1H NMR (400 
MHz, CDCl3) δ 7.23 (s, 1H), 7.11 (d, J = 8.2, 1H), 6.94 (d, J = 8.2, 1H), 4.21 – 4.14 (m, 1H), 
3.92 (t, J = 7.2, 2H), 3.39 (t, J = 6.7, 2H), 2.62 (t, J = 7.6, 2H), 2.00 – 1.47 (m, 10H), 1.35 (dd, J 
= 7.4, 14.7, 2H), 1.05 – 0.84 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 169.86, 138.06, 134.92, 
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126.54, 122.68, 122.36, 110.26, 42.46, 35.22, 33.82, 33.33, 32.24, 31.88, 26.83, 25.36, 22.24, 
13.95. MS (ESI) m/z 356.7, 358.7 (M+ + 2). 
3-(6-bromohexyl)-6-butylbenzo[d]thiazol-2(3H)-one (6.18h, RB23) 74%. 1H NMR (400 
MHz, DMSO-d6) δ 7.43 (s, 1H), 7.18 (dd, J = 8.3, 24.7, 2H), 3.88 (t, J = 7.2, 2H), 3.43 (dd, J = 
29.6, 36.3, 4H), 2.54 (dd, J = 13.9, 21.6, 2H), 2.02 – 1.93 (m, 1H), 1.87 – 1.17 (m, 14H), 0.86 (t, 
J = 7.3, 4H). 13C NMR (101 MHz, DMSO-d6) δ 168.98, 137.86, 135.28, 127.14, 122.75, 121.87, 
111.53, 42.53, 40.45, 40.24, 40.03, 39.82, 39.61, 35.35, 34.83, 33.75, 32.57, 27.62, 27.44, 25.69, 
22.13, 14.20. MS (ESI) m/z 370.6, 372.6 (M+ + 2). 
General Procedure for the preparation of RB74, RB26, RB28, RB30, RB32, RB10, RB14, 
RB16, RB18, RB20, RB22, RB24, RB34, RB36, RB38, RB40, RB70. 
3-(2-(azepan-1-yl)ethyl)-6-propionyl benzo[d]thiazol-2(3H)-one (6.16a, RB74). 3-(2-
bromoethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (RB57) (1.0 g, 3.18 mmol), potassium 
carbonate (1.3 g, 9.54 mmol) and azepane (0.36 ml, 3.18 mmol)  were added to 3 ml of DMF. 
The reaction mixture was stirred and heated at 600C for two hours. After completion, the reaction 
mixture was cooled to room temperature and poured into water and the product was extraxted in 
ethyl acetate and the organic layer was washed with brine. The solvent was evaporated under 
reduced pressure and the product was purified by column chromatography over silica gel using 
methylene chloride: methanol (9:1) to give 0.8 g (77 %) of 3-(2-(azepan-1-yl)ethyl)-6-propionyl 
benzo[d]thiazol-2(3H)-one as an oil. 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.91 (d, J = 8.3, 
1H), 7.14 (d, J = 8.5, 1H), 4.02 (t, J = 6.9, 2H), 2.95 (q, J = 7.1, 2H), 2.80 (t, J = 6.9, 2H), 2.73 – 
2.63 (m, 4H), 1.54 (d, J = 20.1, 8H), 1.19 (t, J = 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 198.79, 
169.92, 140.79, 132.03, 126.80, 122.97, 122.74, 110.36, 55.79, 54.85, 41.61, 31.55, 28.25, 26.86, 
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8.31. MS (ESI) m/z 333 (M+ + H). 
6-propionyl-3-(2-(pyrrolidin-1-yl)ethyl)benzo[d]thiazol-2(3H)-one  (6.16b, RB75) 60%. 1H 
NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.95 (d, J = 8.5, 1H), 7.16 (d, J = 8.5, 1H), 4.10 (dd, J = 
15.7, 8.2, 2H), 2.99 (q, J = 7.2, 2H), 2.87 – 2.74 (m, 2H), 1.79 (d, J = 3.0, 4H), 1.23 (t, J = 7.2, 
3H). HRMS m/z 305.1324 (Cal), found 305.1313 (M+ + H). 
3-(2-(azocan-1-yl)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.16c, RB77) 85%. 1H NMR 
(400 MHz, CDCl3) δ 8.07 (d, J = 1.6, 1H), 7.97 (dd, J = 8.5, 1.7, 1H), 7.20 (d, J = 6.2, 1H), 4.09 
(s, 2H), 3.06 – 2.93 (m, 2H), 2.86 (t, J = 7.2, 2H), 2.69 (s, 4H), 1.54 (s, 10H), 1.24 (t, J = 7.2, 
3H). 13C NMR (101 MHz, CDCl3) δ 199.01, 170.13, 140.86, 132.19, 126.95, 123.23, 122.96, 
110.35, 55.60, 54.37, 41.86, 31.71, 28.16, 27.41, 26.09, 8.46. MS (ESI) m/z 347.73 (M+ + H). 
3-(3-(azepan-1-yl)propyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.16d, RB26) 74%. 1H 
NMR (400 MHz, CDCl3) δ 8.06 (d, J = 1.6, 1H), 7.95 (dd, J = 8.5, 1.7, 1H), 7.33 – 7.23 (m, 1H), 
4.06 (t, J = 7.0, 2H), 3.00 (q, J = 7.2, 2H), 2.69 – 2.59 (m, 4H), 2.55 (t, J = 6.7, 2H), 1.99 – 1.88 
(m, 2H), 1.64 (d, J = 18.7, 8H), 1.24 (t, J = 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 199.03, 
170.21, 141.03, 132.19, 126.95, 123.15, 122.86, 110.63, 55.67, 54.93, 41.49, 31.71, 28.01, 27.03, 
25.86, 8.46. HRMS m/z 347.1793 (Cal), found 347.1797 (M+ + H). 
3-(4-(azepan-1-yl)butyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.16e, RB28) 72%. 1H NMR 
(400 MHz, CDCl3) δ 8.06 (d, J = 1.5, 1H), 7.95 (dd, J = 8.5, 1.7, 1H), 7.15 (d, J = 8.5, 1H), 4.06 
– 3.93 (m, 2H), 2.99 (q, J = 7.2, 2H), 2.69 – 2.57 (m, 4H), 2.57 – 2.48 (m, 2H), 1.77 (dd, J = 
15.0, 7.7, 2H), 1.69 – 1.53 (m, 10H), 1.23 (t, J = 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 
198.96, 170.10, 140.73, 132.20, 126.95, 123.22, 122.92, 110.38, 57.35, 55.58, 43.01, 31.69, 
27.90, 27.06, 25.48, 24.59, 8.43. HRMS m/z 361.1950 (Cal), found 361.1940 (M+ + H). 
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3-(5-(azepan-1-yl)pentyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.16f, RB30) 77%. 1H 
NMR (400 MHz, CDCl3) δ 8.05 (d, J = 1.5, 1H), 7.94 (dd, J = 8.5, 1.6, 1H), 7.08 (d, J = 8.5, 
1H), 3.96 (t, J = 7.4, 2H), 2.98 (q, J = 7.2, 2H), 2.67 – 2.54 (m, 4H), 2.50 – 2.39 (m, 2H), 1.75 
(dt, J = 15.1, 7.6, 2H), 1.65 – 1.47 (m, 10H), 1.38 (dd, J = 15.0, 7.8, 2H), 1.22 (t, J = 7.2, 3H). 
13C NMR (101 MHz, CDCl3) δ 198.89, 170.04, 140.70, 132.16, 126.93, 123.20, 122.90, 110.21, 
57.87, 55.55, 43.18, 31.65, 27.84, 27.58, 27.11, 27.06, 24.73, 8.40. Anal Calcd for 
C21H30N2O2S.1HCl: C, 61.37; H, 7.60; N, 6.82. Found: C, 61.25; H, 7.54; N, 6.71. HRMS m/z 
375.2106 (Cal), found 375.2124 (M+ + H). 
3-(6-(azepan-1-yl)hexyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.16g, RB32) 76%. 1H 
NMR (400 MHz, CDCl3) δ 8.04 (d, J = 1.5, 1H), 7.92 (dd, J = 8.5, 1.6, 1H), 7.07 (d, J = 8.5, 
1H), 3.93 (t, J = 7.4, 2H), 2.96 (q, J = 7.2, 2H), 2.65 – 2.54 (m, 4H), 2.47 – 2.37 (m, 2H), 1.71 
(dd, J = 14.7, 7.5, 2H), 1.58 (d, J = 19.1, 8H), 1.50 – 1.28 (m, 6H), 1.20 (t, J = 7.2, 3H). 13C 
NMR (101 MHz, CDCl3) δ 198.82, 169.96, 140.66, 132.10, 126.89, 123.14, 122.85, 110.17, 
58.05, 55.50, 43.13, 31.60, 27.74, 27.63, 27.26, 27.16, 27.02, 26.71, 8.36. Anal. Calcd for 
C22H32N2O2S.1HCl: C, 62.17; H, 7.83; N, 6.59. Found: C, 62.02; H, 7.79; N, 6.49.  HRMS m/z 
389.2263 (Cal), found 389.2265 (M+ + H). 
3-(3-(azepan-1-yl)propyl)-6-butyrylbenzo[d]thiazol-2(3H)-one (6.16h, RB36) 78%. 1H NMR 
(400 MHz, CDCl3) δ 8.06 (s, 1H), 7.94 (d, J = 8.5, 1H), 7.32 – 7.24 (m, 1H), 4.06 (t, J = 7.0, 
2H), 2.92 (dd, J = 11.3, 18.7, 2H), 2.65 (s, 4H), 2.58 (d, J = 6.6, 2H), 1.95 (d, J = 6.8, 2H), 1.77 
(dd, J = 7.3, 14.7, 2H), 1.64 (d, J = 22.9, 8H), 1.01 (t, J = 7.4, 3H). 13C NMR (101 MHz, CDCl3) 
δ 198.44, 170.07, 140.87, 132.30, 126.92, 123.03, 122.80, 110.49, 100.01, 55.52, 54.82, 41.36, 
40.31, 27.75, 26.91, 25.66, 17.90, 13.88. HRMS m/z 361.1950 (Cal), found 361.1940 (M+ + H). 
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3-(4-(azepan-1-yl)butyl)-6-butyrylbenzo[d]thiazol-2(3H)-one (6.16i, RB38) 78%. 1H NMR 
(400 MHz, CDCl3) δ 8.04 (d, J = 1.5, 1H), 7.93 (dd, J = 8.5, 1.6, 1H), 7.14 (d, J = 8.5, 1H), 4.04 
– 3.93 (m, 2H), 2.92 (t, J = 7.3, 2H), 2.65 – 2.56 (m, 4H), 2.50 (t, J = 7.2, 2H), 1.75 (dt, J = 14.6, 
7.3, 4H), 1.66 – 1.51 (m, 10H), 0.99 (t, J = 7.4, 3H). 13C NMR (101 MHz, CDCl3) δ 198.50, 
170.04, 140.71, 132.34, 126.98, 123.17, 122.95, 110.35, 57.32, 55.56, 43.00, 40.36, 27.96, 27.03, 
25.46, 24.62, 17.96, 13.95. Anal. Calcd for C21H30N2O2S.1HCl: C, 61.37; H, 7.60; N, 6.82. 
Found: C, 61.27; H, 7.62; N, 6.63. MS (ESI) m/z 375.7 (M+ + H).. 
3-(5-(azepan-1-yl)pentyl)-6-butyrylbenzo[d]thiazol-2(3H)-one (6.16j, RB40) 75%. 1H NMR 
(400 MHz, CDCl3) δ 8.06 (d, J = 1.5, 1H), 7.95 (dd, J = 8.5, 1.7, 1H), 7.09 (d, J = 8.5, 1H), 3.97 
(t, J = 7.4, 2H), 2.93 (t, J = 7.3, 2H), 2.70 – 2.59 (m, 4H), 2.53 – 2.43 (m, 2H), 1.84 – 1.71 (m, 
4H), 1.68 – 1.51 (m, 10H), 1.44 – 1.34 (m, 2H), 1.01 (t, J = 7.4, 3H). 13C NMR (101 MHz, 
CDCl3) δ 198.53, 170.13, 140.73, 132.41, 127.06, 123.25, 123.02, 110.24, 57.87, 55.55, 43.19, 
40.41, 27.67, 27.59, 27.09, 27.00, 24.73, 18.00, 13.99. HRMS m/z 389.2263 (Cal), found 
389.2246 (M+ + H). Anal. Calcd for C22H32N2O2S.1HCl.0.25H2O: C, 61.52; H, 7.86; N, 6.52. 
Found: C, 61.87; H, 7.85; N, 6.45. 
3-(6-(azepan-1-yl)hexyl)-6-butyrylbenzo[d]thiazol-2(3H)-one (6.16k, RB70) 82%. 1H NMR 
(400 MHz, CDCl3) δ 8.05 (s, 1H), 7.94 (d, J = 8.5, 1H), 7.08 (d, J = 8.5, 1H), 3.95 (t, J = 7.4, 
2H), 3.45 (s, 2H), 2.92 (t, J = 7.3, 2H), 2.65 – 2.54 (m, 4H), 2.47 – 2.37 (m, 2H), 1.76 (dt, J = 
14.9, 7.4, 5H), 1.58 (s, 9H), 1.39 (dd, J = 31.1, 16.2, 7H), 1.00 (t, J = 7.4, 3H). 13C NMR (101 
MHz, CDCl3) δ 198.53, 170.10, 140.74, 132.39, 127.06, 123.24, 123.01, 110.23, 58.10, 55.54, 
43.20, 40.40, 27.69, 27.62, 27.21, 27.09, 26.75, 18.00, 13.99. Anal. Calcd for 
C23H34N2O2S.1HCl: C, 62.92; H, 8.03; N, 6.38. Found: C, 62.73; H, 7.97; N, 6.30. MS (ESI) m/z 
403.79 (M+ + H). 
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3-(3-(azepan-1-yl)propyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.19a, RB10) 73%. 1H NMR 
(400 MHz, CDCl3) δ 7.21 (s, 1H), 7.08 (q, J = 8.2, 2H), 3.98 (t, J = 7.1, 2H), 2.58 (t, J = 5.3, 6H), 
2.51 (t, J = 6.7, 2H), 1.93 – 1.81 (m, 2H), 1.68 – 1.53 (m, 10H), 0.93 (t, J = 7.3, 3H). 13C NMR 
(101 MHz, CDCl3) δ 169.87, 137.66, 135.39, 126.49, 122.63, 122.24, 110.63, 55.62, 55.12, 
41.10, 37.62, 28.27, 26.97, 25.96, 24.78, 13.73. HRMS m/z 333.2001 (Cal), found 333.1986 (M+ 
+ H). 
3-(4-(azepan-1-yl)butyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.19b, RB14) 75%. 1H NMR 
(400 MHz, CDCl3) δ 7.23 (s, 1H), 7.15 – 7.07 (m, 1H), 6.99 (d, J = 8.2, 1H), 3.94 (t, J = 7.4, 
2H), 2.70 – 2.57 (m, 6H), 2.56 – 2.48 (m, 2H), 1.76 (dt, J = 15.0, 7.5, 2H), 1.70 – 1.53 (m, 12H), 
0.94 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 170.02, 137.86, 135.19, 126.62, 122.79, 
122.43, 110.56, 57.51, 55.56, 42.67, 37.70, 27.87, 27.08, 25.52, 24.86, 24.60, 13.80. MS (ESI) 
m/z 347 (M+ + H).  
3-(5-(azepan-1-yl)pentyl)-6-propyl-2,3-dihydrobenzo[d]thiazole (6.19c, RB16) 78%. 1H 
NMR (CDCl3): δ 7.26 (s, 1H), 7.13 (d, J = 7.6 Hz, 1H), 6.97 (d, J = 8 Hz, 1H), 3.95 (t, J = 7.6 
Hz, 2H), 2.76 (2H), 2.60 (m, J = 8.4 Hz, 2H), 1.80 (m, J = 7.6 Hz, 2H), 1.72 (2H), 1.66 (m, J = 
7.6 Hz, 2H), 1.42 (dd, J = 7.6 Hz, 2H), 0.96 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3): δ 170.14, 
138.03, 134.79, 126.75, 122.51, 122.37, 110.41, 57.19, 54.42, 53.34, 41.95, 37.56, 26.90, 24.68, 
23.82, 23.71, 23.68,13.66. MS (ESI) m/z 361 (M+ + H). 
3-(6-(azepan-1-yl)hexyl)-6-propyl-2,3-dihydrobenzo[d]thiazole (6.19d, RB18) 70%. 1H NMR 
(400 MHz, CDCl3) δ 7.22 (s, 1H), 7.10 (d, J = 8.1, 1H), 6.93 (d, J = 8.2, 1H), 3.90 (t, J = 7.3, 
2H), 2.71 – 2.62 (m, 4H), 2.59 (t, J = 7.6, 2H), 2.53 – 2.43 (m, 2H), 1.78 – 1.69 (m, 2H), 1.69 – 
1.56 (m, 10H), 1.51 (dd, J = 14.8, 7.5, 2H), 1.45 – 1.28 (m, 4H), 0.93 (t, J = 7.3, 3H). 13C NMR 
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(101 MHz, CDCl3) δ 169.93, 137.79, 135.17, 126.59, 122.75, 122.41, 110.40, 58.09, 55.45, 
42.80, 37.65, 27.64, 27.41, 27.19, 27.06, 27.01, 26.73, 24.81, 13.77. MS (ESI) m/z 375 (M+ + H). 
3-(3-(azepan-1-yl)propyl)-6-butylbenzo[d]thiazol-2(3H)-one (6.19e, RB20) 78%. 1H NMR 
(400 MHz, CDCl3) δ 7.23 (s, 1H), 7.09 (q, J = 8.2, 2H), 3.99 (t, J = 7.1, 2H), 2.61 (dd, J = 10.5, 
6.3, 6H), 2.54 (t, J = 6.8, 2H), 1.90 (dd, J = 13.9, 6.9, 2H), 1.69 – 1.56 (m, 10H), 1.36 (dt, J = 
14.8, 7.3, 2H), 0.93 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 170.00, 137.99, 135.40, 
126.51, 122.72, 122.27, 110.70, 55.67, 55.17, 41.17, 35.31, 33.92, 28.22, 27.03, 25.98, 22.31, 
14.01.  MS (ESI) m/z 347 (M+ + H). 
3-(4-(azepan-1-yl)butyl)-6-butylbenzo[d]thiazol-2(3H)-one hydrochloride (6.19f, RB34) 
78%. 1H NMR (400 MHz, CDCl3) δ 7.23 (s, 1H), 7.11 (d, J = 8.2, 1H), 6.98 (d, J = 8.2, 1H), 
3.94 (t, J = 7.4, 2H), 2.62 (t, J = 5.3, 6H), 2.55 – 2.47 (m, 2H), 1.76 (dt, J = 15.0, 7.4, 2H), 1.58 
(td, J = 15.7, 8.6, 13H), 1.35 (dq, J = 14.6, 7.3, 2H), 0.93 (t, J = 7.3, 3H). 13C NMR (101 MHz, 
CDCl3) δ 169.98, 138.05, 135.15, 126.54, 122.79, 122.36, 110.55, 57.51, 55.56, 42.69, 35.32, 
33.93, 27.96, 27.07, 25.52, 24.67, 22.31, 14.01. HRMS m/z 361.2314 (Cal), found 361.2307 (M+ 
+ H). 
3-(5-(azepan-1-yl)pentyl)-6-butylbenzo[d]thiazol-2(3H)-one (6.19g, RB22) 69%. 1H NMR 
(400 MHz, CDCl3) δ 7.22 (s, 1H), 7.10 (d, J = 8.2, 1H), 6.94 (d, J = 8.2, 1H), 3.92 (t, J = 7.0, 
2H), 3.06 – 2.95 (m, 4H), 2.82 – 2.73 (m, 2H), 2.60 (t, J = 7.7, 2H), 1.91 – 1.71 (m, 8H), 1.66 (s, 
4H), 1.62 – 1.52 (m, 2H), 1.44 – 1.27 (m, 4H), 0.91 (t, J = 7.3, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.11, 138.23, 134.90, 126.71, 122.61, 122.37, 110.49, 57.51, 54.84, 42.25, 35.25, 
33.85, 26.97, 24.97, 24.75, 24.14, 22.26, 13.95. MS (ESI) m/z 375.9 (M+ + H). 
3-(6-(azepan-1-yl)hexyl)-6-butylbenzo[d]thiazol-2(3H)-one (6.19h, RB24) 72%. 1H NMR 
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(400 MHz, CDCl3) δ 7.26 – 7.23 (m, 1H), 7.15 – 7.09 (m, 1H), 6.98 – 6.91 (m, 1H), 3.98 – 3.86 
(m, 2H), 2.71 – 2.59 (m, 6H), 2.54 – 2.43 (m, 2H), 1.78 – 1.71 (m, 2H), 1.70 – 1.57 (m, 11H), 
1.55 – 1.46 (m, 2H), 1.44 – 1.31 (m, 6H), 0.98 – 0.90 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 
170.02, 138.08, 135.20, 126.58, 122.85, 122.42, 110.46, 58.18, 55.55, 42.88, 35.34, 33.96, 27.72, 
27.61, 27.29, 27.18, 27.12, 26.82, 22.35, 14.04, 1.14. HRMS m/z 389.2627 (Cal), found 
389.2621 (M+ + H). 
3-(2-(azepan-1-yl)ethyl)-6-(2-bromoethyl)benzo[d]thiazol-2(3H)-one (6.19 i, RB6-233-67) 
73%. 1H NMR (400 MHz, CDCl3) δ 7.28 (s, 1H), 7.17 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 8.2 Hz, 
1H), 4.12 – 3.99 (m, 2H), 3.57 (t, J = 7.3 Hz, 2H), 3.18 (t, J = 7.3 Hz, 2H), 2.90 – 2.80 (m, 2H), 
2.80 – 2.70 (m, 4H), 1.61 (d, J = 26.7 Hz, 8H). MS (ESI) m/z 383.08, 385.03 (M+ + 2). 
6.5 Synthesis of benzo[d]thiazol-2(3H)-one Analogues with Piperazine and 
Homopiperazine. 
Substituted piperazine derivatives (6.22a-g) were prepared by reductive amination using 
appropriate aldehydes/ketones (Scheme 5)285-286. 
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6.21c, RB6-272-45 -(CH2)2CH3 2 H 
 
6.22a, RB3-108-26 
 
H 
 
2 
CF3
 
6.22b, RB3-121-50  
H 
 
2 
 
 6.22c, RB3-122-52 H 2 
 
6.22d, RB3-125-58 
O  
 
2 
 
6.22e, RB4-160-23 
O  
1 
 
6.22f, RB4-162-27 
O  
2 
 
  
6.22g, RB6-273-47 -(CH2)2CH3 2 CH3 
 
Reagent and Conditions: (a) 1,2-Dibromoethane, K2CO3, DMF, 600C, 3h; (b) K2CO3, DMF, 
600C, 2-3h; (c) Reductive amination (substrate: aldehyde or ketone), NaBH(OAc)3/NaBH3CN, 
MeOH, rt, 2-6 h.  
3-(2-(1,4-diazepan-1-yl)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.21b, RB3-124-56) 
60%. 1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.95 (dd, J = 8.5, 1.5, 1H), 7.13 (d, J = 8.5, 
1H), 4.06 (t, J = 6.8, 2H), 2.99 (q, J = 7.2, 3H), 2.89 (dt, J = 13.9, 6.5, 6H), 2.78 (dd, J = 11.2, 
5.6, 4H), 1.81 – 1.70 (m, 2H), 1.23 (t, J = 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 198.92, 
170.16, 140.78, 132.24, 126.92, 123.15, 122.97, 110.29, 57.92, 55.12, 54.81, 48.98, 47.21, 41.70, 
31.69, 30.14, 8.42.  
3-(2-(4-(2-(trifluoromethyl)benzyl)-1,4-diazepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one 
(6.22a, RB3-108-26) 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 7.8, 1H), 7.60 (d, J = 7.9, 1H), 
7.51 (t, J = 7.6, 1H), 7.44 – 7.39 (m, 1H), 7.35 – 7.27 (m, 2H), 7.14 (ddd, J = 17.3, 12.0, 4.5, 
2H), 4.09 – 4.01 (m, 2H), 3.78 (s, 2H), 2.86 (dd, J = 9.9, 4.5, 4H), 2.83 – 2.77 (m, 2H), 2.72 – 
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2.63 (m, 4H), 1.84 – 1.76 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 169.91, 139.04, 137.24, 
131.76, 130.24, 126.60, 126.31, 123.03, 122.79, 122.68, 110.68, 58.17, 58.15, 55.84, 55.59, 
54.78, 54.54, 54.35, 41.18, 27.95. MS (ESI) m/z  (M+ + H) 436.2. 
3-(2-(4-cyclohexyl-1,4-diazepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one (6.22b, RB3-121-50). 
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 7.8, 1H), 7.35 – 7.26 (m, 1H), 7.15 (t, J = 7.7, 1H), 
7.08 (d, J = 8.0, 1H), 4.10 – 3.99 (m, 2H), 2.79 (ddd, J = 12.8, 10.8, 5.5, 10H), 2.45 (s, 1H), 1.87 
– 1.73 (m, 6H), 1.61 (d, J = 12.3, 1H), 1.20 (d, J = 7.8, 4H), 1.08 (s, 1H). 13C NMR (101 MHz, 
CDCl3) δ 169.97, 137.30, 126.36, 123.07, 122.87, 122.75, 110.73, 64.48, 54.86, 54.42, 51.20, 
50.20, 41.17, 29.03, 26.44, 26.17. MS (ESI) m/z  (M+ + H) 360.3. 
3-(2-(4-cyclopentyl-1,4-diazepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one (6.22c, RB3-122-52). 
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 7.7, 1H), 7.29 (dd, J = 12.8, 5.2, 1H), 7.14 (t, J = 7.2, 
1H), 7.07 (d, J = 8.0, 1H), 4.09 – 3.97 (m, 2H), 2.91 – 2.77 (m, 7H), 2.72 (t, J = 5.6, 4H), 1.79 
(dd, J = 11.4, 5.8, 4H), 1.65 (d, J = 8.3, 2H), 1.51 (dd, J = 7.4, 4.8, 2H), 1.41 (dd, J = 13.8, 5.3, 
2H). 13C NMR (101 MHz, CDCl3) δ 169.93, 137.26, 126.33, 123.05, 122.84, 122.73, 110.68, 
66.51, 55.39, 55.04, 54.44, 53.69, 52.53, 41.14, 30.33, 27.86, 24.31. MS (ESI) m/z  (M+ + H) 
346.78. 
3-(2-(4-cyclohexyl-1,4-diazepan-1-yl)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.22d, 
RB3-125-58). 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 1.6, 1H), 7.95 (dd, J = 8.5, 1.7, 1H), 
7.13 (d, J = 8.5, 1H), 4.05 (t, J = 6.8, 2H), 2.99 (q, J = 7.2, 2H), 2.80 (ddd, J = 25.4, 12.8, 6.4, 
10H), 2.51 (s, 1H), 1.90 – 1.73 (m, 6H), 1.61 (d, J = 12.5, 1H), 1.23 (m, J = 7.2, 8H). 13C NMR 
(101 MHz, CDCl3) δ 198.92, 170.15, 140.79, 132.23, 126.95, 123.13, 122.93, 110.35, 64.71, 
54.92, 54.36, 51.29, 49.98, 41.55, 31.68, 28.78, 26.29, 26.05, 8.43. MS (ESI) m/z  (M+ + H) 
  124 
416.19. 
3-(2-(4-(cyclopropylmethyl)piperazin-1-yl)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one 
(6.22e, RB4-160-23) 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 1.5, 1H), 7.95 (dd, J = 8.5, 1.6, 
1H), 7.13 (d, J = 8.5, 1H), 4.09 (t, J = 6.9, 2H), 2.99 (q, J = 7.2, 2H), 2.66 (dd, J = 21.9, 15.0, 
9H), 2.24 (d, J = 6.6, 2H), 1.23 (t, J = 7.2, 3H), 0.84 (s, 1H), 0.50 (q, J = 5.7, 2H), 0.15 – 0.01 
(m, 3H). 13C NMR (101 MHz, CDCl3) δ 198.95, 170.12, 140.75, 132.20, 126.91, 123.15, 122.93, 
110.32, 63.72, 55.12, 53.38, 53.24, 40.86, 31.68, 8.41, 8.37, 3.99. MS (ESI) m/z  (M+ + H) 
374.10. 
3-(2-(4-(cyclopropylmethyl)-1,4-diazepan-1-yl)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one 
(6.22f, RB4-162-27). 1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 1.6, 1H), 7.95 (dd, J = 8.5, 1.7, 
1H), 7.14 (d, J = 8.5, 1H), 4.06 (t, J = 6.9, 2H), 2.99 (q, J = 7.2, 2H), 2.87 – 2.73 (m, 10H), 2.38 
(d, J = 6.4, 2H), 1.80 (dt, J = 11.6, 6.0, 2H), 1.24 (t, J = 7.2, 3H), 0.91 – 0.80 (m, 1H), 0.53 – 
0.45 (m, 2H), 0.11 – 0.04 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 198.95, 170.14, 140.85, 
132.22, 126.93, 123.17, 122.95, 110.36, 63.40, 55.44, 55.21, 54.63, 54.21, 41.65, 31.70, 27.59, 
8.84, 8.44, 4.08. . MS (ESI) m/z 388.08 (M+ + H). 
6.6 N-Cycloalkylsubstituted analogues 
Analogues with N-cycloheptyl/N-cycloheptyl, N-methyl and N-cyclooctyl/N-cyclooctyl, N-
methyl substitutions were synthesized as illustrated in Scheme 6. 
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Compound No. X R1 R2 
6.25a, RB81 O 
 
H 
6.25b, RB6-278-57 O 
 
H 
6.25c, RB6-268-37 H2 
 
H 
6.25d, RB6-279-59 H2 
 
H 
6.26a, RB6-270-41 H2 
 
CH3 
6.26b, RB6-291-81 O 
 
CH3 
6.26c, RB6-292-83 H2 
 
CH3 
 
Reagents and Conditions: (a) 1,2-dibromoethane, K2CO3, DMF, 600C, 3h; (b) 
cycloheptylamine/cyclooctanamine, K2CO3, DMF, 600C, 2-3h; (c) paraformaldehyde/ 
acetaldehyde, MeOH, rt, 6h. 
3-(2-(cyclooctylamino)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.25a, RB81) 60%. 1H 
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NMR (400 MHz, CDCl3) δ 8.06 (d, J = 1.5, 1H), 7.95 (dd, J = 8.5, 1.6, 1H), 7.22 (d, J = 8.5, 
1H), 4.09 (t, J = 6.8, 2H), 3.05 – 2.93 (m, 4H), 2.70 (s, 1H), 2.02 (d, J = 13.0, 1H), 1.68 (t, J = 
12.5, 4H), 1.60 – 1.34 (m, 11H), 1.23 (t, J = 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 198.92, 
170.34, 140.85, 132.28, 127.01, 123.15, 122.90, 110.48, 57.71, 44.34, 43.56, 32.42, 31.69, 27.29, 
25.80, 24.00, 8.42. HRMS m/z 361.1950 (Cal), found 361.1951 (M+ + 1). 
3-(2-(cycloheptylamino)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.25b, RB6-278-57) 
62%. 1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.95 (d, J = 8.5, 1H), 7.22 (d, J = 8.5, 1H), 
4.09 (t, J = 6.8, 2H), 2.99 (dt, J = 10.0, 7.0, 5H), 2.68 (s, 1H), 1.79 (d, J = 8.1, 2H), 1.56 (d, J = 
34.9, 7H), 1.37 (d, J = 5.5, 5H), 1.23 (t, J = 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 198.95, 
170.37, 140.87, 132.30, 127.01, 123.17, 122.92, 110.48, 58.85, 44.47, 43.60, 34.78, 31.70, 28.33, 
24.28, 8.43.  
3-(2-(cyclooctylamino)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.25c, RB6-268-37) 58%. 
1H NMR (400 MHz, CDCl3) δ 7.23 (s, 1H), 7.11 (d, J = 8.3, 1H), 7.04 (d, J = 8.2, 1H), 4.04 (t, J 
= 7.0, 2H), 2.95 (t, J = 7.0, 2H), 2.70 (s, 1H), 2.64 – 2.55 (m, 2H), 1.76 – 1.60 (m, 8H), 1.55 (d, J 
= 11.4, 4H), 1.45 (dd, J = 20.9, 9.1, 7H), 0.94 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 
170.26, 137.98, 135.28, 126.71, 122.72, 122.45, 110.53, 57.67, 44.52, 43.29, 37.68, 32.62, 27.31, 
25.85, 24.83, 24.09, 13.78. MS (ESI) m/z 347.03 (M+ + H). 
3-(2-(cycloheptylamino)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.25d, RB6-279-59) 
60%. 1H NMR (400 MHz, CDCl3) δ 7.23 (s, 1H), 7.12 (d, J = 8.3, 1H), 7.05 (d, J = 8.2, 1H), 
4.05 (t, J = 7.0, 2H), 2.96 (t, J = 7.0, 2H), 2.74 – 2.65 (m, 1H), 2.64 – 2.55 (m, 2H), 1.81 (dd, J = 
15.2, 7.7, 3H), 1.64 (dq, J = 14.8, 7.4, 4H), 1.57 – 1.46 (m, 4H), 1.37 (dd, J = 10.4, 5.8, 4H), 
0.94 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 170.28, 138.01, 135.27, 126.73, 122.73, 
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122.47, 110.54, 58.87, 44.58, 43.22, 37.69, 34.81, 28.33, 24.84, 24.36, 13.79.  
3-(2-(cyclooctyl(methyl)amino)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.26a, RB6-270-
41) 62%. 1H NMR (400 MHz, CDCl3) δ 7.23 (s, 1H), 7.13 (d, J = 8.2, 1H), 7.03 (d, J = 8.2, 1H), 
4.10 – 3.96 (m, 2H), 2.75 – 2.66 (m, 3H), 2.65 – 2.56 (m, 2H), 2.38 (s, 3H), 1.74 – 1.52 (m, 
10H), 1.42 (d, J = 6.8, 7H), 0.94 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 170.07, 137.91, 
135.26, 126.75, 122.68, 122.43, 110.56, 64.00, 50.08, 41.69, 38.32, 37.69, 29.57, 26.53, 26.50, 
25.62, 24.83, 13.79. MS (ESI) m/z 361.08.  
3-(2-(cycloheptyl(methyl)amino)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (6.26b, RB6-
291-81) 59%. 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 1.6, 1H), 7.96 (dd, J = 8.5, 1.6, 1H), 
7.18 (d, J = 8.4, 1H), 4.05 (t, J = 6.8, 2H), 2.99 (q, J = 7.2, 2H), 2.71 (t, J = 6.9, 2H), 2.55 (s, 
1H), 2.35 (s, 3H), 1.76 – 1.57 (m, 4H), 1.42 (ddd, J = 50.8, 14.3, 6.5, 8H), 1.24 (t, J = 7.2, 3H). 
13C NMR (101 MHz, CDCl3) δ 199.00, 170.18, 141.04, 132.17, 126.96, 123.07, 122.86, 110.54, 
65.40, 50.33, 42.16, 38.33, 31.68, 30.06, 27.88, 25.64, 8.44.  
3-(2-(cycloheptyl(methyl)amino)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.26c, RB6-292-
83) 60%. 1H NMR (400 MHz, CDCl3) δ 7.23 (s, 1H), 7.16 (d, J = 8.3, 1H), 7.10 (d, J = 8.3, 1H), 
4.16 – 4.06 (m, 2H), 2.91 – 2.73 (m, 3H), 2.60 (t, J = 7.6, 2H), 2.47 (s, 3H), 1.84 (s, 2H), 1.64 
(td, J = 14.8, 7.4, 4H), 1.58 – 1.33 (m, 8H), 0.94 (t, J = 7.3, 3H). 13C NMR (101 MHz, CDCl3) δ 
170.20, 138.18, 134.89, 127.01, 122.57, 122.49, 110.63, 65.63, 50.18, 40.83, 37.67, 29.63, 27.68, 
25.42, 24.81, 13.77.  
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6.7 Synthesis of 3-(2-(azepan-1-yl)ethyl)-6-(methoxymethyl)benzo[d]thiazol-2(3H)-one 
 
Scheme 7 
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Reagents and conditions: (a) AlCl3-DMF, chloroacetyl chloride, 800C, 4h; (b) Pyridine, 900C, 
3h; (c) 2.5 N NaOH, 4h; (d) Ethanol, H2SO4 (cat.), reflux, 8h; (e) 1,2-dibromoethane, K2CO3, 
DMF, 600C, 3h; (f) Hexamethyleneimine, K2CO3, DMF, 600C, 3h; (g) LiAlH4 (2.4 M in THF), 
rt, 30 min; (h) NaH, CH3I, 00C, 30 min.   
1-(2-oxo-2-(2-oxo-2,3-dihydrobenzo[d]thiazol-6-yl)ethyl)pyridin-1-ium (6.28, RB6-281-63a). 
A suspension of 6-(2-bromoacetyl)benzo[d]thiazol-2(3H)-one (1.0 g) in pyridine (10 ml) was 
stirred at 900C for 3h, then allowed to cool to room temperature. The precipitate was collected by 
filtration and washed with EtOH. The product was used for the next without purification and 
characterization. 
2-oxo-2,3-dihydrobenzo[d]thiazole-6-carboxylic acid (6.29, RB6-281-63b). 1-(2-oxo-2-(2-
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oxo-2,3-dihydrobenzo[d]thiazol-6-yl)ethyl)pyridin-1-ium was dissolved in 2.5 N NaOH (10 ml), 
and the solution was stirred at 800C for 4h. The mixture was acidified with concentrated HCl to 
pH 2.0, and the resulting precipitate was collected by filtration and washed with MeOH. The 
product was used for the next step without purification. 70.6% yield as a white solid. 1H NMR 
(400 MHz, DMSO-d6) δ 12.23 (s, 1H), 8.13 (s, 1H), 7.85 (d, J = 8.3, 1H), 7.18 (d, J = 8.3, 1H). 
13C NMR (101 MHz, DMSO-d6) δ 170.74, 166.88, 140.19, 128.28, 125.24, 124.35, 123.72, 
111.37. 
ethyl 2-oxo-2,3-dihydrobenzo[d]thiazole-6-carboxylate (6.30, RB6-282-64). To a solution of 
2-oxo-2,3-dihydrobenzo[d]thiazole-6-carboxylic acid (600 mg, 3.07 mmol) in EtOH (25 ml), 
H2SO4 (1.2 ml) was added and refluxed for 8h. The reaction mixture was concentrated in vacuo, 
the residue was neutralized with a saturated solution of NaHCO3. The product was extracted in 
ethyl acetate and the organic layer was concentrated in vacuo. The product was purified by flash 
chromatography on silica gel (0 - 10% MeOH/DCM) to afford 0.55g (79.7%) of ethyl 2-oxo-2,3-
dihydrobenzo[d]thiazole-6-carboxylate as a white solid.  1H NMR (400 MHz, DMSO-d6) δ 12.42 
– 12.03 (m, 1H), 8.19 – 8.11 (m, 1H), 7.89 – 7.80 (m, 1H), 7.21 – 7.13 (m, 1H), 4.34 – 4.20 (m, 
2H), 1.34 – 1.25 (m, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.45, 165.09, 140.32, 127.89, 
124.12, 124.00, 123.73, 111.24, 60.68, 14.16. MS (ESI) m/z 222 (M-1). 
ethyl 3-(2-bromoethyl)-2-oxo-2,3-dihydrobenzo[d]thiazole-6-carboxylate (RB6-283-65). 1H 
NMR (400 MHz, CDCl3) δ 8.15 (s, 1H), 8.05 (d, J = 8.5, 1H), 7.18 (d, J = 8.5, 1H), 4.44 – 4.33 
(m, 4H), 3.64 (t, J = 6.8, 2H), 1.41 (t, J = 7.1, 3H). 13C NMR (101 MHz, CDCl3) δ 170.18, 
165.62, 140.13, 128.48, 126.04, 124.52, 122.69, 110.23, 61.39, 44.47, 26.94, 14.46.  
 
ethyl 3-(2-(azepan-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazole-6-carboxylate (6.31, RB6-
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284-67). 1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 1.3, 1H), 8.03 (d, J = 8.5, 1H), 7.18 (d, J = 
8.5, 1H), 4.38 (q, J = 7.1, 2H), 4.08 (t, J = 7.0, 2H), 2.85 (t, J = 7.0, 2H), 2.79 – 2.69 (m, 4H), 
1.59 (d, J = 22.0, 8H), 1.40 (t, J = 7.1, 3H). 13C NMR (101 MHz, CDCl3) δ 170.14, 165.83, 
140.86, 128.32, 125.49, 124.27, 122.75, 110.40, 61.27, 55.92, 54.92, 41.68, 28.28, 26.98, 14.46. 
MS (ESI) m/z 349 (M+1). 
3-(2-(azepan-1-yl)ethyl)-6-(hydroxymethyl)benzo[d]thiazol-2(3H)-one (6.32, RB6-286-71a).  
A solution of LiAlH4 (0.16g, 4.05 mmol) in THF (1.5 ml) was cooled to 00C in ice-water bath. 
Solution of 3-(2-(azepan-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazole-6-carboxylate (0.47g, 
1.35 mmol) was added to the LiAlH4 solution at 00C. The reaction mixture was allowed to warm 
to room temperature and stirred for 30 minutes. After completion, the reaction mixture was 
quenched with water (0.15 ml) followed by 15% NaOH solution (0.15 ml) and then with water 
(0.5 ml). The mixture was filtered and the filtrate was concentrated under reduced pressure. The 
product was purified by flash column chromatography to give 3-(2-(azepan-1-yl)ethyl)-6-
(hydroxymethyl)benzo[d]thiazol-2(3H)-one (40 mg, 10%) as an oil. 1H NMR (400 MHz, CDCl3) 
δ 7.43 (s, 1H), 7.28 (d, J = 8.0, 1H), 7.04 (d, J = 8.3, 1H), 4.67 (s, 2H), 4.05 – 3.93 (m, 2H), 3.11 
(s, 1H), 2.82 – 2.65 (m, 6H), 1.59 (d, J = 21.4, 8H). 13C NMR (101 MHz, CDCl3) δ 170.08, 
136.52, 125.38, 122.94, 121.42, 110.62, 64.63, 55.75, 54.64, 41.10, 28.04, 26.97. MS (ESI) m/z 
307.11 (M+ + H). 
(3-(2-(azepan-1-yl)ethyl)-2,3-dihydrobenzo[d]thiazol-6-yl)methanol (6.33, RB6-286-71b). 
This compound was obtained as a side product of the LiAlH4 reduction reaction. 1H NMR (400 
MHz, CDCl3) δ 7.04 (s, 1H), 6.92 (d, J = 8.0, 1H), 6.35 (d, J = 8.0, 1H), 4.80 (s, 2H), 4.48 (s, 
2H), 3.24 (t, J = 7.0, 2H), 2.71 (dd, J = 12.4, 6.5, 6H), 2.62 – 2.45 (m, 1H), 1.69 – 1.56 (m, 8H). 
13C NMR (101 MHz, CDCl3) δ 147.51, 131.96, 127.61, 125.02, 121.64, 107.24, 65.11, 58.03, 
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55.92, 54.89, 47.43, 27.92, 27.05. MS (ESI) m/z 293.13 (M+ + H). 
3-(2-(azepan-1-yl)ethyl)-6-(methoxymethyl)benzo[d]thiazol-2(3H)-one (6.34, RB6-290-79). 
A solution of (3-(2-(azepan-1-yl)ethyl)-2,3-dihydrobenzo[d]thiazol-6-yl)methanol (0.15 g, 0.5 
mmol) in THF (0.2 ml) was cooled to 00C in an ice-water bath. Sodium hydride (60% dispersion 
in mineral oil) (24 mg, 0.98 mmol) was added to the solution. Iodomethane (0.062 ml, 0.98 
mmol) was added to the reaction mixture and it was allowed to warm to room temperature. After 
completion, the reaction mixture was quenched with cold water and extracted with ethyl acetate. 
The organic layer was collected dried over sodium sulfate and concentrated. The product was 
purified with HPLC to give 3-(2-(azepan-1-yl)ethyl)-6-(methoxymethyl)benzo[d]thiazol-2(3H)-
one (30  mg) as an oil. 1H NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 7.31 – 7.24 (m, 1H), 7.10 (d, 
J = 8.2, 1H), 4.45 (s, 2H), 4.14 – 3.99 (m, 2H), 3.45 – 3.35 (m, 3H), 2.89 – 2.80 (m, 2H), 2.79 – 
2.70 (m, 4H), 1.60 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 169.98, 136.82, 133.40, 126.11, 
122.97, 122.17, 110.64, 74.31, 58.22, 55.79, 54.76, 41.29, 28.20, 27.00. MS (ESI) m/z 321.11 
(M+ + H). 
6.8 Synthesis of Monofluorinated and gem-difluorinated derivatives 
Monofluorinated (Scheme 8) and bis-fluorinated (Scheme 9) analogues of SN56 were 
synthesized. To synthesize monofluorinated derivatives, benzylic ketone (6.16a and 6.36b) was 
reduced to a secondary alcohol by sodium borohydride reduction (6.37a&b) followed by 
nucleophilic fluorination of the benzylic carbon by deoxofluor288. 
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Reagents and condition: (a) AlCl3-DMF, Propionyl chloride, 450C - 800C, 4h; (b) 1,2-
dibromoethane, K2CO3, DMF, 600C, 3h; (c) Hexamethyleneimine, K2CO3, DMF, 600C, 2h; (d) 
NaBH4, MeOH, 00C - rt, 1h; (d) Deoxofluor, CH2Cl2, 00C - rt, 1h. 
6-propionylbenzo[d]oxazol-2(3H)-one (6.35, RB80) 40%. Dimethylformamide (4.0 ml, 115 
mmol) was slowly added to aluminium chloride (26.5 g, 200 mmol) under vigorous stirring. The 
mixture was heated at 450C and benzo[d]oxazol-2(3H)-one (2.70 g, 20 mmol) was added. After 
30 min propionyl chloride (3.0 ml, 35 mmol) was added and the reaction mixture was heated at 
850C for 5h. The hot mixture was then carefully poured onto ice and the crude product was 
collected by filtration washed with water and air-dried. The solid was recrystallized from ethanol 
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to give 1.45 g (37.95%) of 6-propionylbenzo[d]oxazol-2(3H)-one as a white solid. 1H NMR (400 
MHz, DMSO-d6) δ 7.80 (d, J = 8.9, 2H), 7.15 (d, J = 8.0, 1H), 2.99 (q, J = 7.1, 2H), 1.06 (t, J = 
7.2, 3H). 13C NMR (101 MHz, DMSO-d6) δ 199.17, 154.88, 143.74, 135.11, 131.33, 125.25, 
109.75, 109.16, 31.43, 8.66. MS (ESI) m/z 190 (M+ - H).  
General Procedure for the preparation of 3-(2-bromoethyl)-6-propionylbenzo[d]oxazol-
2(3H)-one (RB82) 55%. 6-propionylbenzo[d] oxazol-2(3H)-one (1.45 g, 7.59 mmol) and 
Potassium carbonate (3.14 g, 22.77 mmol) was added to 6 ml of dimethylformamide. The 
mixture was heated at 600C and 1,2-dibromoethane (5.62 ml, 60.72 mmol) was added. The 
mixture was stirred and heated at 600C for 3 h. The mixture was cooled and poured into water. 
The product was extracted in Ethyl acetate and washed with saturated aqueous NaCl. The solvent 
was evaporated under reduced pressure and the product was purified by column chromatography 
over silica gel using Hexane: Ethyl acetate (9:1) to give 1.97 gm (87.17 %) of 3-(2-bromoethyl)-
6-propionylbenzo[d]oxazol-2(3H)-one. 1H NMR (400 MHz, CDCl3) δ 7.91 (dd, J = 8.2, 1.5, 
1H), 7.84 (d, J = 1.4, 1H), 7.14 (d, J = 8.2, 1H), 4.28 (t, J = 6.3, 2H), 3.71 (t, J = 6.3, 2H), 3.00 
(q, J = 7.2, 2H), 1.24 (t, J = 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 198.85, 154.23, 142.69, 
134.97, 132.44, 125.16, 109.95, 108.24, 44.38, 31.82, 27.69, 8.42.  
3-(2-(azepan-1-yl)ethyl)-6-propionylbenzo[d]oxazol-2(3H)-one (6.36, RB83) 75%. 1H NMR 
(400 MHz, CDCl3) δ 7.88 (d, J = 8.2, 1H), 7.80 (s, 1H), 7.09 (d, J = 8.2, 1H), 3.92 (t, J = 6.5, 
2H), 2.99 (q, J = 7.2, 2H), 2.88 (t, J = 6.5, 2H), 2.75 – 2.61 (m, 4H), 1.64 – 1.46 (m, 8H), 1.23 (t, 
J = 7.2, 3H). 13C NMR (101 MHz, CDCl3) δ 199.01, 154.67, 142.72, 135.56, 131.89, 124.96, 
109.61, 108.20, 55.89, 55.20, 41.36, 31.76, 28.40, 26.95, 8.45, 1.13. MS (ESI) m/z 317.6 (M+ + 
H). 
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General procedure for the preparation of RB78 and RB84. 
3-(2-(azepan-1-yl)ethyl)-6-(1-hydroxypropyl)benzo[d]thiazol-2(3H)-one (6.37a, RB78) 85%. 
RB74 (0.36 gm, 1.08 mmol) was dissolved in excess of methanol. The solution was cooled to 
00C on an ice bath. Excess of NaBH4 was added to the solution in portions and the solution was 
stirred at room temperature for 1-2 hrs. Upon completion, the solution was concentrated, 
quenched with water and product was extracted in DCM. The product was purified by flash 
column chromatography using DCM:MeOH (99:1) to give 0.34 gm (94.4 %) 3-(2-(azepan-1-
yl)ethyl)-6-(1-hydroxypropyl) benzo[d]thiazol-2(3H)-one. 1H NMR (400 MHz, CDCl3) δ 7.43 
(d, J = 1.4, 1H), 7.28 (dd, J = 8.3, 1.5, 1H), 7.06 (d, J = 8.3, 1H), 4.62 (t, J = 6.6, 1H), 4.07 – 
3.97 (m, 2H), 2.85 – 2.77 (m, 2H), 2.76 – 2.69 (m, 4H), 2.11 (s, 2H), 1.79 (ddt, J = 20.9, 13.6, 
6.7, 2H), 1.68 – 1.52 (m, 9H), 0.92 (t, J = 7.4, 3H). 13C NMR (101 MHz, CDCl3) δ 170.06, 
139.98, 136.67, 124.36, 123.00, 120.39, 110.58, 75.65, 55.86, 54.85, 41.39, 32.23, 28.34, 27.06, 
10.23. MS (ESI) m/z 335.9 (M+ + H). 
3-(2-(azepan-1-yl)ethyl)-6-(1-hydroxypropyl) benzo[d]oxazol-2(3H)-one (6.37b, RB84)  
(95%). 1H NMR (400 MHz, CDCl3) δ 7.22 (s, 1H), 7.15 (d, J = 8.0, 1H), 6.96 (d, J = 8.0, 1H), 
4.62 (t, J = 6.5, 1H), 3.87 (t, J = 6.8, 2H), 2.85 (t, J = 6.8, 2H), 2.76 – 2.63 (m, 4H), 2.24 (s, 1H), 
1.78 (ddt, J = 20.9, 13.7, 6.8, 2H), 1.64 – 1.50 (m, 8H), 0.91 (t, J = 7.4, 3H). 13C NMR (101 
MHz, CDCl3) δ 154.91, 142.95, 139.72, 130.72, 121.56, 108.22, 107.90, 75.81, 55.80, 55.09, 
40.99, 32.30, 28.37, 27.01, 10.20. MS (ESI) m/z 319.66 (M+ + H). 
General Procedure for the preparation of RB79 and RB85.  
3-(2-(azepan-1-yl)ethyl)-6-(1-fluoropropyl) benzo[d]thiazol-2(3H)-one (6.38a, RB79).   
Deoxofluor (0.206 ml, 1.12 mmol) was added to a solution of 3-(2-(azepan-1-yl)ethyl)-6-(1-
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hydroxypropyl)benzo[d]thiazol-2(3H)-one (RB78) (0.34 gm, 1.02 mmol) in anhydrous DCM in 
a 25 ml RBF. The solution was vigorously stirred at room temperature under argon for 2 hours. 
Upon completion the mixture was poured into a saturated solution of Na2CO3. The product was 
extracted in DCM and dried over Na2SO4. The solution was filtered and solvent was evaporated 
under reduced pressure. The product was purified by flash column chromatography using 
DCM:MeOH (99:1) give 180 mg (53 %) of 3-(2-(azepan-1-yl)ethyl)-6-(1-
fluoropropyl)benzo[d]thiazol-2(3H)-one. 1H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 7.31 – 7.24 
(m, 1H), 7.13 (d, J = 8.3, 1H), 5.36 (ddd, J = 47.4, 7.4, 5.5, 1H), 4.12 – 4.02 (m, 2H), 2.89 – 2.81 
(m, 2H), 2.80 – 2.72 (m, 4H), 2.09 – 1.78 (m, 2H), 1.59 (dd, J = 14.9, 12.0, 8H), 0.98 (t, J = 7.4, 
3H). 13C NMR (101 MHz, CDCl3) δ 169.92, 137.26, 135.56, 135.35, 124.18, 124.12, 123.08, 
120.22, 120.15, 110.66, 96.30, 94.60, 55.85, 54.81, 41.37, 30.38, 30.13, 28.22, 27.01, 9.51, 9.45. 
Anal Calcd for C18H25FN2OS.1C2H2O4.0.2H2O: C, 55.85; H, 6.42; N, 6.51. Found: C, 55.91; H, 
6.33; N, 6.55. MS (ESI) m/z 337.6 (M+ + H). 
Procedure for the preparation of 3-(2-(azepan-1-yl)ethyl)-6-(1-fluoropropyl) 
benzo[d]oxazol-2(3H)-one (6.38b, RB85)  47.7 %. 1H NMR (400 MHz, CDCl3) δ 7.20 (s, 1H), 
7.14 (d, J = 8.0, 1H), 7.01 (d, J = 8.0, 1H), 5.46 – 5.26 (m, 1H), 3.89 (t, J = 6.7, 2H), 2.87 (t, J = 
6.7, 2H), 2.78 – 2.64 (m, 4H), 2.07 – 1.79 (m, 3H), 1.66 – 1.49 (m, 8H), 0.98 (t, J = 7.4, 3H). 13C 
NMR (101 MHz, CDCl3) δ 154.66, 142.77, 135.02, 134.81, 131.36, 121.40, 121.33, 108.21, 
107.61, 107.54, 96.35, 94.64, 55.71, 55.01, 41.00, 30.33, 30.09, 28.30, 26.87, 9.37, 9.31. HRMS 
m/z 321.1978 (Cal), found 321.1962 (M+ + H). 
Bisfluorination was carried out by oxidative fluorodesulfurization of dithioacetals using HF-
Pyridine and Selectfluor289. 
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Reagents and condition: (a) AlCl3-DMF, acylhalide/anhydride, 450C - 800C, 4h; (b) 1,2-
ethanedithiol, BF3-diethyletherate, CHCl3, rt, 6h; (c) CH2Cl2-DMF, HF-pyridine, selectfluor, 00 
C-rt, 2h; (d) Dibromoalkane, K2CO3, DMF, 600C, 3h; (e) cycloalkylamine, K2CO3, DMF, 600C, 
2h. 
6-(2-methyl-1,3-dithiolan-2-yl)benzo[d]oxazol-2(3H)-one (6.40a, RB4-185-73) 1H NMR (400 
MHz, DMSO-d6) δ 7.59 (d, J = 1.3, 1H), 7.49 (dd, J = 8.3, 1.7, 1H), 7.00 (d, J = 8.2, 1H), 3.43 
(dddd, J = 16.1, 13.9, 8.9, 6.8, 4H), 2.08 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 155.07, 
143.46, 140.08, 129.81, 122.64, 109.14, 108.81, 68.39, 40.71, 34.09. 
6-(2-ethyl-1,3-dithiolan-2-yl)benzo[d]thiazol-2(3H)-one (6.40b, RB5-214-31) 1H NMR (400 
MHz, CDCl3) δ 10.59 (s, 1H), 7.82 (d, J = 1.6, 1H), 7.60 (dd, J = 8.5, 1.9, 1H), 7.13 (d, J = 8.5, 
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1H), 3.48 – 3.30 (m, 2H), 3.25 (dt, J = 12.4, 7.8, 2H), 2.37 (dd, J = 14.4, 7.2, 2H), 0.91 (dd, J = 
18.1, 10.8, 3H). 13C NMR (101 MHz, CDCl3) δ 173.70, 140.53, 134.38, 125.98, 123.58, 121.39, 
111.35, 74.87, 39.30, 38.94, 12.17. 
6-(1,1-difluoroethyl)benzo[d]oxazol-2(3H)-one (6.41a, RB4-191-85) 1H NMR (400 MHz, 
DMSO-d6) δ 11.84 (s, 1H), 7.48 (s, 1H), 7.34 (d, J = 8.1, 1H), 7.15 (d, J = 8.1, 1H), 1.96 (t, J = 
18.7, 3H). 13C NMR (101 MHz, DMSO-d6) δ 154.85, 143.63, 132.28, 122.63, 120.93, 120.86, 
120.80, 109.97, 106.92, 106.86, 106.80, 25.86, 25.83, 25.54, 25.26. 
6-(1,1-difluoroethyl)-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-
one (6.42a, RB4-195-93) 1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 7.9, 2H), 7.02 (d, J = 8.2, 
1H), 6.95 (t, J = 8.6, 2H), 6.86 (dd, J = 9.0, 4.6, 2H), 3.89 (t, J = 7.1, 2H), 3.18 – 3.06 (m, 4H), 
2.67 – 2.54 (m, 4H), 2.44 (t, J = 7.3, 2H), 2.03 – 1.80 (m, 5H), 1.62 (dd, J = 14.8, 7.5, 2H). 13C 
NMR (101 MHz, CDCl3) δ 158.42, 156.05, 154.59, 148.03, 142.58, 133.05, 132.36, 121.53, 
120.61, 117.89, 117.82, 115.68, 115.46, 108.07, 107.08, 107.02, 57.64, 53.27, 50.18, 42.36, 
26.46, 26.16, 25.86, 25.66, 23.90. MS (ESI) m/z 434.13 (M+ + H). 
6-(1,1-difluoropropyl)benzo[d]thiazol-2(3H)-one (6.41b, RB5-215-33) 1H NMR (400 MHz, 
CDCl3) δ 10.54 (s, 1H), 7.54 (s, 1H), 7.38 (t, J = 9.0, 1H), 7.30 – 7.18 (m, 1H), 2.24 – 2.09 (m, 
2H), 1.00 (t, J = 7.5, 3H). 13C NMR (101 MHz, CDCl3) δ 173.51, 136.52, 136.51, 133.10, 
132.83, 132.55, 124.23, 123.89, 123.83, 123.77, 119.68, 119.62, 119.55, 111.81, 32.78, 32.50, 
32.21, 7.05, 7.00, 6.95. 
3-(2-(azepan-1-yl)ethyl)-6-(1,1-difluoropropyl)benzo[d]thiazol-2(3H)-one (6.42b, RB5-219-
41) 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.41 (d, J = 8.5, 1H), 7.16 (d, J = 8.4, 1H), 4.06 
(t, J = 7.1, 2H), 2.90 – 2.80 (m, 2H), 2.80 – 2.69 (m, 4H), 2.16 (tq, J = 15.1, 7.4, 2H), 1.60 (d, J 
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= 21.3, 8H), 1.00 (t, J = 7.5, 3H). 13C NMR (101 MHz, CDCl3) δ 169.83, 138.32, 136.69, 
134.94, 132.62, 132.35, 132.07, 127.98, 123.83, 123.47, 123.41, 123.35, 123.15, 123.05, 122.76, 
121.42, 121.18, 119.74, 119.67, 119.61, 110.49, 110.45, 55.89, 54.90, 41.65, 41.48, 32.75, 32.47, 
32.18, 29.57, 29.49, 28.40, 27.00, 22.23, 7.05, 7.00. MS (ESI) m/z 355.2 (M+ + H). 
6.9 Synthesis of 3-(2-(2-methylazepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one 
The 2-methylazepane (6.46, Scheme 10) was synthesized from cyclohexanone using the 
successive Beckman rearrangement-alkylation protocol290. The desired product (6.48, RB6-255-
11) was obtained by the coupling of 2-methylazepane and compound 6.47 (Scheme 10). 
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Reagents and condition: (a) NH2OH.HCl, Na2CO3, EtOH/H2O, reflux, 2h; (b) MsCl, Et3N, 
DCM, -230C; (c) (i) trimethylaluminium, toluene, (ii) DIBAL (1M in hexanes), KF; (d) K2CO3, 
DMF, 600C, 3h. 
Cyclohexanone oxime (6.44, RB6-251-03) A solution of hydroxylamine hydrochloride (2.08 g, 
30 mmol) and Sodium carbonate (1.06 g, 10 mmol) in water (20 ml) was added to a stirred 
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solution of cyclohexanone (2.07 ml, 20 mmol) in ethanol (45 ml). The reaction mixture was 
refluxed for 2 hours and then it was concentrated under reduced pressure. The solids were 
filtered, washed with water and hexanes and dried to give cyclohexanone oxime as white 
crystalline solid.  1H NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 2.84 – 1.92 (m, 4H), 1.89 – 1.02 
(m, 6H). 13C NMR (101 MHz, CDCl3) δ 160.75, 32.05, 26.85, 25.77, 25.55, 24.51. 
cyclohexanone O-methylsulfonyl oxime (RB6-252-05) A solution of cyclohexanone oxime (3.4 
g, 30 mmol) was cooled to -200 C in a CCl4/dry-ice bath. To this solution triethyl amine (5 
ml, 36 mmol) and methanesulfonyl chloride (2.56 ml, 33 mmol) was added. The reaction mixture 
was allowed to warm to room temperature and stirred for 1hour. Upon completion the solution 
was washed with 10% solution of NaHCO3. The organic layer was collected, dried over Na2SO4 
and concentrated. The product was used for the next step without purification and 
characterization. 
2-methylazepane hydrochloride (6.46, RB6-253-07) 1H NMR (400 MHz, CDCl3) δ 9.66 (s, 
1H), 9.31 (s, 1H), 3.39 (s, 1H), 3.28 (s, 1H), 3.14 (s, 1H), 2.06 (s, 1H), 1.97 – 1.76 (m, 5H), 1.62 
(d, J = 10.1, 2H), 1.53 (d, J = 6.7, 3H). 13C NMR (101 MHz, CDCl3) δ 55.00, 44.78, 33.74, 
26.90, 25.15, 24.86, 20.44. 
3-(2-(2-methylazepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one (6.48, RB6-255-11) 
21% yield 1H NMR (400 MHz, CDCl3) δ 7.23 (s, 1H), 7.12 (d, J = 8.2, 1H), 7.01 (s, 1H), 3.97 (s, 
2H), 2.84 (dd, J = 54.3, 26.1, 5H), 2.61 (t, J = 7.6, 2H), 1.63 (dt, J = 35.2, 17.6, 9H), 1.38 (s, 
2H), 0.95 (t, J = 7.2, 6H). 13C NMR (101 MHz, CDCl3) δ 169.94, 137.69, 135.42, 126.56, 
122.70, 122.37, 110.45, 57.91, 50.22, 49.12, 42.42, 37.66, 35.82, 28.82, 28.72, 25.27, 24.80, 
19.89, 13.77. 
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6.10 Synthesis of 6-(3-fluoropropyl)-3-(2-(1-methylazepan-2-yl)ethyl)benzo[d]thiazol-2(3H)-
one.  
Ethyl, 2-cyclohexanone acetate (6.49) was converted by Schmidt reaction and LiAlH4 reduction 
to a seven membered substituted azepane ring (6.51)291 which was then Boc protected on the 
nitrogen followed by conversion of hydroxyl group to bromo using appel reaction. 
Bromoethylazepane (6.52) was then coupled to the benzothiazolone analogue (6.54) followed by 
Boc-deprotection and hydrolysis of the ester. The hydroxyl derivative (6.57) was then fluorinated 
by deoxofluor. 
Scheme 11a 
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Reagents and Conditions: (a) H2SO4, NaN3, 00C, 8h; (b) LiAlH4, Dioxane/THF, reflux, 4h; (c) 
(Boc)2O, Et3N, 500C, 5min; (d) PPh3, CBr4, DCM, 00C to rt, 2h. 
ethyl 2-(7-oxoazepan-2-yl)acetate (6.50, RB5-234-69) Ethyl cyclohexanone-2-acetate (4.4 ml, 
24.36 mmol) was added to concentrated H2SO4 (26 ml) at 00C. Sodium azide (1.58 g, 24.36 
mmol) was added to the reaction mixture in batches while maintaining the temperature at 00C. 
The reaction mixture was allowed to warm to room temperature and stirred for 8 hours. Upon 
completion, the reaction mixture was poured into ice-water and neutralized with concentrated 
NH4OH solution. The solution was extracted several times with n-butanol (with 10% CH2Cl2). 
The organic layer was concentrated and the product was purified by flash column 
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chromatography on aluminium oxide (grade II) using DCM:MeOH to give ethyl 2-(7-
oxoazepan-2-yl)acetate (83%) as an oil. 1H NMR (400 MHz, CDCl3) δ 6.31 (s, 1H), 4.14 (q, J = 
7.1, 2H), 3.77 (s, 1H), 2.57 – 2.37 (m, 4H), 1.95 (d, J = 10.6, 1H), 1.80 (d, J = 13.9, 2H), 1.67 – 
1.34 (m, 3H), 1.25 (t, J = 7.1, 3H). 13C NMR (101 MHz, CDCl3) δ 177.72, 170.63, 136.49, 
61.06, 50.77, 40.70, 36.81, 35.50, 29.38, 23.02, 14.24. 
2-(azepan-2-yl)ethanol (6.51, RB5-240-81). Ethyl 2-(7-oxoazepan-2-yl)acetate (4.0 g, 20 
mmol) dissolved in 5ml THF and 5 ml dioxane was added dropwise to a solution of LiAlH4 (2.0 
M) in THF. The reaction mixture was refluxed for 4 hours. Upon completion, the reaction 
mixture was cooled in ice-water. The reaction mixture was quenched with water and 15% NaOH 
solution. The precipitate was removed by filtration. It was washed with diethyl ether and the 
filtrate was concentrated under reduced pressure. The product was used for the next step without 
further purification. 1H NMR (400 MHz, CDCl3) δ 3.92 (s, 2H), 3.86 – 3.70 (m, 2H), 2.99 – 2.82 
(m, 2H), 2.76 (d, J = 14.3, 1H), 1.83 (s, 1H), 1.71 (d, J = 6.9, 3H), 1.65 – 1.50 (m, 2H), 1.50 – 
1.37 (m, 3H), 1.33 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 63.51, 59.98, 45.68, 37.83, 37.35, 
31.85, 27.34, 26.39. 
tert-butyl 2-(2-hydroxyethyl)azepane-1-carboxylate (RB5-243-87). Di-tert-butyl dicarbonate 
(2.53 g, 11.6 mmol) was added to a solution of 2-(azepan-2-yl)ethanol (0.83 g, 5.8 mmol) and 
triethyl amine (8.7 ml) in methanol (50 ml). The reaction mixture was heated at 500C for 5 
minutes. Upon completion, the reaction mixture was concentrated and the residue was stirred in 
dilute HCl (pH 2-3) for 10 minutes. The product was extracted in ethyl acetate. The organic layer 
was dried over Na2SO4 and concentrated under reduced pressure. The product was purified by 
flash column chromatography using 15% ethyl acetate in hexane to give tert-butyl 2-(2-
hydroxyethyl)azepane-1-carboxylate (1.1 g, 78%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 
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4.24 – 3.96 (m, 1H), 3.63 – 3.47 (m, 2H), 3.40 (dd, J = 11.8, 9.5, 1H), 2.65 – 2.53 (m, 1H), 2.01 
(t, J = 6.9, 1H), 1.85 – 1.57 (m, 5H), 1.45 (d, J = 7.4, 9H), 1.33 – 1.11 (m, 5H). 13C NMR (101 
MHz, CDCl3) δ 157.75, 79.90, 58.52, 51.22, 41.61, 37.07, 35.27, 29.86, 29.03, 28.51, 25.14. 
tert-butyl 2-(2-bromoethyl)azepane-1-carboxylate (6.52, RB5-244-89). A solution of tert-
butyl 2-(2-hydroxyethyl)azepane-1-carboxylate (1.1 g, 4.52 mmol) and triphenyl phosphine 
(2.96 g, 11.30 mmol) in dichloroethane (5 ml) was cooled to 00C in an ice-water bath. A solution 
of CBr4 (4.5 g, 13.56 mmol) was added to the reaction mixture dropwise and the reaction 
mixture was allowed to warm to room temperature and stirred for 2 hours. Upon completion the 
reaction mixture was filtered to remove the solids and the filtrate was concentrated. The product 
was purified by flash column chromatography using 10% ethyl acetate in hexane to give tert-
butyl 2-(2-bromoethyl)azepane-1-carboxylate (0.94 g, 68%) as an oil. 1H NMR (400 MHz, 
CDCl3) δ 4.10 (m, 1H), 3.65 (dd, J = 53.0, 14.3, 1H), 3.46 – 3.26 (m, 2H), 2.70 (m, 1H), 2.09 – 
1.58 (m, 7H), 1.47 (d, J = 8.3, 9H), 1.22 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 155.59, 79.62, 
79.16, 54.14, 53.90, 42.15, 38.73, 38.37, 34.46, 34.25, 30.33, 29.69, 29.60, 28.94, 28.55, 28.47, 
28.27, 24.98, 24.79. 
tert-butyl 2-(2-bromoethyl)azepane-1-carboxylate (6.52) was coupled to 3-(2-oxo-2,3-
dihydrobenzo[d]thiazol-6-yl)propyl benzoate (6.54). The boc group was removed by treating 
6.54 with 1.0 M HCl in ether. The compound was then N-methylated by reductive amination 
using paraformaldehyde to give compound 6.56. The benzoic ester was deprotected to give a 
hydroxy derivative followed by nucleophilic fluorination using deoxofluor to give compound 
6.58 as shown in Scheme 11b. 
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Reagents and Conditions: (a) 3-Chloropropionyl chloride, AlCl3-DMF, 450C to 800C, 4h; (b) 
TES, TFA, rt, 4h; (c) Benzoic acid, 25% aq. NaOH, HMPA, 1100C, 6h; (d) K2CO3, DMF, 600C, 
3h; (e) 1.0 M HCl in ether, MeOH/THF, rt, 24h; (f) Paraformaldehyde, MeOH, rt, 2h, 
NaBH3CN, 6h; (g) NaOH, MeOH/H2O, reflux, 6h; (h) Deoxofluor, DCM, -780C to rt, 2h. 
tert-butyl 2-(2-(6-(3-(benzoyloxy)propyl)-2-oxobenzo[d]thiazol-3(2H)-yl)ethyl) azepane -1-
carboxylate (6.55, RB5-245-91) 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.6, 2H), 7.56 (d, J 
= 7.1, 1H), 7.45 (t, J = 7.4, 2H), 7.35 – 7.23 (m, 2H), 7.15 (d, J = 8.1, 1H), 6.90 (dd, J = 31.9, 
8.3, 1H), 4.35 (t, J = 6.3, 2H), 4.29 – 4.16 (m, 1H), 4.01 (s, 1H), 3.84 (s, 1H), 3.74 – 3.62 (m, 
1H), 2.82 (s, 3H), 2.20 – 2.06 (m, 3H), 1.78 (s, 4H), 1.65 (s, 3H), 1.47 (d, J = 21.3, 9H), 1.27 (s, 
4H). 13C NMR (101 MHz, CDCl3) δ 169.59, 166.60, 156.38, 136.48, 136.29, 135.36, 135.18, 
133.03, 130.32, 129.59, 128.43, 126.66, 123.18, 122.58, 122.44, 110.50, 110.27, 79.77, 79.38, 
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64.08, 53.70, 52.84, 42.18, 40.50, 34.68, 32.90, 32.75, 32.12, 30.54, 29.69, 29.00, 28.61, 25.18, 
24.95. 
3-(3-(2-(1-methylazepan-2-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazol-6-yl)propyl benzoate 
(6.56, RB5-247-95) 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.1, 2H), 7.57 (t, J = 7.4, 1H), 
7.44 (t, J = 7.7, 2H), 7.28 (d, J = 7.0, 1H), 7.16 (d, J = 8.2, 1H), 7.06 (d, J = 8.3, 1H), 4.36 (t, J = 
6.4, 2H), 3.99 (t, J = 7.4, 2H), 2.99 (d, J = 14.8, 1H), 2.82 (t, J = 7.4, 4H), 2.41 (s, 3H), 2.19 – 
2.05 (m, 2H), 1.84 (s, 1H), 1.79 – 1.43 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 166.68, 136.53, 
136.29, 135.73, 133.08, 130.38, 129.65, 128.49, 126.68, 123.13, 122.39, 110.93, 64.20, 63.73, 
55.16, 40.98, 37.75, 32.15, 31.94, 30.60, 27.74, 26.40, 26.19. 
6-(3-hydroxypropyl)-3-(2-(1-methylazepan-2-yl)ethyl)benzo[d]thiazol-2(3H)-one (6.57, 
RB5-248-97) 1H NMR (400 MHz, CDCl3) δ 7.27 (s, 2H), 7.14 (d, J = 8.3, 1H), 7.07 (d, J = 8.2, 
1H), 4.00 (t, J = 7.4, 2H), 3.68 (t, J = 6.3, 2H), 3.01 (d, J = 14.7, 1H), 2.88 – 2.69 (m, 4H), 2.43 
(s, 3H), 1.96 – 1.84 (m, 3H), 1.82 – 1.72 (m, 2H), 1.63 (d, J = 15.9, 7H). 13C NMR (101 MHz, 
CDCl3) δ 170.06, 137.01, 135.50, 126.74, 122.97, 122.42, 110.88, 62.06, 61.38, 55.20, 40.91, 
37.81, 34.46, 31.83, 31.76, 27.71, 26.12. MS (ESI) m/z 349.23 (M+ + H). 
6-(3-fluoropropyl)-3-(2-(1-methylazepan-2-yl)ethyl)benzo[d]thiazol-2(3H)-one (6.58, RB5-
249-99) 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 5.0, 1H), 7.14 (d, J = 8.2, 1H), 7.07 (d, J = 
8.2, 1H), 4.46 (dt, J = 47.2, 5.8, 2H), 3.99 (t, J = 7.5, 2H), 3.04 – 2.91 (m, 1H), 2.74 (m, 4H), 
2.39 (s, 3H), 2.10 – 1.92 (m, 2H), 1.88 – 1.77 (m, 1H), 1.73 (dd, J = 13.1, 7.8, 2H), 1.57 (dd, J = 
23.4, 18.9, 7H). 13C NMR (101 MHz, CDCl3) δ 169.88, 136.06, 135.79, 126.65, 123.10, 122.40, 
110.89, 83.76, 82.12, 60.89, 55.08, 41.03, 37.59, 32.40, 32.21, 32.03, 31.08, 31.03, 27.75, 26.65, 
26.23. MS (ESI) m/z 351.18 (M+ + H). 
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CHAPTER 7. CONCLUSION 
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Sigma receptors have been reported to be involved in the toxic and locomotor effects of cocaine 
and methamphetamine. Search for novel and effective agents for the treatment of drugs of abuse 
has been a focus of our research group. In the search to discover novel and selective agents 
targeting sigma receptors I have designed a series of compounds based on benzothiazolone and 
benzoxazolone scaffold. Through the structure activity study I have been able to identify several 
structural features necessary for achieving high affinity and subtype selectivity. 
Current project has been an extension of a previous study in which Yous et al. reported a small 
series of benzothiazolone compounds with high affinity and specificity for sigma receptors. In 
this study, derivatized 2(3H)-benzothiazolone, (3-(2-(azepan-1-yl)ethyl)-6-
propylbenzo[d]thiazol-2(3H)-one) was reported to have high affinity (0.56 nM) and selectivity 
(over 1000 fold) for sigma-1 receptor over sigma-2 receptor. CM304, (3-(2-(azepan-1-yl)ethyl)-
6-(3-fluoropropyl)benzo[d]thiazol-2(3H)-one) was synthesized in our laboratory and was found 
to have subnanomolar affinity for sigma-1 subtype and high selectivity over sigma-2 subtype. 
Both the compounds share a core benzothiazolone scaffold. This prompted me to investigate the 
structure-activity-relationship (SAR) of 3,6-disubstituted benzo[d]thiazole-2(3H)one for affinity 
and selectivity at sigma receptors.  The studies have shown that a 2-3 carbon linker between 
2(3H)-benzothiazolone and the azepane ring is critical for high affinity and selectivity for sigma-
1 receptor. Analogues gradually loose selectivity as the linker length increases. Substitution at 
the 6-position affects the affinity for sigma-1 receptor however it has a marginal effect on 
selectivity. However some dramatic difference in the subtype binding was observed when I 
substituted the azepane ring with smaller cycloalkylamine rings. Analogues with a pyrrolidine 
ring sunstitution in place of azepane were found to lose affinity at both the receptor subtypes. In 
this study, 3-(2-(azepan-1-yl)ethyl)-6-propionylbenzo[d]thiazol-2(3H)-one (RB74) was 
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identified as a compound with high affinity (4.5 nM) for sigma-1 receptor and a 500 fold 
selectivity over sigma-2 receptor. Several analogues were identified which retained low 
nanomolar affinity for sigma-1 subtype and some analogues exhibited a more than 30-fold 
preference for sigma-1 vs sigma-2 subtype. Further, because dramatic differences in subtype 
binding were observed in this synthetic series, this study provides useful data for the continued 
development of pharmacophore models for both σ receptor subtypes. 
In this study I have made several attempts to improve the metabolic profile of our lead sigma-1 
selective compounds SN56 and CM304. Through the lead optimization study I was able to 
obtained valuable information regarding the possible routes of metabolism. The information 
gathered during the SAR and metabolic stability studies will be helpful in developing novel 
ligands with improved therapeutic and pharmacokinetic profile.  
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SYMBOLS AND ABBREVIATIONS 
 
 
 
DAT                                dopamine transporter 
o C                                   degree Celsius 
5-HT                              5-hydroxytryptamine 
i.p.                                   intraperitoneal 
KDa                                 kilodalton 
MDMA                                               3,4-methylenedioxymethamphetamine  
mg                                   milligram 
mg/kg                              milligram/kilogram 
uM                                   micromolar 
nM                                   nanomolar 
NMDA                            N-methyl-D-aspartate 
NET                                 norepinephrine transporter 
ON                                   oligonucleotides 
PCP                                  phencyclidene 
SERT                               serotonin transporter 
SSRI                                selective serotonin reuptake inhibitor 
psi     pounds per square inch 
HbCD     2-hydroxypropyl-β-cyclodextrin  
µ     mu, micro 
κ     kappa 
σ                                                          sigma 
HIV     Human immunodeficiency virus 
ND     Not determined 
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